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This thesis consists of four chapters. 
Chapter 1 provides an overview of metallosupramolecular chemistry, detailing the 
three main approaches to self-assembled metallosupramolecular architectures: the 
ligand direct approach, the symmetry interaction approach, and the weak link 
approach. The various applications of these systems are discussed with regards to 
their molecular recognition properties. A series of [Pd2(L)4]4+ cages designed and 
produced by the Crowley group is introduced and their achievements and failings 
of binding the inorganic anticancer drug cisplatin are outlined. The necessity to 
address the failings of these systems is the foundation for one of the aims of this 
project. The other goals of this project are centred around structurally similar, but 
functionally different [Pd2(L)4]4+ cages. These are investigated as molecular reaction 
vessels and their potential to enhance the rate of [4+2] Diels Alder cycloaddition 
reactions are studied. 
Chapter 2 describes the global struggle against cancer, and how inorganic drug 
molecules such as cisplatin are used to combat the fatal disease. Advances in the 
use of metallosupramolecular architectures as drug delivery vectors are discussed, 
in particular [Pd2(L)4]4+ cage systems. Work building on the cages first developed 
by the Crowley group is detailed. Terminal coordinating pyridine groups have 
been substituted for quinoline and isoquinoline units in the new cages. The 
quinoline system no longer has the ability to bind cisplatin due to a twisting caused 
by steric clashes of the quinoline units. As these units are situated over the external 
faces of the palladium(II) metal ions, they provide protection from biological 
nucleophiles and therefore increase the kinetic robustness of the cage. This is 
reflected in the increased, sub-micromolar anticancer activity, the highest activity 
of any [Pd2(L)4]4+ system to date. However, like cisplatin, the system displayed very 
little discrimination between cancerous cells and healthy tissue. 
Chapter 3 introduces a new [Pd2(L)4]4+ cage system whereby the central pyridine 
ring is replaced with a rotationally flexible, redox active ferrocene moiety. X-ray 
crystallography confirmed the structure of both the BF4- salt and the PF6- salt. The 
coordination chemistry of an alteration of the ferrocene-based ligand, whereby a 3-
pyridyl donor is replaced by a 4-pyridyl donor, is also studied. Again, a single 
architecture was generated (and confirmed through X-ray crystallography), in this 
case a [Pd3(L)6]6+ prism. The exploration of the host-guest properties of both 
systems revealed them to interact strongly with the toluenesulfonate anion. While 
the cages retained the redox properties of ferrocene, the ferrocene units in each 
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ligand did not interact with each other, and the electrochemical signals were 
unperturbed upon the introduction of the guest. 
Chapter 4 details the history and current state of artificial enzymes, with particular 
emphasis on metallosupramolecular structures and more specifically, how 
[Pd2(L)4]4+ cages accelerate the rate of bimolecular [4+2] Diels Alder cycloaddition 
reactions. The work presented in this chapter is a continuation of a project started 
by the Lusby group in which the original [Pd2(L)4]4+ cage developed by Crowley 
was shown to not only accelerate the cycloaddition, but also alter the chemo- and 
regio-selectivity of the products. Electronic alterations to the cage have been 
explored in this section with regard to the catalytic activity. The new cages 
maintained their hosting abilities however altering the electronics only seemed to 












CDDP cisplatin, cis-diamminedichloroplatinum(II) 
CIS complexed induced shift 
CKABP 2’-carboxy-3-keto-D-arabinitol 1,5-bisphosphate 
COSY correlation spectroscopy 
CuAAC  copper(I)-catalysed azide alkyne cycloaddition 
CV cyclic voltammetry 
DBA dibenzylideneacetone 
DCM dichloromethane 




DNA deoxyribonucleic acid 
DNT 2,4-dinitrotoluene 
DOSY diffusion ordered spectroscopy 
dppz dipyridophenazine 
EDS ethane-1,2-disulfonate 
EDTA ethylenediaminetetraacetic acid 
eq. equivalent(s) 
ERN oestrogen receptor-negative 
ERP oestrogen receptor-positive 
EPR enhanced permeability and retention 
ESI-TOF MS electrospray ionisation time-of-flight mass spectrometry 
EtOAc ethyl acetate 
Fc ferrocene 
FDA Food and Drug Administration 
HEK-293 human embryonic kidney 
HL-60 human acute myelocyte leukaemia 
HL-60/CDDP cisplatin-resistant human acute myelocyte leukaemia 
HL-60/Dox doxorubicin-resistant human acute myelocyte leukaemia 
HOMO highest occupied molecular orbital 
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HSC human squamous carcinoma 
HT-29 human colorectal adenocarcinoma 
HR-ESI MS high resolution electrospray ionisation mass spectrometry 
IC50 concentration required for 50% inhibition of cell viability 
kcx carboxylated lysine 
LUMO lowest unoccupied molecular orbital 
MA methylanthracene 
MI maleimide 
MLCT metal-to-ligand charge transfer 
MMFF Merck molecular force field 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NMR nuclear magnetic resonance 
NOESY nuclear Overhauser effect spectroscopy 
OTf triflate, trifluoromethanesulfonate 
PAHs polycyclic aromatic hydrocarbons 
PCD 6,13-pentacenedione 
PDT photodynamic therapy 
PEG polyethylene glycol 
PPG 3-phosphoglycerate 
ppm parts per million 
py pyridine 
RNA ribonucleic acid 
ROESY rotating frame nuclear Overhauser effect spectroscopy  
ROS reactive oxygen species 
RT room temperature 
RuBisCO ribulose-1,5-bisphosphate carboxylase/oxygenase 
RuBP ribulose-1,5-bisphosphate 
SAR structure activity relationship 








TOCSY total correlation spectroscopy 
TOS p-toluenesulfonate 




General experimental information 
Unless otherwise stated, all reagents were purchased from commercial sources and 
used without further purification. The solvents used were laboratory grade. 
Petroleum ether refers to the fraction of petrol boiling in the range 40-60 °C, 
isopropyl alcohol (IPA), methanol (MeOH), dichloromethane (DCM), 
ethylenediaminetetraacetate (EDTA), ethynyltrimethylsilane (TMS-acetylene), 
tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), dimethylformamide (DMF). 
0.1 M Ammonium hydroxide/ethylenediaminetetraacetic acid (NH4OH/EDTA) 
solution was made up by mixing EDTA (30 g) and NH4OH(aq) (30%, 100 mL) in 
water (900 mL). Microwave assisted reactions were performed in a CEM Focused 
Microwave Synthesis System, Discover S-Class (CEM Corporation, NC), at 200 W. 
1H and 13C NMR spectra were collected on either a 400 MHz Varian 400-MR or a 
Varian 500 MHz AR spectrometer. Chemical shifts (δ) are reported in parts per 
million (ppm) and referenced to residual solvent peaks (CDCl3: 1H δ 7.26 ppm, 13C 
δ 77.2 ppm; CD3CN: 1H δ 1.94 ppm, 13C δ 1.3 & 118.3 ppm; d6-DMSO: 1H δ 2.50 
ppm, 13C δ 39.5 ppm; CD3NO2: 1H δ 4.33, 13C δ 57.3, d7-DMF: 1H δ 8.03, 2.92 & 2.75, 
13C δ 163.2, 34.9 & 29.8). Coupling constants (J) are reported in Hertz (Hz). Standard 
abbreviations indicating multiplicity were used as follows: m = multiplet, sex = 
sextet, quin = quintet, q = quartet, t = triplet, dt = double triplet, d = doublet, dd = 
double doublet, s = singlet, dtd = double triple doublet, ddd = double double 
doublet, dq = double quartet. Microanalyses were conducted at the Campbell 
Microanalytical Laboratory at the University of Otago. High resolution 
electrospray ionisation mass spectra (HR ESI-MS) were collected on either a Bruker 
microTOF-Q spectrometer or a Shimadzu LCMS-9030 spectrometer. UV-visible 
absorption spectra were acquired with a Perkin Elmer Lambda-950 
spectrophotometer.   
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Element colour scheme  
Unless otherwise stated, the elements present in solid state X-ray structures, DFT 

















































Zinc (grey blue) 
    
 
In the main body of the thesis, the X-ray structures and optimised models are 
presented in a variety of styles. The asymmetric units of reported X-ray structures 
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 Metallosupramolecular chemistry 
1.1.1 Self-assembly 
The phenomenon that is self-assembly describes the ability of a system to 
organise itself into the energetically favourable thermodynamic product. Ideally 
this would be quantitative, however kinetic traps lie along the reaction 
pathway. In the quest to avoid these traps, chemists have had to use materials 
with self-corrective capabilities to access the favourable products. Self-
correction is imbued into the system through the use of reversible interactions 
that are weaker than covalent bonds, such as π-bonding, dipole and/or ion 
interactions, hydrogen or anion bonding or metal-ligand interactions. While 
hydrogen bonding interactions are prevalent, and in many cases a structural 
necessity in natural systems, metal ions can provide more predictable 
interactions. For instance, one can easily imagine how an octahedral metal 
centre can dictate the geometry of a coordination complex, however if the same 
geometric product was to be produced through hydrogen bonding interactions, 
further thought must be put into the design of the components. Metal-ligand 
bonds can also add interesting features and properties into a system that other 
types of non-covalent interactions simply cannot. Electrochemical properties 
from redox-active metal centres can generate architectures ripe for use as 
molecular wires1 and hydrogen production,2 and light-emitting and -absorbing 
materials containing metal-ligand interactions can be easily tuned through 
alteration of the ligand and/or metal ion.3, 4 Metal ions are less common in the 
biological world hence metal ion-based architectures can possess interesting or 
novel biomedical properties.5  
The pioneering studies by Makoto Fujita in the early 1990’s laid the foundations 
for metal ion-based self-assembly, in which many chemists have found their 
niche. The original “Fujita square”6 (Figure 1.1) comprises four 4,4’-bipyridine 
(bpy) ligands which bridge four ethylenediamine (en) cis-capped palladium(II) 
ions. The thermodynamic product, the square, is formed preferentially over the 
kinetically favoured oligomeric chain and the smaller, entropically favoured, 





Figure 1.1: Formation of the thermodynamic product, the "Fujita square" (X-ray structure) from cis-
capped palladium(II) nitrate and 4,4'-bipyridine.7 The [4 + 4] oligomer (MMFF model) is entropically 
disfavoured and the [3 + 3] triangle (MMFF model) is enthalpically disfavoured. Hydrogen atoms, 
solvent molecules and counterions have been omitted for clarity. 
It is clear that the generation of metallosupramolecular architectures is 
governed by the coordination sphere of the metal ion and the geometry of the 
ligand. As is the case with the “Fujita square”, the favoured product is 
determined by contributions from enthalpy and entropy. These notions drive 
the formation of the smallest possible cyclic architecture that does not contain 
disfavoured strain in the bonds. Due to the innumerable ligand and metal-ion 
combinations, and the myriad possible resulting architectures, differing 
techniques have been established to utilise self-assembly in forming desirable 
products. 
1.1.2 Ligand directed approach  
As is displayed in Figure 1.1, the 4,4’-bipyridine ligand has antiparallel bonding 
directionalities, and the palladium metal is cis-capped with ethylenediamine. 
This is the basis of the ligand directed approach. The metal must have some of 
the coordination sites blocked off otherwise control over the final assembly will 
be lost. Ethylenediamine is a common cis-capping unit for square planar metals, 
as are bis-phosphines and 2,2’-bipyridine units. For octahedral metals, bis-2,2’-
bipyridines and arenes are mostly used to imbue order into the many systems 
that can be achieved through this method (Figure 1.2). Squares, rectangles, 





Figure 1.2: The ligand-directed approach; selected examples of a) ligands with antiparallel bonding 
directionalities, b) metals with blocked coordination sites and c) X-ray structures8, 9 of assemblies 
accessible with this approach ([Pd6(L)4]12+ octahedron,8 [Ru6(L2)(L’3)]6+ trigonal prism9). Hydrogen 
atoms, solvent molecules and counterions have been omitted for clarity. 
1.1.3 Symmetry interaction approach 
The symmetry interaction approach is in direct juxtaposition with the ligand-
directed approach, as the metal ions have no capping units, and therefore no 
directionality. To have order in these systems, the ligands must have roughly 
parallel bonding directionalities. Metal ions may have ancillary ligands such as 
anions or solvent molecules, and the structurally integral ligands may be mono- 
or poly-dentate. Various combinations of “naked” metal ions and ligands with 
parallel bonding motifs can lead to a huge range of structures including 
macrocycles, [M2L4]n+ cage-like architectures, octahedra, tetrahedra, grids and 




interaction approach is the report by McMorran and Steel describing the 
generation of the first coordinatively saturated [Pd2(L)4]4+ cage-type 
architecture (Figure 1.3c middle).10 Using solvated palladium(II) ions and bis-
pyridine based ligands, the quadruply-stranded helicate was synthesised 
through self-assembly in acetonitrile. The flexibility of the ligand allowed the 
cage to “breathe” and thus accommodate a range of anionic guests.11 
 
Figure 1.3: The symmetry interaction approach; selected examples of a) ligands displaying parallel 
binding modes; b) “naked” metal ions displaying anti-parallel coordination modes; c) X-ray structures 
of assemblies formed from monodentate ligands ([Ag2(L)2]2+ macrocycle,12 [Pd2(L)4]4+ cage,13 [Pd6(L)8]12+ 
octahedron14) and d) X-ray structures of assemblies formed from polydentate ligands ([Fe2(L)3]4+ 
mesocate,15 [Cu6(L)6 grid]6+,16 [Fe4(L)6]8+ tetrahedron17). Hydrogen atoms, solvent molecules and 





1.1.4 Weak link approach 
The weak link approach combines the symmetry interaction approach with 
hemilabile donor atoms in a third method of avoiding kinetic traps to generate 
metallosupramolecular architectures. Mirkin and co-workers developed this 
approach using the system shown in Figure 1.4,18 in which the bis-bidentate 
ligand, comprised of strong (phosphine) and weak (ether oxygen) donor atoms, 
complexes to rhodium(I) in a square planar arrangement. This produces a 
“closed” macrocycle to which a stronger ligand is then introduced. The 1,4-
phenylenediisocyanide ligand displaces the weaker oxygen donors to form the 
“open” macrocycle with a bound guest; the fourth coordination site is occupied 
by acetonitrile solvent molecules. Other stronger monodentate ligands such as 
chloride or carbon monoxide also produce the open macrocycle.19, 20 
Furthermore, using tris-bidentate flexible ligands, as opposed to bis-bidentate 
ligands, provides an analogous trinuclear structure.21 
 
Figure 1.4: The 'weak-link' approach; a bis-bidentate ligand with phosphorus and oxygen donors is 
complexed to rhodium(I) to form a [2 + 2] 'closed' macrocycle. Addition of a bis-monodentate ligand, 
1,4-phenylenediisocyanide, followed by CH3CN displaces the weak oxygen donors to form the ‘open’ 
macrocycle with a guest, of which the X-ray structure is shown. Hydrogen atoms, solvent molecules and 





 Host-guest chemistry 
Many supramolecular systems possess internal cavities due their inherent cyclic 
geometries. The structures most prevalent in the literature have cavities of 
generally well-defined shape and have distinct chemical properties, however 
they lack the specificity towards substrate guest molecules observed in 
enzymes. Weak, non-covalent interactions govern the nature in which hosts and 
guests interact. These can be hydrogen bonds (classical or non-classical), π-π 
interactions or van der Waals forces. Being able to tune the strength of these 
interactions, and the geometric properties of a cavity, can lead to enhanced 
interactions, and thus a step closer to the vastly more complex systems found in 
the natural world. As chemists try to mimic molecular architectures derived by 
Nature, many potential applications for host-guest systems have inevitably 
emerged. 
1.2.1 Molecular reaction vessels 
Natural enzymes use supramolecular interactions to bind substrates in order to 
catalyse specific reactions. Stereoselectivity is high, and due to minimal product 
inhibition, turnover frequencies are also high. For more than 100 years, scientists 
have desired to create artificial enzymes capable of mimicking the activity of 
those found in Nature.22, 23 However only in the last two decades have chemists 
attempted this feat using metallosupramolecular systems.24  
The Fujita group have generated a closed octahedral cage system8 and an open 
bowl-shaped structure using cis-capped Pd(II) units as the vertices.25 Within the 
bowl-shaped architecture, they were able to perform a [2+2] photodimerisation 
of naphthoquinone which produced only the syn-dimer in >98% yield  
(Figure 1.5a). In the absence of the host, the reaction produced more of the anti-
dimer (21% yield) than the syn-dimer (2% yield). In the octahedral coordination 
host, the photodimerisation of acenaphthylene again produced the syn-dimer in 
high yield (>98%) (Figure 1.5b). The “uncatalysed” reaction proceeded in an 
indiscriminate manner, yielding 17% of the anti-dimer and 19% of the syn-
dimer. The supramolecular forces which facilitate the host-guest interactions are 
strong enough to overcome the steric crowding of having two guests inside one 
host. The two guest molecules are then obliged to form the form the syn-dimer, 
whereas in the absence of the host, the guests are free of constraints and hence 






Figure 1.5: a) X-ray structure of [syn(dimerised-naphthoquinone)Pd6(en)6(2,4,6-tris-3-(pyridinyl)-1,3,5-
triazine)4]12+,25 and b) the reaction scheme of the photodimerisation of acenaphthylene: in the absence 
of the cage, a low-yielding mixture between the syn- and anti-configurations is formed; the syn-isomer 
is formed in high yield in the presence of the octahedral cage. Guest molecule shown in space-filling 
style, hydrogen atoms, solvent molecules and counterions have been omitted for clarity. 
Ward and co-workers have demonstrated their ability to catalyse the Kemp 
elimination reaction through the use of an octanuclear cobalt(II) cube.26 The 
substrate binds relatively strongly in the cavity (Ka = 4000 M-1) and in the 
presence of the correct amount of hydroxide (the authors established the 
catalysis is pH dependent), kcat/kuncat reaches 106. Ward and co-workers suggest 
that high catalytic activity is based on the orthogonal interactions between the 
bound guest and the aqueous base. Ion-pairing effects result in the 
accumulation of hydroxide around the periphery of the cage, creating a high 
local concentration of base, as well as partially desolvating the base rendering it 
more reactive. The reaction centre of the guest is thereby always in close 
proximity to the base, regardless of its orientation inside the cavity. The 
negatively charged product of the reaction favours a more polar environment, 
exiting the cage and leaving the cavity vacant for another substrate molecule. 
High turnover numbers were achieved through this mechanism. As a 
continuation of this study, the Ward group were able to succeed in creating an 
autocatalyst,27 whereby the negatively charged, basic product assumes the role 
of the hydroxide in the primary study. By altering the amount of chloride 
present in solution they were able to control the rate at which the catalytic 
reaction proceeds. More chloride slows down the reaction, while less chloride 
increases the rate. The reaction progress profiles display sigmoidal behaviour 
regardless of chloride concentration as the production of 2-cyanophenolate 
increases the reaction rate due to the product being more easily desolvated than 





Figure 1.6: X-ray structure of [benzisoxazole[Co8(2,2'-[1,5-naphthalenediylbis(methylene-1H-
pyrazole-1,3-diyl)]bis-4-pyridinemethanol)12]16+,26 and the Kemp elimination reaction producing 2-
cyanophenolate. Guest shown in space-filling style, methylene alcohol groups (for host), hydrogen 
atoms, solvent molecules and counterions have been omitted for clarity. 
Acceleration of the Diels-Alder cycloaddition reaction28 has been well 
documented in the literature,29-31 and several studies on natural intramolecular 
Diels-Alderases have been reported,32 however encapsulating the starting 
material(s) inside synthetic metallosupramolecular architectures has not been 
extensively studied. Early exploits in this direction revealed a distinct lack of 
catalytic turnover due to product inhibition, hence the avoidance of using 
metallosupramolecular systems to catalyse ring-forming reactions. In spite of 
this, Lusby and co-workers have recently developed an elegant system  
(Figure 1.7), exhibiting enzyme-like characteristics. High catalytic activity and 
efficient turnover are defined by multiple hydrogen-bonding interactions, 
which can modulate the reactivity. The [Pd2(L1)4]4+ cage (C1), first produced by 
Crowley and co-workers,33 features inwardly pointing acidic protons at the top 
and bottom of the cavity, perfect for hydrogen bonding to small molecules with 
dicarbonyl functionality. The use of the large anion tetrakis[3,5-
bis(trifluoromethyl)phenyl]borate (BArF) and relatively non-polar organic 
solvents such as dichloromethane (DCM) leave the cavity vacant for guest 
molecules. The rationale for the high catalytic activity is given by a stabilised 
transition state and a weaker binding affinity for the product. The lone-pair of 
electrons on the central pyridine units stabilise the transition state with 
favourable N---H(C) interactions, while the larger and non-planar products 





Figure 1.7: MMFF model of [p-benzoquinonePd2(2,6-bis-3-(pyridinylethynyl)pyridine)4]4+,34 and the 
intermolecular [4+2] Diels-Alder cycloaddition reaction between p-benzoquinone and isoprene 
(orange/yellow). See Section 4.3.1 for more details. Guest shown in space-filling style, hydrogen atoms 
have been omitted for clarity. 
1.2.2 Encapsulation of pollutants and reactive species 
Environmental pollutants are another target for chemists to consider as guests. 
Small organic and inorganic molecules can be taken up and contained within 
host systems with ease and efficiency.35 For example, Maverick and co-workers 
have shown that a [Cu2(L)2]2+ macrocycle has the ability to uptake carbon 
dioxide (CO2) from the atmosphere and chemically transform it into oxalic acid 
(Figure 1.8).36 When exposed to normal air, the macrocycle will selectively bind 
two molecules of CO2. The Cu(I) centres then act as reductants, reducing the 
CO2 to oxalate, themselves becoming oxidised to Cu(II) in the process. Addition 
of HCl or HNO3 to the oxalate-bridged Cu(II) dimer resulted in protonation of 
oxalate to oxalic acid and the regeneration of the empty macrocycle, still in the 
Cu(II) state. Reduction with ascorbate reformed the original free Cu(I) dinuclear 
macrocycle. This is a special case as the authors were able to selectively 
encapsulate an environmental pollutant and then catalytically convert it into a 





Figure 1.8: X-ray structures of [Cu2(bis-(2-pyridyl-1,2,3-triazole)-1,3-phenylmethylene)2]n+ as a) the Cu(I) 
empty macrocycle; b) uptake and reduction of two CO2 molecules results in the formation of the 
bridging oxalate dianion; and c) protonation of the bridged system ejects oxalic acid and generates an 
empty Cu(II) macrocycle which is then chemically reduced using ascorbate to the starting Cu(I) 
macrocycle.36 Hydrogen atoms, solvent molecules and counterions have been omitted for clarity. 
Some environmental pollutants such as polyaromatic hydrocarbons (PAHs) are 
rigid, planar and have large π-surface areas. Thoughtful design of host 
molecules can lead to high binding affinities of PAHs, and thus quarantine the 
pollutant. One such family of architectures from Peinador and co-workers, 
comprises rectangular macrocycles synthesised through the ligand directed 
approach, with two cis-capped Pd(II) or Pt(II) corners. Bipyridinium or 
diazapyrinium units situated on the long edge provide aromatic π-π 
interactions in addition to the electrostatic interactions imparted by their 
cationic nature (Figure 1.9a). Coupled with the hydrophobic effect, this 
combination of interactions produces association constants in the order of  
Ka = 106 M-1 (or Ka = 107 M-2 for 1:2 host-guest complexes) in aqueous 
environments.37-39  
Three-dimensional environmental pollutants require different host structures. 
An iron(II) tetrahedron (Figure 1.9b) reported by Nitschke and co-workers has 
the ability to sequester SF6,40 a greenhouse gas roughly 24 times more potent 
than CO2. The strength of the host-guest interaction is reported as Ka = 104 M-1 
and further studies revealed that the host has no affinity for other gases such as 
CO2, N2O or C2H4. The presence of the host increased the aqueous solubility of 
SF6 30-fold, and finally the authors were able to controllably release the guest 
through chemical (disassembly of the host) or physical (increased temperatures 





Figure 1.9: X-ray structures of a) [pyrenePt2(en)2(2-[4-(4-pyridinylmethyl)phenyl]-benzo[lmn][3,8]
phenanthrolinium)2]6+,37 and b) [SF6Fe4(4,4'-bis((E)-(2-pyridinylmethylene)amino)-[1,1'-biphenyl]-
2,2'-di-sulfonate)6]5+.40 Guests shown in space-filling style, sulfonate groups (for b), hydrogen atoms, 
counterions and solvent molecules have been omitted for clarity. 
The same tetrahedral cage has been employed for the encapsulation of highly 
reactive white phosphorus,41 rendering P4 air-stable and water-soluble.17 
Exposing an aqueous solution of the host to solid P4 resulted in the formation of 
the host-guest complex (Figure 1.10a). The authors reported that NMR spectra 
of the host-guest system remained unchanged over 4 months after continuous 
contact with the atmosphere. The suggested rationale for this stability is while 
diatomic oxygen can effectively access the phosphorus, the intermediate formed 
upon reaction of P4 and O2 would be too large for the cavity of the tetrahedron. 
The safe removal of P4 from the cage was also studied. Benzene was layered on 
top of an aqueous solution of the host-guest complex. In a far greater 
concentration, dissolved aqueous benzene displaced the P4. The biphasic 
mixture, with P4 now dissolved in benzene, was left open to the atmosphere. No 
longer constrained by the confines of the cage, P4 regained its reactivity and was 
converted to relatively safe and easy-to-handle aqueous H3PO4.  
The containment of radical initiators within metallosupramolecular 
architectures has also been explored. Yoshizawa and co-workers have studied 
how their [Pd2(L)4]4+ cage encapsulates 2,2’-azobisisobutyronitrile (AIBN) 
(Figure 1.10b), 2,2’-azobis(2-methylbutyronitrile) (AMBN) and 2,2’-azobis(4-
methoxy-2,4-dimethylvaleronitrile) (AMMVN).42 These initiators proceed 
through the release of dinitrogen by photo or thermal stimuli, thus it is 
necessary for AIBN and the related initiators to be stored in the dark and low 





Figure 1.10: X-ray structures of a) [P4Fe4(4,4'-bis((E)-(2-pyridinylmethylene)amino)-[1,1'-biphenyl]-
2,2'-di-sulfonate)6]5+,17 and b) [2,2’-azobisisobutyronitrilePd2((3,3'-((4,5,6-tris(2-methoxyethoxy)-1,3-
phenylene)bis-9,10-(anthracenediyl))dipyridine)4]4+.42 Guests shown in space-filling style, sulfonate 
groups (for a), methoxyethoxy groups (for b) hydrogen atoms, counterions and solvent molecules have 
been omitted for clarity. 
The enclathration of the initiators was achieved through suspension of the guest 
molecules in a 9:1 D2O/CH3CN solution, resulting in significantly increased 
photo and thermal stability: the presence of UV light did not activate the guest 
and furthermore the initiators remained stable for several weeks at room 
temperature and for over 10 hours at 50 °C. In spite of being encapsulated by 
the cage, the initiators were still able to perform radical polymerisation 
reactions. An aqueous solution of the host-guest complex was introduced to a 
solution of methyl methacrylate in toluene. The authors witnessed the 
spontaneous release of the initiator from the host, and upon the introduction of 
a thermal or photo stimulus, the polymerisation reaction was observed to 
proceed.  
1.2.3 Encapsulation of drug molecules 
As with other types of guests, small drug molecules present chemists with an 
interesting challenge: to create a storage and/or delivery vector to increase 
potency and minimise side effects of existing drugs. A lot of focus has been on 
anticancer drugs and drug delivery in attempt to reduce harmful side effects 
and/or increase drug efficacy. There are two ways in which tumour cells can be 
targeted: passively and actively. Compounds exhibiting active targeting possess 
functional groups which have a naturally higher affinity for tumour tissue over 
normal cells due to overexpression of receptors on the surfaces of tumour cells, 
from disorders to normal regulatory and metabolic pathways. Appending 
sugars to peptides,43 or grafting vitamins to the surface of nanoparticles44 have 




On the other hand, passive targeting takes advantages of the differences in the 
topology of normal and cancerous tissues. The enhanced permeability and 
retention (EPR) effect (Figure 1.11) is exploited as macromolecules are able to 
pass through large endothelial vacancies, a result of rapid tumour cell 
reproduction. In most cases, the drugs themselves are typically small enough to 
pass through the endothelium of healthy cells, leading to harmful side effects, 
however if a drug delivery vector is large enough (5 – 40 kDa) it should be able 
to selectively transport an encapsulated drug only to tumour cells. Another 
consequence of the “mis-managed” reproduction is the loss of normal 
lymphatic drainage. Thus once a drug delivery vector is inside a tumour, it will 
be retained for longer and hence there will be ample time to release the drug 
through a variety of methods.45  
 
Figure 1.11: The EPR effect. 
One of the biggest challenges to consider when designing a metallosupra-
molecular drug delivery vector is its robustness towards nucleophiles. The 
bloodstream not only contains red and white blood cells, but also plasma which 
facilitates the transport of hormones and nutrients, among other vital chemicals 
around the body. The majority of molecules found in blood are able to act as 
nucleophiles and therefore have the potential to coordinate to metal ions. Thus, 
a metal-containing drug delivery vector must be stable enough towards 




reached its destination to minimise harmful side effects. However, a successful 
delivery vehicle must be able to release its cargo when required. This can be 
achieved through a number of ways,45 examples of which include partial or 
complete disassembly of the host (Figure 1.12), which can be accomplished by 
nucleophiles. Kinetic robustness towards nucleophiles is therefore an important 
characteristic of a metallosupramolecular drug delivery vehicle. 
 
Figure 1.12: Cartoon representation of nucleophilic degradation of metallosupramolecular architectures 
resulting in either partial ligand displacement (top) or full ligand displacement (bottom).  
As an example of passive targeting, Therrien and co-workers have shown that 
a hexanuclear ruthenium(II) cage can encapsulate square planar metal 
complexes: [M(acac)2]2+ (M = Pd(II) or Pt(II), acac = acetylacetonato,  
Figure 1.13).9 The well-recognised antineoplastic properties of platinum(II) 
compounds,46 and the strong anticancer potential of ruthenium,47, 48 encouraged 
the authors to examine the cytotoxicity of their system against A2780 human 
ovarian cancer cells. Their findings showed that both the free platinum(II) and 
palladium(II) guests were inactive, however the empty host displayed moderate 
cytotoxicity. Fortunately, the host-guest complexes exhibited increased activity: 
the platinum(II)-containing species was roughly twice as active as the free host 
and the palladium(II)-containing species was more than an order of magnitude 
more cytotoxic than the empty cage (IC50 = 1 µM vs. 23 µM, 72 h treatment). The 
authors suggest that the palladium(II) guest can be more readily ejected from 
the cage than its platinum(II) counterpart. They also propose a mechanism of 
action: the cage is assimilated into the cancerous tissue, releases its hidden 






Figure 1.13: X-ray structure of [Pt(acetylacetonato)2Ru6(iPrC6H4Me)6(2,4,6-tris(pyridin-4-yl)-1,3,5-
triazine)2(2,5-dihydroxy-1,4-benzo-quinonato)3]6+,9 guest shown in space-filling style, hydrogen atoms, 
counterions and solvent molecules have been omitted for clarity. 
The Crowley group have also devised metallosupramolecular systems capable 
of binding platinum(II) based anticancer drugs. Cis-diamminedichloro-
platinum(II) (Cisplatin, CDDP) has long been recognised as a class-leading 
anticancer drug since the first report in 1969,46 however the dose is limited due 
to unwanted side effects such as nephro- and neurotoxicity. By encapsulating it 
in a palladium(II) coordination cage, Crowley and co-workers aimed to increase 
selectivity and reduce harmful side effects. A [Pd2(L1)4]4+ (L1 = 2,6-bis(3-
ethynylpyridinyl)pyridine)12 lantern-shaped capsule was shown to be able to 
encapsulate two molecules of CDDP (Figure 1.14a).33 The hydrogen bonding 
network which lines the internal cavity of the cage enables binding of the guest 
(albeit weakly) in polar organic solvents such as acetonitrile and 
dimethylformamide (DMF), however when placed in dimethylsulfoxide 
(DMSO) or aqueous environments, the vast excess of DMSO or water 
outcompetes the hydrogen bonding sites of the cavity and displaces the CDDP 
guest molecules, thus invalidating the original hypothesis. Despite being unable 
to deliver the desired drug, the authors still examined the cytotoxic properties 
of the ligand and cage against MDA-MB231 breast cancer, A549 lung cancer cell 
lines and a non-malignant control (MCF-10A breast tissue). Results showed that 
the ligand was inactive, and the palladium(II) cage displayed modest activity  
(IC50 = 40 – 70 M, 24 h treatment). A subsequent study described appending 
functionality to the central core pyridine through the copper(I) catalysed azide 
alkyne cycloaddition (CuAAC) “click” reaction.49 The intention was to examine 
if targeting groups or fluorophores could be attached to the cage to increase its 
efficacy. The authors were able to substitute a range of functional groups, whilst 




were not carried out. Further investigations aimed to increase lipophilicity and 
stability of the cage by changing the ligand to a hexyl-substituted triazole based 
system (Figure 1.14b).50 While the cavity was much smaller, and therefore 
unable to bind CDDP, the authors we able to show that the ligand and the 
corresponding [Pd2(L)4]4+ architecture were significantly more cytotoxic  
(IC50 = 18 – 90 M for the ligand and IC50 = 6 – 8 M for the cage, 24 h treatment). 
The rationale for the increased activity was based on the hexyl chains providing 
steric protection for the exo-face of the Pd(II) centres in addition to increasing 
hydrophobicity. 
 
Figure 1.14: a) X-ray structure of [(CDDP)2Pd2(2,6-bis(3-ethynylpyridinyl)pyridine)4]4+,33 and b) MMFF 
model of [Pd2(4,4'-(1,3-phenylene)bis[1-hexyl-1H-1,2,3-triazole)4]4+.50 Guests shown in space-fill style,  
hexyl chains (for b) have been truncated, hydrogen atoms not involved with guest binding interactions, 
solvent molecules and counterions have been omitted for clarity. 
Spurred on by the promise of the improved system, Crowley and co-workers 
began modifying the original tripyridyl cage to enhance anticancer activity. To 
increase aqueous solubility, polyethylene glycol (PEG) chains were appended 
to the 3-position of the peripheral pyridine rings of the system (L6 = (2,6-bis((5-
(2-(2-methoxyethoxy)ethoxy)pyridin-3-yl)ethynyl)-pyridine), Figure 1.15).51 
The exo-functionalised cage demonstrated its CDDP binding abilities in CH3CN 
were unperturbed. Upon addition of four equivalents of chloride (as a proxy for 
biological nucleophiles) the cage was shown to undergo a transformation to a 
[Pd2(L6)2Cl4] neutral macrocycle. Adding excess chloride to the cage was then 
shown to cause complete disassembly. The authors were also able to reversibly 
capture and release endo- and exo-hedrally bound guests. Re-uptake of the guest 
was achieved through addition of silver(I) ions to coordinate the chloride and 
thus reform the lantern-shaped cage (Figure 1.15). While this was a novel 
method of switching between two metallosupramolecular systems, the issue of 
stability and steric protection of CDDP in aqueous environments remained. 




provided interesting insight into the stability issue.52 With the amines in the 3-
position (L-3A), there was minimal improvement in the half-lives of the cages 
in the presence of a common biological nucleophile such as histidine (t1/2 = 18 
minutes for C1 vs. t1/2 = 25 minutes for the L-3A system), however with the 
amines in the 2-position (L-2A, Figure 1.16a), kinetic stability was vastly 
superior (t1/2 = 46 hours) due to the steric protection of the palladium(II) centre 
by the amino groups, and the more electron rich donor moiety. 
 
Figure 1.15: X-ray structures of a) [guestC6]4+, and b) [Pd2(L6)2Cl2] + guest, PEG chains have been 
truncated, hydrogen atoms, solvent molecules and counterions have been omitted for clarity. 
The functionality in the 3-position once again had no effect on the ability of the 
cage to host CDDP in DMF, on the other hand the binding event was no longer 
apparent when the 2-amino cage was used as the host. This was rationalised by 
the twisting of the cavity induced by the orientation of the 2-amino substituents 
around the exo-faces of the palladium(II) centres (Figure 1.16b). The twisting 
altered the hydrogen bonding network of the cage cavity (specifically the 
internally directed protons ortho- to the coordinating nitrogen atoms) disabling 
the necessary spatial interactions required for CDDP binding inside the cage 
cavity. Other studies by Crowley and co-workers, aiming to increase the 
encapsulation properties of the cage by exchanging the alkyne linkers for aryl 
linkers, described how these steric and electronic changes can lead to no 
observable CDDP binding.53 Thus subtle differences in the cage structure were 
enough to completely turn off the weak host-guest interactions of CDDP and 





Figure 1.16: X-ray structure of C-2A, a) as side-view; and b) as top-down view exhibiting the hydrogen 
bonding interactions between the 2-amino functional groups of the ligands; non-amino hydrogen 
atoms, solvent molecules and counterions have been omitted for clarity. 
A remarkable feature of the amino functionalised ligands was their ability to 
replace less electron-rich ligands from preformed [Pd2(L)4]4+ cages, thus 
enabling the production of unique heteroleptic cage systems.54 Upon addition 
of four equivalents of L-3A to C1, the homoleptic C-3A cage was generated, 
however adding four equivalents of L-2A to the parent system did not create 
the homoleptic cage C-2A. Instead, the authors observed the formation of a 
heteroleptic species: [Pd2(L1)2(L-2A)2]4+. Density functional theory (DFT) 
calculations suggested that the homoleptic species should have formed as the 
lowest energy structure, however addition of more L-2A did not result in its 
production. The authors reason that the heteroleptic cage is not the 
thermodynamic product of the displacement reaction, but a metastable kinetic 
intermediate. Through competition experiments with L6, it was proved that the 
ligands were in a cis arrangement, with the amino groups exhibiting similar 
hydrogen bonding interactions as shown in Figure 1.16b. 
“The whole is greater than the sum of its parts” – Aristotle  
Different research groups have examined the effect of using anthracene panels 
to link ligands,55, 56 while others studied how exo-functionalised systems behave 
within biological systems.57-59 Currently the best reported anticancer activity 
exhibited by a [Pd2(L)4]4+ cage (Figure 1.17) is IC50 = 1.1 M (72 h treatment).56 
The anthracene-linked system by Yoshizawa and co-workers surpasses the 
activity of CDDP against HL-60/Dox (doxorubicin-resistant human acute 
myelocyte leukaemia) by over 5-times (see section 2.2.2 for more details). 
Interestingly, when two caffeine molecules were bound within the cage, the 
cytotoxicity increased to IC50 = 0.7 M against HL-60. As a “free” guest 
molecule, caffeine has no observable cytotoxic activity. Akin to the study by 
Therrien and co-workers, the Yoshizawa group has shown how a host-guest 





Figure 1.17: X-ray structure of [Pd2(3,3'-[[4,5,6-tris(2-methoxyethoxy)-1,3-phenylene]di-10,9-
anthracenediyl]bis[pyridine])4]4+, hydrogen atoms, solvent molecules and counterions have been 





 Project aims 
The capacity for [Pd2(L)4]4+ metallosupramolecular architectures to act as hosts 
for a variety of small organic and inorganic guests has been well studied. 
However, there is still potential for these systems to be improved. The feasibility 
of cage systems as drug delivery vectors remains an area for development. 
Building upon previous work in the Crowley group, the enhancement in the 
kinetic stability of [Pd2(L)4]4+ cage molecules, through steric changes in the 
ligand, has been studied as the first part of this project.  
Few palladium(II) cages have included redox active sub-components into the 
core structure of the system, thus the second section of the project aims to 
discuss how the inclusion of ferrocene units affects not only the formation of the 
desired cage, but also the host-guest chemistry and redox nature of the ferrocene 
itself.  
The final part of this project targets the use of cages as catalytic reaction vessels. 
It also examines how changing the electronic and structural properties of cages 
impacts the host-guest interactions and the rate at which the cage catalyses 
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 Cancer and platins 
As the leading cause of death in the economically developed world, there are 
huge motives for discovering methods to treat cancer.60 Cancer is not just one 
disease; it is a collection of diseases, thereby making it much harder to treat. 
These diseases are generally caused by mutations in DNA, leading to increased 
rates of cell division and inhibition of apoptotic pathways: the standard 
regulation of cell death. This in turn leads to the formation of tumours which 
impede the normal functions of the affected organs. If left untreated, tumours 
can cause severe pain, suffering and eventually death. 
Although the vast majority of the drugs commonly used to treat cancerous 
neoplasms are wholly organic,61 roughly half of all patients receiving 
chemotherapeutic treatment are given a platinum-based drug.62 The use of 
platinum to treat cancer arose from Barnett Rosenberg’s somewhat 
serendipitous discovery of the antineoplastic properties of cis-
diamminedichloroplatinum(II) (Cisplatin, CDDP, Figure 2.1a) in the 1960’s.46 
While CDDP was shown to be effective at inhibiting the growth of cancerous 
tissue, the presence of several severe side effects and other shortcomings could 
not be overlooked. Nevertheless, the success of CDDP inspired inorganic 
chemists to develop more platinum complexes with various ligands and with 
different oxidation states (Pt(II) and Pt(IV) prodrugs).63 The result of testing 
these new platinum compounds for their antineoplastic effects was a structure-
activity relationship (SAR) which stipulated that a platinum complex had to 
have square-planar geometry, contain two cis-amine ligands, possess two cis-
anionic ligands and be charge neutral.64 The amine ligands or the anionic 
ligands could be substituted by chelating diamines or dicarboxylate ligands, 
respectively. Furthermore, it was important that the anionic ligands were not 
coordinated too weakly, else exorbitantly high toxicity levels were observed, or 
too strongly, otherwise activity would be significantly lessened.  
From this set of rules came widespread drug development programs focussed 
on methodical ligand variation. Two new platinum(II) drugs were born out of 
these programs: carboplatin (Figure 2.1b) and oxaliplatin (Figure 2.1c), both 
receiving approval from the US Food and Drug Administration (FDA) to be 





Figure 2.1: Tube representations of neutral platinum(II) based anticancer agents: a) CDDP, b) 
carboplatin and c) oxaliplatin. 
All three platins shown in Figure 2.1 are postulated to have similar modes of 
action (Figure 2.2): entering the cell through passive diffusion (Figure 2.2b) or 
active transport via the copper transporters (Figure 2.2c), before entering the 
nucleus (Figure 2.2e) and coordinating predominantly to the most basic and 
nucleophilic site in DNA: the N7 position of guanine residues.66 CDDP differs 
slightly from the other two as the chloride ligands are substituted for water 
molecules once inside the cell due to the extra/intracellular difference in 
chloride concentration (Figure 2.2a and d respectively).67 The chelating 
dicarboxylate of carboplatin and oxaliplatin undergoes exchange to the diaqua 
species much more slowly than the chloride ligand of CDDP. Once activated, 
the platinum centre binds to adjacent guanine residues to create cross-linking 
(Figure 2.2).68 Alternatively, guanine residues of different DNA strands can be 
brought together by coordinating to platinum, creating interstrand cross-links. 
Intrastrand and interstrand cross-links can cause significant buckling in the 
DNA double helix, leading to disrupted DNA reproduction and ultimately 
resulting in premature apoptosis.63 
While CDDP is very effective at curing cancers, specifically testicular cancer (for 
which cure rates have exceeded 95%),69 it also damages normal cells as there is 
no real driving force for CDDP to be specific to only neoplastic tissue. This 
results in dose-limiting side effects such as nephrotoxicity and neurotoxicity, 
along with a wider range of more minor side effects. The improvement of 
cytotoxic agents is hence a necessary endeavour, one which many research 





Figure 2.2:  CDDP mechanism of action: a) extracellular equilibrium between neutral dichloride and 
dicationic diaqua species; b) entry into the cell through the bilayer as the neutral dichloride species; c) 
entry into the cell through the copper transport system as the dicationic diaqua species; d) intracellular 
equilibrium between neutral dichloride and dicationic diaqua species; and e) entry into the nucleus as 
the electrophilic, dicationic species and interaction with DNA (X-ray structure of an intrastrand adduct 





 Cytotoxic metallosupramolecular architectures  
Inspired  by the success of CDDP and other metallodrugs70 there is emerging 
interest in exploiting metallosupramolecular architectures for anticancer  
activity.5, 71-73 While many metal-containing complexes are toxic, the vast 
majority lack the specificity required to be effective anticancer agents.74-77 
Several research groups have attempted to address this through examining how 
metallosupramolecular architectures are able to bind DNA78-81 and RNA,82, 83 
and interact with proteins,84, 85 again with specificity for neoplastic tissue as a 
primary focus.  
In 1995, Jean-Marie Lehn described the interaction of a Cu(I) doubly-stranded 
helical architecture with a DNA duplex.81 Following this, Hannon and co-
workers have extensively studied how Fe(II) triply-stranded helicates recognise 
DNA. The main focus of the investigation was to design architectures with 
novel modes of DNA-binding interactions, and hence exhibit new types of 
activity in biological systems. In 1997, the Hannon group synthesised a pyridyl 
imine ligand through Schiff-base condensation chemistry, and complexed it to 
Ni(II) ions to yield ΔΔ (P) (Figure 2.3a) and ΛΛ (M) [Ni2(L)3]4+ helicates,86 and 
to Fe(II) ions some years later.87 The optical isomers were able to be separated 
by using chiral filter paper and subsequently both demonstrated the capacity to 
non-covalently recognise DNA (Figure 2.3b). This was confirmed through 1H 
NMR NOESY correlations,87 and later through X-ray crystallography.88  
 
Figure 2.3: X-ray structures of a) ΔΔ-[Ni2(L)3]4+,86 and b) ΛΛ-[Fe2(L)3]4+ in a three-way Y-junction of a 
DNA palindromic hexanucleotide: 5’-d-(CGTACG)-3’,88 hydrogen atoms, solvent molecules and 




While Hannon and co-workers were able to separate their optical isomers, Scott 
and co-workers devised an elegant system whereby the chirality of the ligand 
dictated the handedness of the metal complex (R leads to Δ and S leads to Λ), 
thereby eliminating the otherwise necessary and involved separation process.89 
The preliminary studies were conducted on mononuclear systems,89, 90 however 
the approach was later applied to the formation of optically pure, dinuclear 
[M2(L)3]4+ “flexicates”.91-93 These “flexicates” (Figure 2.4a) were shown to exhibit 
excellent antimicrobial activity against both Gram-negative and Gram-positive 
bacteria, and successive generations of “flexicates” (Figure 2.4b) displayed sub-
micromolar anticancer activity against human ovarian carcinoma (A2780cisR) 
cells,93 and human colon carcinoma (HCT116 p53++) cells.92 Mechanistic studies 
revealed unexpected results: the metallohelices bound very weakly to naked 
calf thymus DNA and did not significantly modify the generation of γ-H2AX (a 
histone widely deemed as a universal indicator for DNA damage).94 Instead, 
studies indicated that the Δ-helices caused accumulation and induced apoptosis 
in HCT116 p53++ cells. Interestingly, neither the Δ- nor Λ-helices showed any 
signs of toxicity towards Gram-positive or Gram-negative bacteria up to two 
orders of magnitude higher than the IC50 values against the cancerous cell lines. 
 
Figure 2.4: a) X-ray structure of ΔΔ-[Zn2(LR,R)3]4+,91 and b) MMFF model of ΔΔ-HHT-[Fe2(LR,R)3]4+,93 
hydrogen atoms, solvent molecules and counterions have been omitted for clarity. 
Another method of interest for anticancer researchers is using light-sensitive 
metal complexes for photodynamic therapy (PDT), a non-invasive medical 
procedure whereby a dormant drug is intravenously delivered directly into the 
cancerous tissue. A specific wavelength of light is then used to irradiate the 




cancer cells by reacting with organic material.95-97 Ruthenium(II) complexes are 
among the most studied systems for their photophysical,98 photochemical99 and 
photobiological100 properties with the majority of the reports focussing on 
[Ru(bpy)3]2+ (where bpy = 2,2’-bipyridine, Figure 2.5a) and its derivatives.101  
 
Figure 2.5: Chemical structures of a) [Ru(bpy)3]2+ and b) [Ru(bpy)2(dppz)]2+. 
Upon irradiation with 420 nm light, the excited 1MLCT state relaxes quickly to 
the lowest energy 3MLCT excited state, the lifetime of which is between 200 ns 
and 5 µs depending on solvation. Substituting one of the bpy ligands for a 
dipyridophenazine (dppz) ligand (as was first done by Barton and co-workers) 
results in fluorescence quenching in protic solvents due to two 3MLCT states of 
slightly different energy.102 Changes in the relative energies of these states with 
respect to environment leads to the unique property of acting as a molecular 
light bulb. When freely solvated in water, the luminescence is low, however 
when bound to DNA, the luminescence increases due to the change in solvation. 
[Ru(bpy)2(dppz)]2+ (Figure 2.5b) was still shown to be able to produce ROS and 
is therefore an early instance of the theranostic potential of polypyridyl Ru(II) 
complexes.103 
2.2.1 Cytotoxic palladium architectures 
While platinum(II)-based architectures are well known to be cytotoxic, the 
inherently inert nature of Pt(II) renders it challenging to use in the generation of 
multinuclear metallosupramolecular systems. Palladium(II) provides an 
interesting alternative in this regard due its self-corrective, labile nature. Similar 
to Pt(II), Pd(II) predominantly forms square planar metal complexes and is 
therefore also diamagnetic, enabling characterisation of Pd(II) complexes 
through NMR spectroscopies. The kinetic inertness of Pt(II) is due to the 
increased energy difference between the 𝑑𝑥𝑦 and 𝑑𝑥2−𝑦2 orbitals, thus more 
energy is required to populate the antibonding orbital. Pd(II) is a weaker-field 
ion, therefore smaller crystal field splitting is observed and hence there is a 




and the lowest unoccupied molecular orbital (LUMO). This makes the 𝑑𝑥2−𝑦2 
orbital more accessible to competing ligands, thus rendering Pd(II) more labile 
than Pt(II).  
 
Figure 2.6: Difference between 𝒅𝒙𝟐−𝒚𝟐  orbitals in d8 Pd(II) and Pt(II). 
Furthermore, Pd(II) is more cost-effective than Pt(II) and studies have shown 
that Pd(II) complexes possess lower toxicities and enhanced structure activity 
relationships.104 These considerations lead to the notion that Pd(II) derived 
anticancer agents should not take a back seat to Pt(II) compounds. As there are 
few Pd(II) complexes for which cytotoxicity has been established, it follows that 
even less mechanistic experiments have been undertaken, however one study 
has detailed how binuclear Pd(0) complexes of dibenzylideneacetone (DBA) act 
against melanoma.105 These complexes are unconventional in that the Pd(0) 
centres coordinate to the ligand through metal-π interactions with the alkene 
functional groups (Figure 2.7a). Interestingly, two freely-exchanging minor and 
major isomers exist at room temperature: the ligand exists predominantly as the 
trans, trans-structure while in the complex, the cis, trans-conformer is 
dominant.106 DFT calculations indicated that the trans-alkene binds more 
strongly to the Pd(0) centre than the cis alkene. The authors also observed the 
formation of a trans, trans-complex, though only as a minor species. The in vivo 
and in vitro toxicity testing of the major complex against human (A375) and 




triggered a 99% decrease of B16 cells and a 96% decrease of A375 cells.107 The 
ligand itself also showed signs of cytotoxicity by inhibiting cell growth and 
inducing apoptosis in human oral cancer cell lines (HSC-2 and HSC-4). Ensuing 
experiments found that the Pd(0) complex inhibits phosphorylated forms of 
certain kinases and hence several pathways necessary for melanoma growth. It 
was also discovered that the complex is well-tolerated in mice when compared 
to other clinical chemotherapies. It remains unproven as to whether the complex 
is an active drug or merely a delivery vehicle for the ligand, however the studies 
suggest that they possess differing modes of action. 
 
Figure 2.7: a) trans, trans-DBA and X-ray structure of [Pd2(cis, trans-DBA)3]105 and b) structure of 
palladacycle AJ-5,108 hydrogen atoms and solvent molecules have been omitted for clarity. 
In addition to the Pd(0) complex, a binuclear Pd(II) palladacycle (Figure 2.7b) 
known as AJ-5 has also been shown to be effective at treating melanoma at 
concentrations 50-times lower than CDDP,108 breast cancer stem cells and 
oestrogen receptor-positive (ERP) and oestrogen receptor-negative (ERN) 
breast cancer cells.109 In all these cell types, AJ-5 was shown to induce breakages 
in double-stranded DNA and inhibit protein kinase pathways which mediate 
apoptosis and autophagy. Promisingly, there were no side effects observed from 
testing AJ-5.104 
Padeliporfin (Figure 2.8), a Pd(II) drug derived from bacteriochlorophyll, has 
been found to be an effective PDT agent against melanoma.110  The negatively 
charged complex was found to exhibit 100% tumour flattening in mice at all 
doses (with the best results at 6 mg kg-1) after only 5 minutes of irradiation  





Figure 2.8: MMFF model of padeliporfin, hydrogen atoms have been omitted for clarity. 
2.2.2 Cytotoxic palladium(II) cages 
In Chapter 1, the formation of the first coordinatively saturated [Pd2(L)4]4+ cage 
from “naked” palladium(II) ions10 was discussed as an example of the 
symmetry interaction approach to access metallosupramolecular architectures. 
Building upon this concept, chemists have designed new ligands for specific 
cage functions. Loosely, a functional ligand requires three ingredients: 1) a core, 
2) a linking unit and 3) a donor moiety to coordinate to palladium(II) ions 
(Figure 2.9).  
 
Figure 2.9: General structure of a ligand designed to form a [Pd2(L)4]4+ cage upon addition of Pd(II) ions, 
colours: core, green; linker, orange; donor, blue. 
For instance, the McMorran ligand system features a phenyl core, ether linkages 
and 3-pyridyl donors, while the main Crowley system consists of a pyridyl core, 
alkyne linkers and 3-pyridyl donors, and the Yoshizawa formula is constituted 
from a phenyl core, aryl linking units (either benzene or anthracene), and again 
3-pyridyl donors (Figure 2.10).111 The system depicted in Figure 2.10 is one of 
many by Yoshizawa and co-workers. One of their research areas is developing 
palladium(II)- and platinum(II)-based cages for use as drug delivery vectors, 





Figure 2.10: Ligand and X-ray structure of a [Pd2(L)4]4+ cage,42 R = O(CH2)2OCH3, solubilising groups 
have been truncated, hydrogen atoms, solvent molecules and counterions have been omitted for clarity. 
By using polyaromatic panels as linking units in their cage systems, the 
Yoshizawa group have been able to encapsulate biologically relevant neutral 
organic guest molecules such as amino acids and DNA nucleobases,55 as well as 
aromatic molecules like pyrene and corranulene.112 Cytotoxicity testing against 
human cancer cell lines (HL-60, SKW-3 and T-24), non-malignant kidney cells 
(HEK-293) and CDDP-resistant cells (HL-60/CDDP) indicated that the host 
systems themselves were active (IC50 values range from 0.9 to 37 µM), and 
perhaps more interestingly, the Pd(II) cage was more active than the Pt(II) 
variant against HL-60 (and HL-60/CDDP) and SKW-3.55, 56 However the Pt(II) 
cage showed enhanced activity against the rest of the cell lines, and showed 
better selectivity towards non-malignant cell lines. Intriguingly, upon addition 
of two equivalents of caffeine to the Pd(II) cage, the cytotoxicity was reduced by 
half, against HL-60, to IC50 = 0.7 µM; and inclusion of two pyrene molecules 
rendered the system less toxic towards all the cell lines. 
Crowley and co-workers have also developed a ligand system with a phenyl 
core but instead of pyridyl donors, the core is directly linked to two hexyl-
decorated 1,2,3-triazole units (Figure 2.11). Upon coordination to Pd(II) ions, in 
a 2:1 ligand/metal ratio, a [Pd2(L)4]4+ helical cage architecture is formed. As 
there are no linking units in the ligand and the fact that the cage is twisted, there 
is very little space inside the cage. Indeed, a single water molecule would 
unlikely be accommodated. Despite this, in vitro testing against human lung 
cancer (A549), CDDP-resistant breast cancer (MDA-MB-231) and prostate 
cancer (DU-145) malignant cell lines, as well as immortalised non-malignant 
breast tissue (MCF-10A) as a non-cancerous control, revealed that the helical 
cage was relatively potent (IC50 values range from 3.4 to 6.9 µM). The increased 




derivatives thereof) from Crowley and co-workers33 was postulated to be due 
to the increased lipophilicity and steric protection of the Pd(II) centre by the 
hexyl chains. Unfortunately, there was little-to-no observed selectivity for 
cancerous tissue over normal cells (IC50 = 8.1 µM vs. MCF-10A).113 
 
Figure 2.11: Bis-1,2,3-triazole ligand and MMFF model of [Pd2(L)4]4+ helicate,50 R = C6H13, R groups have 




 Quinoline-containing palladium(II) cages 
The vast majority of the [Pd2(L)4]4+ cages examined to date feature pyridyl 
donors, so in an effort to improve the biological properties of these systems we 
describe the use of isoquinoline and quinoline-derived ligands for the assembly 
of two new [Pd2(L)4]4+ architectures. While it is well known that isoquinoline 
and quinoline ligands can bind to palladium(II)114 and platinum(II)115 their use 
as donor systems in ligands for the generation metallosupramolecular 
architectures has not been extensively explored.116-120 The Clever group is one 
of few who have investigated the use of (iso)quinoline as donor groups to create 
[Pd2(L)4]4+ cage systems. They have utilised the electronic properties of 
isoquinoline in conjunction with fluorinated dithienylethene to create a 
photoswitchable cage (Figure 2.12a).121 The Clever group have also taken 
advantage of the fact that isoquinoline can be functionalised in a greater variety 
of places than pyridine, and hence increased functionality can be accessed. 
Exploiting this, they have been able to access heteroleptic trans-cage systems 
(Figure 2.12b) by using complementary ligand geometries.122 
 
Figure 2.12: X-ray structures of a) [Pd2(3,3'-[(3,3,4,4,5,5-hexafluoro-1-cyclopentene-1,2-diyl)bis[(5-
methyl-4,2-thiophenediyl)-2,1-ethynediyl]]bis-pyridine)4]4+,121 and b) [Pd2(10-hexyl-2,7-bis[2-(8-
isoquinolinyl)ethynyl]-9(10H)-acridinone)2(9-hexyl-3,6-bis[2-(3-pyridinyl)ethynyl]-9H-
carbazole)2]4+,122 hexyl chains have been truncated (for b), hydrogen atoms, solvent molecules and 
counterions have been omitted for clarity. 
Using quinoline units to coordinate palladium(II), the Clever group have 
developed an interesting bowl-like system.119 The bis-monodentate ligand was 
reacted with Pd(II) in a 4:2 ratio. Intriguingly, the expected [Pd2(L)4]4+ cage was 
only present as the minor species, while the major product was a 
[Pd2(L)3(CH3CN)2]4+ bowl-shaped structure. Host-guest studies revealed that 




anthracene (An) to this host-guest complex revealed the system was able to 
perform Diels-Alder cycloaddition reactions in the absence of light. 
Furthermore, equimolar addition of terephthalate to the host-guest complex 
facilitated the generation of bowl dimers (Figure 2.13b) containing two fullerene 
guest molecules. 
 
Figure 2.13: X-ray structure of [C60Pd2(L)3(CH3CN)2]4+ and a) the reaction between the host-guest 
system with anthracene (An) in the absence of light giving [C60An⊂Pd2(L)3Cl2]2+ (X-ray structure); and 
b) the reaction between the host-guest system and terephthalate giving [2C60⊂Pd4(L)6(BDC)2]4+ (MMFF 
model).119  Guests shown in space-fill style, hydrogen atoms, solvent molecules and counterions have 
been omitted for clarity. 
These quinoline derived systems feature different electronic and steric 
properties compared to pyridyl systems thus this chapter examines the effect of 
using quinoline units in our cages in terms of the changes to the host-guest 
chemistry with CDDP, the stability of the cages in the presence of nucleophiles 




 [Pd2(L)4]4+ cages – the next generation 
The synthesis of the new quinoline (L2) and isoquinoline (L3) based ligands 
(Figure 2.14a) was facile. Using commercially available building blocks (3-
bromoquinoline (1) and 4-bromoisoquinoline (4), respectively, and 
ethynyltrimethylsilane), successive Sonogashira carbon-carbon cross coupling 
reactions (Figure 2.15) produced the ligands in good yields (L2 = 86% and L3 = 
78%, for full synthetic details see Experimental and Scheme 2.1).  
 
 
Figure 2.14: a) L1 and the two new (iso)quinoline ligands (L2 and L3), b) the scheme to afford L2 and L3 
using Sonogashira carbon-carbon cross coupling reactions; conditions: (i) ethynyltrimethylsilane, CuI, 
[Pd(PPh3)2Cl2], (iPr2)NH, 80 °C; (ii) Na2CO3, MeOH, RT; (iii) 2,6-dibromopyridine, CuI, [Pd(PPh3)2Cl2], 
(iPr2)NH, 80 °C.  
1H and 13C NMR spectroscopic data were consistent with the formation of the 
ligands with support from high-resolution electrospray mass spectrometry 
(HR-ESI-MS). Peaks corresponding to protonated and sodiated ligand were 
observed at m/z = 382.1320 and 404.1132, respectively, for L3 and similar peaks 





Figure 2.15: The palladium(II) and copper(I) catalysed Sonogashira cycle. 
With the ligands in hand, the complexation with [Pd(CH3CN)4](BF4)2 in 
acetonitrile was examined. The cage formation was monitored using 1H NMR 
spectroscopy (CD3CN, 298 K) and showed that mixing [Pd(CH3CN)4](BF4)2 and 
L2 in a 1:2 ratio at room temperature led to the formation of what was assumed 
to be a mixture of different cage isomers. All the proton resonances exhibited 
the expected downfield shifts. The reaction was monitored using 1H NMR 
spectroscopy for 24 hours at room temperature however little to no changes 
were observed and the spectrum still displayed multiple proton resonances. A 
1H diffusion ordered (DOSY) experiment (CD3CN, 298 K) on the mixture 
showed that all the different proton resonances had the same diffusion co-
efficient consistent with the postulate that the reaction mixture contains a series 





Figure 2.16: a) Scheme to afford C2 and C3 and b) partial 1H DOSY NMR spectrum (500 MHz, CD3CN, 
298 K) of the initial mixture of L2 and [Pd(CH3CN)4](BF4)2. Conditions for a):  (i) [Pd(CH3CN)4] (BF4)2, 
MeCN, 65 °C for C2 and RT for C3.  
The assembly reaction between L2 with [Pd(CH3CN)4](BF4)2 was then carried 
out at 65 °C, in CD3CN and again monitored using 1H NMR spectroscopy 
(Figure 2.17). After 5 minutes, the same complicated series of proton resonance 
were observed. However, with continued heating this slowly resolved into a 
single series of resonances after 7 hours, consistent with the formation of a single 
cage isomer (Figure 2.17). 
 
Figure 2.17: Partial stacked 1H NMR spectra (500 MHz, CD3CN, 338 K) monitoring the formation of 




Satisfyingly, the behaviour of L3 with [Pd(CH3CN)4](BF4)2 in acetonitrile was 
very different. The rapid (<2 min) and quantitative formation of the expected 
C3∙BF4 cage was observed through 1H NMR spectroscopy (Figure 2.18d). This 
was similar to what was observed with the parent tripyridyl cage system (C1).33 
 
Figure 2.18: Partial stacked 1H NMR spectra (400 MHz, CD3CN, 298 K) of a) L2, b) isolated C2⋅BF4, c) C3 
and d) isolated C3⋅BF4. 
Pleasingly, both C2∙BF4 and C3∙BF4 could be isolated as powdered solids in 
good yields (88% and 92%, respectively) though precipitation by adding diethyl 
ether into the acetonitrile reaction mixtures. 1H NMR spectroscopy (CD3CN,  
298 K) of the solids exhibited the expected downfield shifts of the signals 
pertaining to protons Ha, Hb and Hf as well as the anticipated downfield shifts 
of the rest of the isoquinoline and quinoline protons resonances (Figure 2.18). 
HR-ESI-MS data also supported the formation of the cages, showing ions 
corresponding to the loss of 2, 3 and 4 tetrafluoroborate (BF4) counterions  









1H DOSY NMR experiments (CD3CN, 298 K) on the ligands (diffusion 
coefficients (D) = 13.1 (L2) and 15.0 (L3) x 10−10 m2 s−1) and cages (D = 4.03 (C2) 
and 4.30 (C3) × 10−10 m2 s−1 were also consistent with the formation of the larger 
[Pd2(L)4]4+ cages (Figure 2.20). 
 
Figure 2.20: Partial 1H DOSY NMR spectra (500 MHz, CD3CN, 298 K) of a) L2 and C2, and b) L3 and C3. 
Upon cooling of a 5 mM acetonitrile solution of C2∙BF4 from 65 °C to room 
temperature, crystals formed of quality suitable for X-ray diffraction. The 
structure was solved in the tetragonal space group P4/mnc with the asymmetric 
unit containing one eighth of the cage and one quarter of a BF4- counterion 
(Figure A1). The other BF4- anion and some acetonitrile molecules could not be 
modelled sensibly thus the SQUEEZE routine was employed to account for the 
diffuse electron density. The data revealed the expected [Pd2(L2)4]4+ cage 





Figure 2.21: X-ray structure of C2⋅BF4; a) full cage, b) view from top and bottom, solvent molecules and 
counterions have been omitted for clarity. 
The Pd-N bond lengths (Pd1-N2 2.045 Å) were similar to what have been 
previously observed for related variations of cage C1, where the Pd-N bond 
lengths range from 2.016 to 2.027 Å.33, 49 The L2 ligands of the cage were twisted 
giving a V-shaped conformation where the terminal quinoline and central 
pyridyl heterocyclic units were not co-planar, quite different to what was 
observed with C1. In X-ray structures of the parent C1 cage, the L1 ligands were 
found to exist in a linear conformation with the heterocyclic units co-planar. The 
twisting also alters the Pd1- Pd1’ distance within C2 relative to C1. The Pd1-
Pd1’ distances in structures for variations of C1 range from 11.49 to 12.24 Å, 
whereas the Pd1-Pd1’ distance for C2 was found to be longer (12.506 Å) 
suggesting that cage C2 has a larger cavity despite featuring the same 2,6-
diethynylpyridine linker units. The [Pd(quinoline)4]2+ units at the top and 
bottom of C2 are twisted in opposite directions, the top cationic unit has a right 
handed twist while the bottom cationic unit has a left handed twist giving an 




Despite extensive efforts to obtain X-ray diffraction quality single crystals of C3, 
all attempts proved futile. Thus, to gain further insight into the structure of C3 
the cage was modelled using Density Functional Theory (DFT) calculations. 
Energy minimization and geometry optimisation of C3 (DFT, BP86 def2-SVP, 
acetonitrile solvation, (see section A2 for full computational details)) showed 
that the cage adopted a lantern shape (Figure 2.22) similar to what was 
previously observed for C1 variations.33, 49 The calculated Pd-N bond distances 
(2.049 Å) and the Pd-Pd’ distance (11.758 Å) match well with those observed 
crystallographically for the related cages. The L3 ligand adopts a linear 
conformation with all the heterocyclic units in each ligand co-planar. The DFT 
calculations indicated that C3 is structurally very similar to the parent C1 cage, 
whereas C2 is more twisted and provides a cavity of different size and shape to 
C1 and C3. 
 
Figure 2.22: DFT optimised model (BP86 def2-SVP, MeCN) of C3 from a) the side and b) the top. 
It is well known that cages similar to C1 can encapsulate CDDP through 
hydrogen bonding interactions in polar organic solvents such as CH3CN and 
N,N-dimethylformamide (DMF).33, 49, 52, 123-126 Therefore, the ability of C2 and C3 
to interact with CDDP in CD3CN was examined using 1H NMR spectroscopy. 
When a CD3CN solution of C3 was exposed to an excess of CDDP, the 1H NMR 
spectrum displayed broadening and a downfield shift (Δδ = 0.03 ppm) of Ha 
(the internally directed proton, Figure 2.23d). This is indicative of weak CDDP 
binding inside the cage cavity. Correspondingly, C2 was also treated with an 
excess of CDDP however the 1H NMR spectrum showed no discernible shifts of 
any of the cage proton resonances (Figure 2.23b). Although disappointing, this 




which was shown to have no interactions with CDDP in d7-DMF.52 The fact that 
the preorganisation of the hydrogen bonding network of the twisted cavities is 
less suited for CDDP binding compared to the lantern shaped C1 and C3 cages 
is reasoned to inhibit the host-guest properties of the former systems. 
 
Figure 2.23: Partial 1H NMR stacked spectra (500 MHz, CD3CN, 298 K) of a) C2∙BF4, b) C2∙BF4 + excess 
CDDP, c) C3∙BF4 and d) C3∙BF4 + excess CDDP. 
Despite only being able to weakly bind CDDP in acetonitrile, the kinetic stability 
of the (iso)quinoline cages in the presence of a common biological nucleophile 
(Cl-) was examined through 1H NMR time-course studies. Upon addition of 8 
eq. of tetrabutylammonium chloride to a 2 mM solution of C2∙BF4 in d6-DMSO, 
the cage showed impressive robustness compared to the parent cage system, 
C1. C2 exhibited minimal signs of decomposition for the first hour, after which 
free ligand was the dominant species in the 1H NMR spectrum (Figure 2.24). 
After 3 hours, proton resonances pertaining to C2 were no longer observable, as 
the main signals in the spectra related to the ligand with a set of minor peaks 
corresponding to a different metal containing species, most likely the neutral 





Figure 2.24: Partial stacked 1H NMR spectra (500 MHz, d6-DMSO, 298 K) of a) C2∙BF4, b) C2∙BF4 + 8 eq. 
Cl- at time t = 0 min, c) t = 10 min, d) t = 20 min, e) t = 30 min, f) t = 1 hr, g) t = 3 hr, h) t = 5 hr and  
i) t = 7 hr.  
When similar experiments were performed on C3, the addition of Cl- anions 
triggered the immediate formation of multiple species as evidenced in the 1H 
NMR spectra (Figure 2.25). Several proton resonances were observed and were 
attributed to the presence of C3, [Cl⊂C3]3+, the neutral [Pd2(L3)2Cl4] macrocycle 
as seen before,50, 51 and uncoordinated L3. After 50 minutes, only free ligand was 
evident in the 1H NMR spectrum.  
Compared with the parent cage C1 (τ1/2 = 2 min), C3 possessed an identical half-
life, however C2 was significantly more stable (τ1/2 = 2 h). The improved 
stability of C2 is seemingly due to the increased steric protection of the 
palladium(II) centre by the quinoline units. The heterocycles encumber 
incoming nucleophiles from the exo-face (Figure 2.26b) however smaller 
nucleophilic units such as chloride anions can still access the palladium(II) 
cation from the inside of the cavity. With the isoquinoline units, they are 
orientated such that there is little to no steric protection of the metal centres 
(Figure 2.26c) and the system heavily resembles that of the tripyridyl system, 





Figure 2.25: Partial stacked 1H NMR spectra (500 MHz, d6-DMSO, 298 K) of a) C3∙BF4, b) C3∙BF4 + 8 eq. 
Cl- at time t = 0 min, c) t = 1 min, d) t = 1.5 min, e) t = 2.5 min, f) t = 5 min, g) t = 10 min, h) t = 20 min,  
i) t = 30 min and j) t = 50 min. 
 
 
Figure 2.26: Space-fill images of the X-ray structures of a) C1126 and b) C2, and c) DFT optimised 
structure of C3. Cages are viewed down the Pd-Pd’ axis. Counterions and solvent molecules have been 




Having displayed improved kinetic robustness in the presence of biological 
nucleophiles in the case of C2, the cages and their uncoordinated ligands were 
assessed for their biological activity. Using the MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) assay127 (Figure 2.27) the cytotoxicities of 
L2, L3, C2 and C3 were determined as half maximal inhibitory concentrations 
(IC50) after 24-hour incubation periods against three human cell lines: A549 
(lung cancer), MDA-MB-231 (CDDP resistant breast cancer) and non-cancerous 
primary cells HDFa (human dermal fibroblasts) (Table 2.1). Perhaps 
unsurprisingly, ligands L2 and L3 demonstrated limited aqueous solubility and 
so data above 1 µM was unobtainable. At concentrations below this, L2 showed 
cytotoxic activity against A549 (IC50 = 0.5 µM) while L3 was effectively 
ineffective. Interestingly, C2 and C3 showed promising cytotoxic action. With 
sub-micromolar IC50 values, C2 was as active as its ligand against A549. C2 was 
marginally less cytotoxic against MDA-MB-231 (IC50 = 1.7 µM) while C3 was 
slightly less active against both malignant cell lines (IC50 = 4.0 and 7.4 µM vs. 
MDA-MB-231 and A549, respectively). Satisfyingly, both cages were 
significantly more active than C1 (IC50 = 57 and 41 µM vs. MDA-MB-231 and 
A549, respectively)50 and CDDP (IC50 = 41 and 9.4 µM vs. MDA-MB-231 and 
A549, respectively).50, 128 Tripyridyl palladium(II) cage systems have been 
reported to have cytotoxic values in the range of 10 to 100 µM after 24-hour 
incubation periods,50, 57, 124, 125 thus it is pleasing that cages C2 and C3 have 
surpassed the 10 µM benchmark. Furthermore, C2 was more active, albeit 
against different malignancies than the hydrophobic anthracene-panelled 
palladium(II) cage system developed by Yoshizawa and co-workers (IC50 values 
range from 0.9 to 37 µM against HL-60, HL-60/Dox, HT-29, T-24 and  
SKW-3).55, 56 The excellent cytotoxicity of C2 against malignant cell lines is 
rationalised through the enhanced kinetic stability against biological 
nucleophiles and the increased lipophilic nature of the ligand system when 





Figure 2.27: MTT (yellow solution in DMSO) is reduced to formazan (purple crystals in DMSO) by 
mitochondrial reductase; cell viability can be inferred from the amount of formazan is produced. 
However, when tested against the non-cancerous cell line (HDFa), C2 and C3 
unfortunately displayed similar cytotoxicity to the malignant cell lines (IC50 
values ranged between 2.6 and 3.0 µM), and hence there is little to no selectivity 
between normal and cancerous tissue. 
Table 2.1: Half-maximal inhibitory concentrations (IC50) of ligands L2 and L3 and cages C2 and C3  
at 24 h. 
Compound 
IC50a (µM) 
MDA-MB-231 A549 HDFa MCF-10Ab 
L1 >100 95.3 ± 9.7 - >100 
L2 >1c 0.5 ± 0.1 >1c - 
L3 >1c >1c >1c - 
C1 56.7 ± 2.2 41.1 ± 3.9 - 71.4 ± 3.9 
C2 1.7 ± 0.1 0.5 ± 0.1 2.6 ± 0.4 - 
C3 4.0 ± 0.3 7.4 ± 1.0 3.0 ± 0.4 - 
CDDP 41.2 ± 3.9 9.4 ± 0.3 89 ± 19 - 
L1,50 C150 and CDDP50, 128 have been added for comparison. aIC50 values given as mean ± standard error. bL1 
and C1 were tested against MCF-10A as a non-cancerous control. cSolubility limited the range of 





 Conclusions & future directions 
This chapter has discussed the synthesis, characterisation, CDDP binding, 
kinetic stability, and anticancer activity of the new quinoline and isoquinoline 
containing metallosupramolecular architectures C2∙BF4 and C3∙BF4. Through X-
ray crystallography, C2 was discovered to possess a twisted cavity whereby the 
two palladium(II) centres assume opposing handednesses and hence the cage is 
presented as an overall meso structure. On the other hand, C3 was shown 
through DFT calculations to adopt a purely lantern-shaped architecture, 
mimicking the previously generated C1 cage. The difference in geometries 
resulted in different chemical properties displayed by the cages. Cage C3 was 
able to weakly bind CDDP in acetonitrile while the twisted C2 cage was shown 
not to interact with the platinum-based drug. The quinoline units of C2 which 
caused the twist provided steric protection for the Pd(II) ions, giving a rationale 
behind the increased kinetic robustness of C2 in the presence of chloride anions 
as a proxy for biological nucleophiles. The half-life of C2 (τ1/2 = 2 h) was 
significantly longer than that of C3 (τ1/2 = 2 min) under the same conditions, 
where the isoquinoline units are orientated away from the Pd(II) centre, thus 
not providing steric protection. The cytotoxic activity of the cages was also an 
improvement on previous studies as submicromolar concentrations were 
achieved against A549 (lung cancer) cells. The enhanced anticancer activity was 
attributed to a combination of hydrophobicity and kinetic stability. 
Disappointingly, the cages failed to exhibit specificity towards cancerous cells 
over normal tissue as similar cytotoxicity was observed against HDFa (human 
dermal fibroblast) cells. 
To combat this lack of discrimination, targeting groups could be appended to 
the ligand to actively target cancerous tissue. Alternatively, the ligand systems 
could be extended to generate larger cage systems capable of exploiting the EPR 
effect. Both of these options would not necessarily result in the retention of the 
cytotoxic activity, so judicial choice must be taken when developing subsequent 






2.6.1 Synthetic Scheme 
 
Scheme 2.1: Synthetic scheme to afford C2·BF4 and C3·BF4. Conditions: (i) ethynyltrimethylsilane, 
[Pd(PPh3)3Cl2], CuI, (iPr)2NH, 80 °C; (ii) Na2CO3, MeOH, RT; (iii) 2,6-dibromopyridine, [Pd(PPh3)3Cl2], 





Synthesis of 2 
The synthesis of 2 was previously reported by Sakamoto et al. in 83% yield.129 
 
1 (2.00 g, 1.31 mL, 9.61 mmol) was added to a glass tube containing (iPr)2NH  
(5 mL) and the solution was degassed with N2 for 10 minutes. CuI (0.183 g, 0.961 
mmol) and Pd(PPh3)2Cl2 (0.169 g, 0.240 mmol) were then added, followed by 
ethynyltrimethylsilane (1.13 g, 1.64 mL, 11.5 mmol). The tube was sealed and 
heated at 80 °C for 16 hours. The resulting mixture was then cooled and taken 
up in CHCl3 and filtered through Celite before being washed with aqueous 
EDTA/NH4OH (0.1 M, 50 mL). The organic layer was separated and washed 
with water (100 mL) and brine (100 mL), then dried over Na2SO4. The solvent 
was removed under reduced pressure and the crude product was purified using 
column chromatography on silica gel (CH2Cl2 to 1:4 acetone/CH2Cl2) to give 2 
as a brown solid (1.73 g, 7.68 mmol, 80%). 1H NMR (400 MHz, CDCl3, 298 K) δ: 
8.92 (d, J = 2.0 Hz, 1H, Ha), 8.28 (d, J = 1.9 Hz, 1H, Hf), 8.09 (d, J = 8.4 Hz, 1H, 
Hb), 7.78 (dd, J = 8.2, 1.4 Hz, 1H, He), 7.72 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H, Hd), 7.56 
(ddd, J = 8.1, 6.9, 1.2 Hz, 1H, Hc), 0.30 (s, 7H, Hg). HR-ESI-MS (MeOH): m/z = 





Synthesis of 3 
The synthesis of 3 was previously reported by Sakamoto et al. in 76% yield.129 
 
2 (1.72 g, 7.67 mmol) and Na2CO3 (1.63 g, 15.3 mmol) were added to MeOH  
(30 mL) and stirred at RT for 30 minutes. The solvent was removed under 
reduced pressure and the resulting crude mixture was taken up in CHCl3 and 
filtered through Celite and silica. The solvent was removed under reduced 
pressure to give 3 as a brown solid (1.06 g, 6.95 mmol, 90%). 1H NMR (400 MHz, 
CDCl3, 298 K) δ: 8.95 (d, J = 2.1 Hz, 1H, Ha), 8.30 (d, J = 1.8 Hz, 1H, Hf), 8.10 (d, 
J = 8.5 Hz, 1H, Hb), 7.80 (dd, J = 8.1, 1.5 Hz, 1H, He), 7.74 (ddd, J = 8.4, 6.9, 1.5 
Hz, 1H, Hd), 7.58 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H, Hc), 3.28 (s, 1H, Hg). HR-ESI-MS 





Synthesis of 5 
The synthesis of 5 was previously reported by Sakamoto et al. in 83% yield.129 
 
A glass tube was charged with (iPr)2NH (4 mL) and THF (1 mL). The solvent 
mixture was purged with N2 for 10 minutes before 4 (923 mg, 4.44 mmol), CuI 
(85.3 mg, 0.444 mmol), Pd(PPh3)2Cl2 (77.8 mg, 0.111 mmol), and finally 
ethynyltrimethylsilane (0.523 mg, 0.758 mL, 5.32 mmol) were added. The tube 
was sealed and heated at 80 °C for 14 hours. The resulting mixture was then 
cooled and taken up in CHCl3 and filtered through Celite before being washed 
with aqueous EDTA/NH4OH (0.1 M, 50 mL). The organic layer was separated 
and washed with water (100 mL) and brine (100 mL), then dried over Na2SO4. 
The solvent was removed under reduced pressure and the crude product was 
purified using column chromatography on silica gel (CHCl3) to give 5 as a 
brown solid (942 mg, 4.18 mmol, 94%). 1H NMR (400 MHz, CDCl3, 298 K) δ: 9.23 
(s, 1H, Hb), 8.73 (s, 1H, Ha), 8.25 (d, J = 8.4 Hz, 1H, Hc), 8.00 (d, J = 8.2 Hz, 1H, 
Hf), 7.82 (ddd, J = 15.4, 6.8, 1.2 Hz, 1H, He), 7.67 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H, 





Synthesis of 6 
The synthesis of 6 was previously reported by Sakamoto et al. in 71% yield.129 
 
5 (746 mg, 3.31 mmol) and Na2CO3 (702 g, 6.62 mmol) were added to MeOH  
(30 mL) and stirred at RT for 30 minutes. The solvent was removed under 
reduced pressure and the resulting crude mixture was taken up in CHCl3 and 
filtered through Celite and silica. The solvent was removed under reduced 
pressure to give 6 as a brown solid (371 mg, 2.42 mmol, 73%). 1H NMR  
(400 MHz, CDCl3, 298 K) δ: 9.29 (s, 1H, Hb), 8.72 (s, 1H, Ha), 8.36 (d, J = 8.5 Hz, 
1H, Hc), 8.11 (d, J = 8.2 Hz, 1H, Hf), 7.95 (t, J = 7.7 Hz, 1H, He), 7.79 (t, J = 7.6 Hz, 






Synthesis of L2 
 
THF (1 mL) and (iPr)2NH (4 mL) were degassed in a glass tube before 2,6-
dibromopyridine (287 mg, 1.21 mmol), 3-ethynylquinoline (3) (390 mg, 2.55 
mmol), CuI (23 mg, 0.12 mmol) and [Pd(PPh3)2Cl2] (22 mg, 0.03 mmol) were 
added. The tube was sealed and heated at 80 °C for 14 hours. After cooling to 
RT, the reaction mixture was dissolved in CHCl3 (10 mL) and was washed with 
an aqueous EDTA/NH4OH solution (0.1 M, 20 mL). The organic layer was 
washed with water (2 x 20 mL) and brine (20 mL) before drying over Na2SO4. 
The solvent was removed under vacuum and the crude product was purified 
through column chromatography (silica gel CH2Cl2 to 1:4 acetone/CH2Cl2) to 
give L2 as a tan solid (403 mg, 1.05 mmol, 86%). 1H NMR (400 MHz, CD3CN, 
298 K) δ: 9.04 (d, J = 1.9 Hz, 2H, Ha), 8.55 (s, 2H, Hf), 8.08 (d, J = 8.5 Hz, 2H, Hb), 
7.95 (d, J = 8.2 Hz, 2H, He), 7.88 (t, J = 7.9 Hz, 1H, Hh), 7.81 (dd, J = 7.7 Hz, 2H, 
Hd), 7.70 – 7.62 (m, 4H, Hg,c). 13C NMR (125 MHz, CD3CN, 298 K) δ: 152.8, 148.2, 
144.1, 140.3, 138.5, 137.7, 131.8, 130.2, 129.0, 128.6, 128.1, 128.0, 91.7, 87.2. HR-
ESI-MS (MeOH): m/z = 382.1324 [L2 + H]+ (calc. for C27H16N3, 382.1339); 
763.2560 [2L2 + H]+ (calc. for C54H33N6, 763.2610); 785.2377 [2L2 + Na]+ (calc. for 
C54H32N6Na, 785.2430). Anal. Calc. for C27H15N3∙0.4H2O C, 83.44; H, 4.10; N, 





Synthesis of L3 
 
THF (1 mL) and (iPr)2NH (4 mL) were degassed in a glass tube before 2,6- 
dibromopyridine (267 mg, 1.12mmol), 4-ethynylisoquinoline (6) (371 mg,  
2.15 mmol), CuI (22 mg, 0.11 mmol) and [Pd(PPh3)2Cl2] (20 mg, 0.028 mmol) 
were added. The tube was sealed and heated at 80 °C for 14 hours. After cooling 
to RT, the reaction mixture was dissolved in CHCl3 (10 mL) and was washed 
with an aqueous EDTA/NH4OH solution (0.1 M, 20 mL). The organic layer was 
washed with water (2 x 20 mL) and brine (20 mL) before drying over Na2SO4. 
The solvent was removed under vacuum and the crude product was purified 
through column chromatography (silica gel CH2Cl2 to 1:4 acetone/CH2Cl2) to 
afford L3 as an off-white solid (335 mg, 0.879 mmol, 78%). 1H NMR (400 MHz, 
CDCl3, 298 K) δ: 9.32 (d, J = 0.8 Hz, 2H, Hb), 8.85 (s, 2H, Ha), 8.53 – 8.48 (m, 2H, 
Hc), 8.16 – 8.10 (m, 2H ,Hf), 7.97 (ddd, J = 8.4, 7.0, 1.2 Hz, 2H, He), 7.86 (dd, J = 
8.3, 7.3 Hz, 1H, He), 7.83 – 7.78 (m, 2H, Hd), 7.71 (dd, J = 7.8, 0.5 Hz, 2H, Hg).  
13C NMR (125 MHz, CD3CN, 298 K) δ: 154.2, 148.1, 144.2, 138.5, 136.2, 132.9, 
132.7, 132.6, 129.4, 129.3, 128.3, 125.5, 89.7, 85.1. HR-ESI-MS (CH3OH): m/z = 
382.1320 [L3 + H]+ (calc. for C27H16N3, 382.1339); 404.1132 [L3 + Na]+ (calc. for 
C27H15N3Na, 404.1158); Anal. Calc. for C27H15N3·0.50CH3CN C, 83.74; H, 4.13; 





Synthesis of C2⋅BF4 
 
L2 (50 mg, 0.13 mmol) and [Pd(CH3CN)4](BF4)2 (29 mg, 0.066 mmol) were 
dissolved in MeCN (10 mL) and heated at 65 °C for 7 hours. The resulting 
solution was cooled to RT and precipitated via addition of diethyl ether. The 
precipitate was collected through filtration and washed with diethyl ether to 
give the product as a tan solid (63 mg, 0.030 mmol 92%). 1H NMR (400 MHz, 
CD3CN, 298 K) δ: 9.73 (s, 8H, Ha), 9.61 (d, J = 8.8 Hz, 8H, Hb), 8.75 (s, 8H, Hf), 
7.80 – 7.93 (m, 16H, He,c), 7.85 (t, J =  7.9 Hz, 4H, Hh), 7.79 (t, J = 7.6 Hz, 8H, Hd), 
7.66 (d, J = 7.8 Hz, 8H, Hg). 13C NMR (125 MHz, CD3CN, 298 K) δ: 156.9, 146.5, 
145.6, 143.5, 142.3, 135.4, 131.0, 130.9, 129.9, 129.6, 128.0, 119.4, 93.8, 84.4.  
19F NMR (470 MHz, CD3CN, 298 K) δ: -155.85. HR-ESI-MS (CH3CN): m/z = 
434.5856 [C2]4+ (calc. for (C27H15N3)4Pd2, 434.5789); 585.7749 [C1(F)]3+ (calc. for 
(C27H15N3)4Pd2·F, 585.7716); 608.4439 [C2(BF4)]3+ (calc. for (C27H15N3)4Pd2·BF4, 
608.4400); 922.1596 [C2(BF4)(F)]2+ (calc. for (C27H15N3)4Pd2·BF4·F, 922.1595); 





Synthesis of C3⋅BF4 
 
L3 (100 mg, 0.26 mmol) and [Pd(CH3CN)4](BF4)2 (58 mg, 0.13 mmol) were added 
to MeCN (15 mL) and stirred at RT for 1 hour. To the resulting mixture was 
added diethyl ether, and the ensuing white precipitate was collected through 
filtration and washed with diethyl ether giving the product as a tan solid  
(120 mg, 0.058 mmol, 88%). 1H NMR (500 MHz, CD3CN, 298 K) δ: 9.99 (s, 8H, 
Hb), 9.40 (s, 8H, Ha), 8.45 (dd, J = 8.2, 1.0 Hz, 8H, Hc), 8.34 (dd, J = 8.5, 1.1 Hz, 
8H, Hf), 8.07 (ddd, J = 8.2, 6.9, 1.2 Hz, 8H, Hd), 7.96 – 7.86 (m, 20H, He,g,h).  
13C NMR (125 MHz, CD3CN, 298 K) δ: 157.2, 145.8, 143.5, 138.6, 137.0, 136.5, 
131.6, 130.6, 129.8, 129.7, 125.8, 120.1, 98.6, 82.3. 19F NMR (470 MHz, CD3CN,  
298 K) δ: -155.52. HR-ESI-MS (CH3CN): m/z = 434.5832 [C3]4+ (calc. for 
(C27H15N3)4Pd2, 434.5789); 585.7744 [C3(F)]3+ (calc. for (C27H15N3)4Pd2·F, 
585.7716); 608.4424 [C3(BF4)]3+ (calc. for (C27H15N3)4Pd2·BF4, 608.4400); 956.1610 





2.6.3 Cytotoxicity assay experimental details 
Reagents: MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) 
and cell culture reagents were purchased from Invitrogen (Auckland, NZ). All 
other chemicals were obtained from Sigma-Aldrich (Auckland, NZ) unless 
stated otherwise.  
Cell Culture: All cell lines were purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) and maintained in Dulbecco’s Modified 
Eagles Medium (DMEM) enriched with 2% FBS and 1% antibiotic. All cells were 
cultured at 37 °C in a humidified atmosphere with 5% CO2 levels.  
Cytotoxicity Evaluation: Cell viability was assessed using the MTT assay.130 96 
well plates were seeded with 5,000 cells per well, and the cells left to adhere for 
24 hours prior to treatment. Cells were then exposed to compounds solubilised 
in DMSO. To control for the effects of DMSO, all cell culture medium had a 
constant DMSO concentration of 0.5% (v/v). Following compound 
administration, cells were washed with PBS and MTT (0.33 mg mL-1 in DMEM) 
added for 3 hours. After MTT incubation, the medium was aspirated and the 
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 Flexible ligands 
Currently, the vast majority of metallosupramolecular architectures are 
constructed with ligands featuring rigid backbones. This imbues the system 
with predictability, producing either cage-like or macrocyclic structures 
through utilisation of the preorganised ligand geometry.131 Conversely when 
donor units are linked together by more flexible subcomponents this generally 
leads to less reliability in the self-assembly process often resulting in mixtures 
of different architectures or unexpected products, however it can also lead to 
stepwise assembly for larger architectures.132 There are a few cases where 
[Pd2(L)4]4+ cages have been built using non-rigid ligands. For example, 
McMorran and Steel11, 133 reported the formation of discrete [Pd2(L)4]4+ cage-
type systems (where L = 1,4-bis(3-pyridyloxy)benzene). The flexibility of the 1,4-
bis(3-pyridyloxy)benzene ligand backbone, provided by the ether linkages, 
facilitated the modulation of the Pd-Pd distance with the inclusion of different 
anions. With increasing anion size (I- < BF4- < ClO4- < PF6-), the Pd-Pd distance 
increases from 7.4 Å to 8.8 Å, respectively (Figure 3.1). 
 
Figure 3.1: Modulation of Pd-Pd distance through anion inclusion.11 X-ray structures of a) [I⊂Pd2(L)4]3+, 
b) [BF4⊂Pd2(L)4]3+, c) [ClO4⊂Pd2(L)4]3+ and d) [PF6⊂Pd2(L)4]3+, anionic guest molecules shown in space-
fill style, hydrogen atoms, remaining counterions and solvent molecules have been removed for clarity. 
Conversely, when the units linking the donor moieties are too flexible, one can 
obtain [Pd(L)2]2+ spiro-type architectures instead of [Pd2(L)4]4+ cage  
structures.134-136 This was observed by Chand and co-workers,134 who studied 
the self-assembly of ligands linked by polyethylene glycol (PEG) components 
with “naked” Pd(II). The flexibility imbued by the organic chain resulted in the 
formation of the entropically favoured [Pd(L)2]2+ loops (Figure 3.2a). With a 
slightly less flexible ester-linked, tripyridyl ligand and “naked” palladium(II) 
ions, a double-cavity cage architecture is accessible (Figure 3.2b). Generation of 
the double-cavity cage can occur directly from the ligand or through a [Pd(L)2]2+ 
spiro-type structure when the metal/ligand ratio is altered from 1:2 to 3:4. 
Heating in a polar coordinating solvent i.e. DMSO results in the exclusive 





Figure 3.2: a) PEG-based flexible ligand and X-ray structure of [Pd(L)2]2+ spiro-type architecture,134 and 
b) ester-linked ligand and X-ray structures of [Pd2(tmeda)(L)]2+ mononuclear complex, [Pd(L)2]2+ spiro-
type compound and [2Cl⊂Pd3(L)4]4+ double-decker cage,136 chloride guests shown in space-fill style, 
hydrogen atoms, counterions and solvent molecules have been omitted for clarity. Conditions: (i) 
Pd(NO3)2, MeCN, RT; (ii) [Pd(tmeda)(NO3)2], DMSO, RT; (iii) Pd(NO3)2, DMSO, RT; (iv) Pd(NO3)2, 




 Ferrocene-based metallosupramolecular systems 
The common stable 18-electron organometallic iron-based sandwich complex 
known as ferrocene (Fc) provides an interesting combination of rigidity coupled 
with rotational flexibility. Additionally, Fc is well-known to be redox active, and 
thus provides extra functionality to any self-assembled system. In fact, Fc has 
been widely used as a pendant or peripheral part of ligands used to generate 
redox active architectures (Figure 3.3).137, 138   
 
Figure 3.3: Examples of Fc units as peripheral moieties: X-ray structures of a) a [Pt12(L)6(dppf)12]24+ 
hexagon from the side and the top,139 and b) a [Pd2(L)4]4+ cage with pendant Fc units,49 hydrogen atoms, 
solvent molecules and counterions have been omitted for clarity. 
However, while quite common,140, 141 1,1’-disubstituted Fc ligands have scarcely 
been used to generate cavity containing metallosupramolecular 
architectures.142-144 Most often, metallomacrocycles,145 where the 1,1’-
disubstituted Fc ligands adopt the syn- conformation with the aromatic “arms” 
π-stacked (Figure 3.4 left), or coordination polymers,140, 141 with the Fc ligands 





Figure 3.4: Cartoon showing generic Fc ligand in syn- and anti-configurations. 
There are few examples where 1,1’-disubstituted Fc ligands have been exploited 
to controllably generate discrete self-assembled metallosupramolecular 
architectures. Von Zelewsky and co-workers have synthesised a chiral bis-
bidentate Fc-based ligand and studied its coordination chemistry with Zn(II), 
Ag(I) and Cu(I) (Figure 3.5).146 Upon complexation, the ligand adopts an anti-
conformation due to the bulky pinene derivatives, and the metal centres assume 
tetrahedral geometries. The pinene groups cause helicity in the [2+2] structure; 
both M and P helicities can be obtained through different solvent systems. For 
example, crystals of the M-helix (Figure 3.5) were accessed through vapour 
diffusion of methanol into chloroform solution, and the P-isomer through 
vapour diffusion of toluene into dichloromethane solution of the dinuclear 
copper(I) complex.  
 
Figure 3.5: Fc-based 2,2’-bipyridylpinene ligand and X-ray structure of helical M-[Cu2(L)2]2+ complex 
formed upon addition of Cu(I), hydrogen atoms, solvent molecules and counterions have been omitted 
for clarity. 
Similar to the work by von Zelewsky, Ziessel and co-workers have also used Fc-
based 2,2’-bipyridine ligands with either amide or ester linkages, and although 
no chiral functional groups are present, a [2+2] helical structure is again formed 
when the ligands are introduced to Cu(I) ions.147 Both the P- and M-isomers 
were able to be accessed (Figure 3.6 right). Once again, the Fc units are in the 
anti-conformation. Contrasting this, when reacted with Cu(II) ions, the Fc 
moieties retain the energetically favourable syn-conformation and a 




left). The Cu(II) centre displays a distorted octahedral geometry due to ligand 
strain. In addition to synthesising the copper complexes from their respective 
metal salts, the Cu(I) complex could be accessed through dilution of a solution 
of the Cu(II) compound, which in turn was found to be energetically favourable 
only at higher concentrations. 
 
Figure 3.6: Fc-based 2,2’-bipyridyl ligand and X-ray structures of the [1+1] [Cu(L)]2+ metallocycle formed 
with Cu(II) ions,148 and the [Cu2(L)2]2+ helical structure generated upon complexation with Cu(I) ions,147 
hydrogen atoms, solvent molecules and counterions have been omitted for clarity. 
Raymond149-152 and others153, 154 have reported the self-assembly of a series of 
bis-bidentate anionic ligands with a range of 3+ metal ions. They have been able 
to generate [M2(L)3]6- helicates and mesocates, as well as [M4(L)6]12- tetrahedra. 
After the pioneering study by Raymond and co-workers155 in which bis-
bidentate catecholamide donor moieties were trialled with many rigid (mainly 
aromatic) linking units, the naphthalene-linked ligand was observed to form a 
tetrahedron upon coordination to Ga(III) with a cavity large enough to be 
exploited for host-guest chemistry (Figure 3.7). The authors have described the 
binding events of cationic organo- and metallo-guest molecules,150 and in some 
cases have shown the capsule to render reactive species (such as [CpRu(cis-1,3,7-





Figure 3.7: X-ray structure of [trimethyl[(2,4,6-trimethylphenyl)methyl]-phosphoniumGa4(L)6]11-,156 
guest shown in space-fill style, hydrogen atoms, solvent molecules and unbound counterions omitted 
for clarity. 
Progressive studies probed the substitution of the naphthalene unit for a more 
flexible Fc moiety.157 Examinations through NMR spectroscopies and HR-ESI-
MS of the self-assembly product of the Fc ligand (Figure 3.8), with iron(II) ions 
indicated that the entropically favoured [Fe2(L)3]4+ helicate formed, with the Fc 
moieties in the anti-conformation (Figure 3.8 bottom). This was generated in 
energetic preference to the more desirable cavity containing [Fe4(L)6]16- 
tetrahedron. The authors also examined the coordination chemistry of the 
ligand with germanium(IV) ions.157  Crystallisation attempts with Ge(IV) lead 
to the isolation of a [Ge2(L)2(µ-OMe)2]2- metallomacrocycle complex, with the Fc 






Figure 3.8: Fc-based catecholamide ligand, X-ray structures of [Ge2(L)2(µ-OMe)2]2- (top) and graphical 
representation of the [Fe2(L)3]4+ helicate formed upon complexation with Fe(II) (bottom),157 hydrogen 




Investigations by Crowley and co-workers on combinations of Fc-based bis-
bidentate N-N donor ligands with Cu(I), Ag(I) and Pd(II) resulted in the 
formation of a coordination polymer, metallomacrocycles and triple-tiered 
architectures.158 Upon complexation of a bis-2-pyridyl-1,2,3-triazole ligand 
(Figure 3.9 top-left) to Cu(I) ions, HR-ESI-MS showed peaks corresponding to 
[Cu(L)]+ and [Cu(L)]2+ and the 1H NMR spectrum displayed broad undefined 
peaks. Ascorbate was added to ensure that the copper centres retained their +1 
oxidation states, thereby eliminating the possibility of paramagnetic broadening 
due to the presence of Cu(II) ions. Unfortunately, the 1H NMR spectrum 
maintained its broadness, however X-ray crystallographic data revealed that 
this was likely due to the formation of a coordination polymer with a 
metal/ligand ratio of 1:1. On the other hand, when the same ligand was reacted 
with an equimolar amount of silver(I) ions, the 1H NMR spectra exhibited sharp, 
well defined peaks, and solid state analysis showed the structure to be a [2+2] 
macrocycle with the Ag(I) ions adopting a square-planar geometry  
(τ4 = 0.083).159 Solution phase studies of a mixture of the ligand and Pd(II) ions 
suggested that two discrete species were being formed, both with 1:1 
stoichiometries. The two products (where the pyridyl-triazole units are eclipsed 
or staggered) were shown to be exchangeable in CD3CN at RT and DFT 
calculations were in accordance with experimental data, suggesting that the 
staggered conformer was only 3 kJ mol-1 lower in energy. In spite of this, the 
eclipsed conformer was preferentially crystallised (Figure 3.9 left), although 
when the crystals were redissolved in CD3CN, 1H NMR spectroscopy revealed 
that after 40 hours, the initial equilibrium between the two species was restored. 
 
Figure 3.9: Fc-based bis-2-pyridyl-1,2,3-triazole ligand and the X-ray structure of the [2+2] [Pd2(L)2]4+ 
metallomacrocycle, and an Fc-based 2-pyridyl-1,2,3-triazole-2,2’-bipyridyl ligand and the X-ray 
structure of the [2+1] [Pd(L)2]2+ triple-tiered structure formed upon complexation with Pd(II),158 




During the same study, the authors also reacted Pd(II) with a low-symmetry Fc 
ligand, where one “arm” was a 2,2’-bipyridine unit and the other is a pyridyl-
triazole, in a 1:2 stoichiometric ratio, resulting in the formation of a triple tiered 
[2+1] complex (Figure 3.9 right). Previous attempts to make a topographically 
similar structure using covalent interactions required significantly more 
synthetic effort.160 Thus this latest approach exemplifies how valuable 
coordination chemistry can be for assembling large structures. Unfortunately, 
this system does not exhibit the same Cu(I) switching mechanism, vide infra, as 
the bis-bipyridine structure due to the weaker relative strength of the triazole 
ligand, thereby indicating potential difficulties when using coordination 
chemistry. In all of these architectures, the Fc units remain in the syn-
conformation due to favourable π-π stacking of the aromatic substituents. The 
same group has also studied the effects of introducing a copper(I) complex of 
6,6’-dimesityl-2,2’-bipyridine to some of the π-stacked systems. The bulky 
substituents, along with the Coulombic charge repulsion of the Cu(I) centres 
resulted in the extension of the system whereby the “arms” of the ligand rotate 
to the anti-configuration (Figure 3.10). 
 
Figure 3.10: X-ray structure of contracted Fc-based covalently bonded triple tiered architecture and 
MMFF model of extended system formed upon addition of two equivalents of [Cu(6,6’-dimesityl-2,2’-
bipyridine)]+,160 L = ancillary ligands, hexyloxy side chains have been truncated to methoxy groups, 




Lindner and co-workers have synthesised 1,1’-bis(3-pyridylethynyl)ferrocene, 
L4, and the related 1,1'-bis(4-pyridylethynyl)ferrocene and studied their 
coordination chemistry with silver(I), nickel(II) and palladium(II).161 With the 
pyridine substituted in the 4-position, complexation with Ni(II) ions in a 1:1 
ratio lead to the formation of a [2+2] macrocycle with the nickel(II) centres 
bridged by two nitrate anions. With the pyridine substituted in the 3-position 
(L4), the ligand was reacted with silver(I) and ligated palladium(II) ions, again 
in an equimolar stoichiometric ratio. Analogous to the nickel(II) complexes, 
both the Ag(I) and Pd(II) compounds formed [2+2] metallomacrocycles  
(Figure 3.11). In all cases, the ligands retain the lower energy, syn-conformation. 
Interestingly, Lindner and co-workers never studied the reaction between L4 
and “naked” dicationic palladium(II) ions in a 2:1 ratio. 
 
Figure 3.11: L4, an MMFF model of the [Pd2(L4)2Cl2]2+ and an X-ray structure of the [Ag2(L4)2]2+ formed 
upon complexing equimolar amounts of L4 and Pd(II) or Ag(I),161 hydrogen atoms, solvent molecules 





 Ferrocene-based [Pd2(L)4]4+ cages 
Given the ratio of ligand to palladium(II) used to generate [Pd2(L)4]4+ cage-like 
architectures is 2:1, and the structural similarity of L4 in the anti-state to L133 
and the known dipyridyl analogue of L1,162 it was postulated that upon 
exposure of “naked” palladium(II) ions to the rotationally flexible ferrocene 
ligand, the desired [Pd2(L4)4]4+ cage-like structures could be readily accessed 
(Figure 3.12). 
 
Figure 3.12: Cartoon of proposed scheme to generate a [Pd2(L4)4]4+ cage from “naked” Pd(II) ions and 
L4. 
Initially, the conformational geometry of L4 and the energies of formation of 
[Pd(L4)2]2+ (cis and trans) and a [Pd2(L4)4]4+ cage, C4, were examined using DFT 
calculations (BP86, def2-SVP, CH3CN solvent field, Appendix 2). The syn- and 
anti-forms were found to be very close in energy, with the syn-π-stacked 
conformation being 2 kJ mol-1 more favourable ( 
Figure 3.13a), consistent with previous literature.145, 163, 164 This was also 
supported by 1H NMR experiments, the proton signals associated with the 3-
pyridyl (Hc−f) arms of L4 were shifted upfield relative to those of the model 
compound 3-pyridylethynyl)ferrocene ( 
Figure 3.13b and c), indicating that L4 ligand predominantly adopts a stacked, 
syn-conformation in solution.  
With regards to the metallosupramolecular architectures, the formation energy 
of the trans-[Pd(L4)2]2+ complex was calculated to be +42 kJ mol-1 higher in 
energy than the starting materials indicating that it was unlikely to form, 
presumably due to the severe bond angle strain observed in the calculated 
structure (Figure 3.14). In contrast, the DFT calculations indicated that both cis-
[Pd(L4)2]2+ (ΔE = -90 kJ mol-1) and the [Pd2(L4)4]4+ cage (ΔE = -131 kJ mol-1) 














Figure 3.13: a) DFT optimised structures of L4 in the syn- and anti-conformations, hydrogen atoms have 
been removed for clarity, and partial stacked 1H NMR spectra (400 MHz, (CD3)2CO, 298 K) of b) 3-














Figure 3.14: DFT optimised structures of L4, trans-[Pd(L4)2]2+, cis-[Pd(L4)2]2+ and C4 with associated 







Spurred on by the promising computational results, the orange Fc ligand  
(λmax = 455 nm, Figure 3.15), L4 (2 eq.), was suspended in acetonitrile and treated 
with either 1 eq. of [Pd(CH3CN)4](BF4)2  or 1 eq. of [Pd(CH3CN)2(Cl)2] and 
AgSbF6 (2 eq.) to give darker orange solutions (λmax = 464 nm, Figure 3.15)  
indicative of complex formation. Precipitation with diethyl ether followed by 
filtration resulted in the formation of orange-red solids in excellent yields 
(78―99%).  
 
Figure 3.15: UV-Visible spectra (MeCN) of L4 (green trace), C4∙SbF6 (blue trace) and C4∙BF4 (red trace). 
HR-ESI-MS enabled the determination of the stoichiometry of the complexes; 
the dominant isotopically resolved palladium-containing species present in the 
mass spectra occurred at m/z = 617.6927 and 666.9897, which were attributed to 
[Pd2(L4)4](BF4)3+ and [Pd2(L4)4](SbF6)3+ ions, respectively. Other peaks corres-
ponding to [Pd2(L4)4]4+ were present in both mass spectra, and a 2+ peak was 





Figure 3.16: Partial HR-ESI-MS (CH3CN) of a) C4∙BF4 and b) C4∙SbF6. It is not uncommon for a [Pd(L)2]2+ 
peak to arise in a mass spectrum of a [Pd2(L)4]4+ cage due to fragmentation,52 however it cannot be ruled 
out that the entropically favoured monometallic species could be present in small amounts. 
Based on the DFT calculations and HR-ESI-MS data, it is assumed that the 
generated architectures have the formula [Pd2(L4)4](X)4 (where X = BF4- or  
SbF6-, C4∙BF4 or C4∙SbF6). In the 1H NMR spectra of the cage complexes  
(Figure 3.17), the resonances of the α-pyridyl protons (Hc and Hf) have shifted 
the furthest downfield relative to the uncoordinated ligand (e.g. Δδ = 0.75 and 
1.00 ppm for C4∙SbF6 and C4∙BF4, respectively), with the other pyridyl proton 
resonances shifting downfield as well. 
 
Figure 3.17: Partial stacked 1H NMR spectra (400 MHz, CD3CN, 298 K) of C4∙SbF6, L4 and C4∙BF4 




1H DOSY NMR spectroscopy (CD3NO2 or CD3CN, 298 K) also provided 
evidence for the formation of larger discrete architectures. The diffusion 
coefficients (D) for C4∙SbF6 and C4∙BF4 were found to be D = 5.46 x 10-10 m2 s-1 
and 6.31 x 10-10 m2 s-1, respectively in CD3NO2. The diffusion coefficient of L4 in 
CD3NO2 was higher (D = 10.9 x 10-10 m2 s-1) suggesting that the complexes are 
significantly larger than the uncoordinated ligand (Figure 3.18).  
 
Figure 3.18: Partial superimposed DOSY 1H NMR spectra (500 MHz, CD3NO2, 298 K) of L4 (green trace), 
C4∙SbF6 (blue trace) and C4∙BF4 (red trace). 
Similarly, the diffusion coefficients (D) for C4∙SbF6 and C4∙BF4 were found to be 
D = 7.16 x 10-10 m2 s-1 and 7.12 x 10-10 m2 s-1, respectively in CD3CN. These values 
were similar to those observed for related [Pd2(L)4]4+ cages (C1, C2 and C3) in 
the same solvent, consistent with the formation of complexes with the 
[Pd2(L4)4]4+ formulation.33, 166-170  
The molecular structures of the C4∙BF4 and C4∙SbF6 metallosupramolecular cage 
architectures were determined unequivocally using X-ray crystallography. X-
ray quality single crystals of C4∙BF4 and C4∙SbF6 were obtained via vapour 
diffusion of diethyl ether into acetonitrile solutions of the respective complexes. 
The X-ray data revealed that lantern-shaped C4 cages, similar to that of our 
previous tripyridyl cages, were generated.33, 166-170 The structure of C4∙BF4 was 
solved in the triclinic space group 𝑃1̅, with two half-cages, four 
tetrafluoroborate counterions and two acetonitrile solvent molecules in the 
asymmetric unit. There were two crystallographically independent cage 




Pd2’ distance of 13.410(2) Å. These are longer than the Pd-Pd distances of 
previous crystallographically characterised Pd(II) cages from within the 
Crowley group, which range from 11.49 to 12.51 Å.33, 162, 166-170 All four Fc units 
in the ligands adopted a lower-energy “eclipsed” orientation, and the ligands 
themselves are in the anti-conformation (average angle between the alkyne 
“arms” θ = 150.38°; ranging from 144.28° - 154.21°). Each cage contains two 
tetrafluoroborate counterions in its cavity, oriented in such a way that there is a 
hydrogen-bonding network between the fluorine atoms of the counterions and 
the internally directed α-pyridyl protons of the ligands (Figure 3.19a), as has 
been observed in other [Pd2(L)4](BF4)4 cage systems.171 While the X-ray data 
obtained for C4∙SbF6 was modest in quality due to weaker diffraction and 
disorder in the counter anions and solvents of crystallisation, the cationic 
portion of the structure was well defined and showed unequivocally that a 
[Pd2(L4)4]4+ system was obtained with an SbF6- anion located within the cavity 
of the cage (Figure 3.19b). MMFF modelling indicated that only one SbF6- anion 
could fit inside the cavity. 
 
Figure 3.19: X-ray structures of a) C4∙BF4 and b) C4∙SbF6, hydrogen atoms, solvent molecules and 
remaining counterions have been omitted for clarity. 
There was diffuse electron density in the centre of C4∙SbF6 (largest peak = 9.44 
Å-3) which could suggest two things: 1) either the SbF6- anion is disordered over 
two sites of the cavity or 2) the density is due to a Fourier ripple caused by the 
heavy antimony atom. The latter option seems more likely and thus the electron 
density could not be modelled appropriately. Additionally, the 1H NMR 
spectroscopic data displays larger downfield shifts of the internally directed 
pyridyl protons for C4∙BF4 than for C4∙SbF6, consistent with the higher 




[Pd(py)4]2+ centres. The Pd1-Pd2 bond distance was 13.397(1) Å. Interestingly, 
both cages (C4∙BF4 and C4∙SbF6) are meso-systems with two L4 ligands in the M- 
configuration and two in the P-configuration. This is also consistent with the 1H 
NMR spectroscopic data which dictates interconversion between the meso and 
helical forms of the cage, i.e. the Fc orientation with regards to the cavity of the 
cage is time-averaged in the 1H NMR spectra. 
Related [Pd2(L)4]4+ cages have been shown to bind neutral inorganic,33, 166-170 and 
organic34, 172, 173 guests and anions174-178 in a variety of solvents. Therefore, we 
examined the interaction of C4∙BF4 and C4∙SbF6 with a variety of guest 
molecules (Figure 3.20): cisplatin (CDDP), 9-methylanthracene (9-MA),111, 112 
2,4-dinitrotoluene (DNT), 1,4-benzoquinone (BQ),34, 172 2,4,7-trinitrofluorenone 
(TNF) and sodium p-toluenesulfonate (TOS)14, 168, 175 guest molecules in 
acetonitrile solutions (rather than nitromethane, due to solubility limitations).  
 
Figure 3.20: Guest molecules screened for binding in cage C4∙BF4, red = no interaction, orange = 
minimal interaction, green = large interaction. 
The C4∙BF4 system displayed only very modest complexation induced shifts 
(CISs) of the Hc proton of the cage in the presence of the guest molecules  
(Figure 3.22). Larger CIS were observed with C4∙SbF6 suggesting that the guest 
molecules interact more strongly with that cage, consistent with observations of 
Lusby and co-workers who showed that anion competition for the cage cavity 
in related [Pd2(L)4]4+ systems affects the strength of the host guest interaction 
with neutral guests.172 19F NMR spectroscopy (CD3CN, CD3NO2 or d6-acetone) 
suggested that the BF4- anions were interacting with the cage, presumably in a 
similar fashion to that observed in the X-ray structure, as the resonance due to 




(Figure 3.22). Unfortunately, 19F NMR spectroscopy with C4∙SbF6 was 
unattainable due to the high spin (I = 7/2) of antimony; there are no discernible 
peaks in the spectrum presumably because of paramagnetic broadening. 
 
Figure 3.21: Partial stacked 1H NMR spectra (400 MHz, CD3CN, 298 K) of a) C4∙BF4 , b) C4∙BF4 with excess 
9-MA, c) C4∙BF4 with excess DNT, d) C4∙BF4 with excess CDDP, e) C4∙BF4 with excess BQ, f) C4∙BF4 with 
excess TNF and g) C4∙BF4 with excess TOS. 
 
Figure 3.22: Partial stacked 19F NMR spectra (376 MHz, (CD3)2CO, 298 K) of a) NaBF4 and C4∙BF4, 
indicating association of the anion within the cage. 
With C4∙SbF6, only very small CIS were observed with 9-MA and DNT  
(Figure 3.23a vs. b and c). While CDDP induced a larger shift  
(Δδ(Hc)CDDP = 0.08 ppm, Figure 3.23a vs. d) of the Hc proton of the cage a 
titration to determine the association constant was impossible due to the poor 
solubility of CDDP in CD3CN. As the remaining guests induced large CIS of 




determined using 1H NMR spectroscopic titrations. The largest CIS, in each 
case, were those of the cage Hc protons (e.g. Δδ(Hc)TOS = 0.43 ppm), consistent 
with guest binding within the cage cavity. The 1H NMR spectroscopic titration 
data was curve fitted using a 1:1 host/guest binding model (Table 3.1) through 
the Bindfit program (supramolecular.org).179   
 
Figure 3.23: Partial 1H NMR stacked spectra (400 MHz, CD3CN, 298 K) of a) C4∙SbF6, b) C4∙SbF6 with 
excess 9-MA, c) C4∙SbF6 with excess DNT, d) C4∙SbF6 with excess CDDP, e) C4∙SbF6 with excess BQ, f) 
C4∙SbF6 with excess TNF and g) C4∙SbF6 with excess TOS. 
The 1:1 host/guest model gave the most reasonable fit (Table 3.1), similar to 
what has been observed with other  related [Pd2(L)4]4+ cages.34, 172, 173 The anionic 
TOS (Ka = 900 ± 100 M-1) guest had the strongest interaction with the cage 
presumably due the stronger electrostatic interaction between the cationic cage 
and the anionic guest supplementing the hydrogen bonding interaction 
between Hc and the sulfonate’s oxygen atoms. The neutral organic guests had 
weaker interactions with C4 (BQ (Ka = 50 ± 4 M-1) and TNF (Ka = 350 ± 30 M-1)) 
but also seem to interact through hydrogen bonding between the acidic internal 
α-pyridyl protons of the cage and the carbonyl and nitro oxygen atoms on the 
guests (Figure 3.24). Presumably, the larger association constant for the TNF-
cage adduct reflects the presence of additional C-H─π and van der Waals 




Table 3.1: Calculated binding constants, root mean squares (RMS) and covariances from the 1:1 
host/guest binding model and the four different 1:2 host/guest binding models (additive, statistical, 
non-cooperative and full) for C4∙SbF6 and TOS in CD3CN. Errors are estimated to be less than 10%. 
Data obtained from supramolecular.org.180 
Fit Binding Constant (TOS, M-1) RMS Covariance 
1:1 K = 900 2.28 x 10-2 2.66 x 10-2 
1:2 (Additive) K1 = 57, K2 = -89 1.17 x 10-2 1.61 x 10-2 
1:2 (Statistical K11 = 4300 1.92 x 10-2 1.81 x 10-2 
1:2 (Non-cooperative) K11 = 60 1.76 x 10-2 1.58 x 10-2 
1:2 (Full) K1 = 0.05, K2 = 1300000 1.69 x 10-2 1.44 x 10-2 
 
 
Figure 3.24: 1H NMR (500 MHz, CD3CN, 298 K) titration curves of C4∙SbF6 with TOS (green trace, Ka = 
900 ± 100 M-1), TNF (blue trace, Ka = 350 ± 30 M-1)  and BQ (yellow trace, Ka = 50 ± 4 M-1). Curve obtained 
by monitoring the internal cage cavity proton Hc. 
Interestingly, HR-ESI-MS data of a mixture of C4∙SbF6 and excess TOS exhibited 
peaks pertaining to both 1:1 and 1:2 host/guest adducts (Figure 3.25), 
suggesting that, under the conditions of which the mass spectrum was obtained, 
two TOS guest molecules were associated with the cage. This could be due to 
ion pairing or it may be indicative of the formation of the 1:2 host/guest adduct. 
However as displayed in Table 3.1, modelling of the 1H NMR spectroscopic 
titration data indicates that the 1:1 host/guest adduct is more likely. HR-ESI-MS 
data of the cage with the other neutral guests was obtained, however only peaks 
relating to the empty host/cage were observed. These results presumably reflect 






Figure 3.25: Partial HR-ESI-MS (CH3CN) of C4∙SbF6 with excess TOS. 
The redox behaviour of L4, C4∙BF4 and C4∙SbF6 was probed through cyclic 
voltammetry (CV) experiments in nitromethane solution (Table 3.2).181, 182 L4 
exhibited the expected single reversible oxidation of the Fc unit with E° = 0.77 V, 
(vs. decamethylferrocene; E° = 0.00 V) in agreement with previous reports (albeit 
in different solvents).161, 183 CV experiments also revealed that both C4∙BF4 and 
C4∙SbF6 are redox active, giving a single oxidation process, at E° = 0.86 V, 
indicating that there was no electronic communication between the four Fc units 
of the cages (ΔE = Epc – Epa = 110 mV, for both systems, Figure 3.27a).  
Table 3.2: Formal electrode potentials (E°)a exhibited by L4, C4∙BF4 and C4∙SbF6 and C4∙BF4 in the 
presence of 10 eq. of each of TOS, TNF and BQ in nitromethane solution. 








aE° = (Epc + Epa)/2. Conditions: nitromethane solvent, 0.1 M NBu4PF6 as supporting electrolyte, ~1 mM 
concentration of electroactive analyte, potentials referenced to the [Fc*]+/0 = 0.00 V of 




Despite exhibiting weaker guest binding through 1H NMR spectroscopic 
studies, C4∙BF4 was used for the host/guest electrochemical experiments as it 
was readily accessible in larger quantities. Regardless of which cage was used, 
the presence of a vast excess of PF6- anions from the electrolyte would likely 
displace most of the original anions from the cage cavities. 19F NMR 
spectroscopy experiments confirmed this as the resonance for the BF4- fluorine 
atoms shifts upfield upon addition of an excess of NBu4PF6- (Figure 3.26), 
suggesting the PF6- anions are displacing the BF4- anions from the cage. 
 
Figure 3.26: Partial stacked 19F NMR spectra (376 MHz, CD3NO2, 298 K) of a) NaBF4, b) C4∙BF4 + excess 
NBu4PF6 and c) C4∙BF4 indicating the PF6- anions from the electrolyte will compete for the cage with the 
guest molecules. 
Thus, CV experiments with C4∙BF4 in the presence of excess (10 eq.) of the guest 
molecules BQ, TNF, and TOS were carried out (Figure 3.27b). Disappointingly, 
no shift (within experimental uncertainty) of the redox potential of the cage was 
observed, suggesting that under these conditions the Fc units of the cages 





Figure 3.27: Cyclic voltammograms (CVs) of a) L4 (green trace), C4∙BF4 (red trace) and C4∙SbF6 (blue 
trace); and b) of C4∙BF4 (red trace), C4∙BF4 in the presence of 10 eq. TOS (green trace), C4∙BF4 in the 
presence of 10 eq. TNF (blue trace) and C4∙BF4 in the presence of 10 eq. BQ (yellow trace), in 




 Larger ferrocene-based palladium(II) architectures 
The 3-pyridyl coordination motif has been used extensively by Crowley and co-
workers49, 51, 54, 185 and many others186-190 to generate [Pd2(L)4]4+ cage molecules. 
Others have also described the production of discrete metallosupramolecular 
architectures using ligands with 4-pyridyl donor units.191-195 To further examine 
if the rotationally flexible but rigid Fc linker unit could be exploited to generate 
other redox active cage systems, the use of the related 4-pyridyl variant of L4 
(L4a, Figure 3.28 top) was examined. The rotational flexibility of Fc means that 
L4a could adopt a range of different “bend” angles, and hence could potentially 
for a range of structurally different metallo-complexes. Lindner and co-workers 
have previously described the synthesis of this ligand and the complex obtained 
upon coordination to nickel(II) ions in a 1:1 stoichiometric ratio.161 In the 
structure reported by the authors, [Ni2(L4a)2(µ-NO3)2(NO3)2], the L4a ligands 
remained in the syn-conformation with the 4-pyridyl units π-π stacking  
(Figure 3.28). 
 
Figure 3.28: Ligand L4a and X-ray structure of [Ni2(L4a)2(µ-NO3)2(NO3)2],161 hydrogen atoms and solvent 
molecules have been omitted for clarity. 
There is an infinite amount of possible “bend” angles that the rotationally 
flexible L4a could adopt. However, related bis(4-pyridylalkyne)aryl ligands 
with different bend angles (60° = L60, 90° = L90, 120° = L120 and 180° = L180) are 
already known (Figure 3.29). Complexation of each of these ligands with Pd(II) 
generated complexes which could be used as proxies for the behaviour of L4a 
with Pd(II). Indeed the complexation of these ligands L60, L90 and L120 with Pd(II) 





Figure 3.29: Ligands L60, L90, L120 and L180 as proxies for different potential bend angles of L4a.197 
Fujita and co-workers have detailed the solvato-controlled formation of a 
[Pd4(L60)8]8+ cube and a [Pd3(L60)6]3+ triangular prism.193 Addition of L60 to 
Pd(NO3)2 in a 2:1 stoichiometric ratio in DMSO led to the larger cubic system, 
while performing the reaction in acetonitrile generated the smaller prismatic 
molecule. It was shown to be possible to interconvert between the two systems 
through addition and removal of acetonitrile (Figure 3.30). The host-guest 
chemistry of the systems was not explored.  
 
Figure 3.30: L60 and X-ray structures of a) the [Pd4(L60)8]8+ cube (blue) formed upon complexation with 
Pd(II) in DMSO and b) the [Pd3(L60)6]6+ semiregular triangular prism (red) formed upon complexation 





The 90° ligand L90 has been shown to generate a [Pd6(L90)12]12+ cubic structure 
with each palladium(II) ion positioned at the centre of each face of the cube. 
Upon complexing L120 with Pd(II) ions in a 2:1 ratio, Fujita and co-workers 
observed the formation of a [Pd12(L120)24]24+ cuboctahedron (Figure 3.31).194 The 
reaction was not studied in acetonitrile, presumably due to solubility limitations 
and the fact that the formation of larger architectures is more favourable in more 
coordinating solvents due to the many necessary self-corrective steps. Several 
endohedrally functionalised derivatives of L120 have been developed and their 
complexation with Pd(II) ions in a 2:1 stoichiometry produces [Pd12(L)24]24+ 
cuboctahedra in all cases. Host-guest studies with these architectures have 
involved the encapsulation of fluorescent molecules,198 anionic monomers for 
polymerisation,194 fullerenes,199 TiO2 nanoparticles200 and small organic 
molecules.201  
 
Figure 3.31: L120 and X-ray structure of the [Pd12(L120)24]24+ cuboctahedron formed upon complexation 
with Pd(II) in DMSO,198 hydrogen atoms, solvent molecules and counterions have been omitted for 
clarity.  
While L180 (and more soluble substituted variants) have been used to form a 
range of metallosupramolecular structures including tubes, triangles, squares 
and rectangles,202-206 there have been no reports, to the best of our knowledge, 
of L180 reacting with “naked” Pd(II) ions. This is perhaps unsurprising as one 
could envisage the formation of a 2-dimensional square grid coordination 
polymer similar to what others have observed when L180 is complexed with 
pseudo square-planar metal ions.207 It is however, still a possible architecture 
that L4a could produce.  
Given the flexibility of L4a, there are a multitude of metallosupramolecular 
architectures possible as mentioned previously. Either a single architecture 
would be cleanly generated, or a mixture of structures would be obtained when 




Initially, the complexation of L4a with “naked” Pd(II) ions was examined in 
DMSO, however a solution of the ligand in DMSO turned from orange to brown 
within minutes, suggesting the rapid decomposition of the ligand. The 1,1’-
diethynyl ferrocene motif has been previously established to be unstable in 
DMSO.208 Thus, the complexation of L4a with [Pd(CH3CN)4](BF4)2 in a 2:1 
stoichiometric ratio was undertaken in acetonitrile. An orange solution of the 
ligand was added to a solution of Pd(II). The resulting deep red solution was 
stirred at room temperature for two hours. Precipitation of the product with 
diethyl ether gave a red solid in excellent yield (95%). HR-ESI-MS studies in 
acetonitrile suggested that the product is the smaller [Pd3(L4a)6]6+ architecture. 
Isotopically resolved peaks corresponding to the triangular prism with the loss 
of 1, 2, 3 and 4 BF4- counterions were observed (Figure 3.32). The generation of 
the smaller species indicates that the self-assembly process is entropically 
driven, as opposed to enthalpically, in this case.  
 
Figure 3.32: Partial HR-ESI-MS (CH3CN) of C4a. 
1H NMR spectroscopy of the solid revealed a distinct set of signals, suggesting 
the formation of a single architecture (Figure 3.33). Downfield shifts of the 
pyridyl protons Hd (Δδ = 0.41 ppm) and Hc (Δδ = 0.14 ppm) were indicative of 




pertaining to Ha and Hb of the Fc moiety transition from two triplets to four 
multiplets upon Pd(II) complexation. This indicates that the Fc units in the 
architecture are not in identical environments and are now locked into a 
staggered orientation, as opposed to eclipsed. 
 
Figure 3.33: Partial stacked 1H NMR spectra (400 MHz, CD3CN, 298 K) of a) L4a and b) C4a. 
Diffusion ordered 1H NMR spectroscopy (500 MHz, CD3CN, 298 K) indicated 
that C4a was larger than the ligand (D = 14.8 x 10-10 m2 s-1 for L4a vs.  







where kB is the Boltzmann constant and η is the viscosity of the solvent, the 
diffusion coefficient, D can be related to the hydrodynamic radius, RH, thus 
determining the size of the generated architecture. For C4a, RH = 12.00 Å. The 
crystallographically characterised triangular prism generated by Fujita and co-
workers, vide supra, has an average radius of 12.24 Å,193 thus providing more 
evidence that C4a exists as a [Pd3(L4a)6]6+ architecture (the cube by Fujita and 
co-workers has an average radius of 13.37 Å). Unfortunately, the DOSY data 
obtained for C4a cannot be referenced to the data for C4 due to different solvent 





Figure 3.34: Partial superimposed DOSY 1H NMR spectra (500 MHz, CD3CN, 298 K) of L4a (green trace), 
C4a (blue trace). 
Thin needle crystals could be generated from an acetonitrile or nitromethane 
solution of C4a via slow diffusion of either diethyl ether, diisopropyl ether or 
THF. Unfortunately, the crystals were weakly diffracting, thus the data was 
collected using the Synchrotron.† Solving the crystal structure in the monoclinic 
space group C2/c revealed the structure to be the smaller [Pd3(L4a)6]6+ 
triangular prism (Figure 3.35a). While the data was of poor quality, the cationic 
portion of the molecule was reasonably well refined, and it was evident that 
only the entropically favoured product was present. The Fc units were all 
eclipsed with an average dihedral “bend” angle of the “arms” of 35.8°  
(range 25.3° - 42.2°). Two BF4- counterions were found to reside in the cavity of 
the structure. The SbF6- variant of C4a was also generated through a similar 
procedure to that of C4∙SbF6, for the express purpose of obtaining superior 
quality X-ray crystal data. The solution to the structure in the trigonal space 
group R3̅ was disordered such that a second molecule was 60° out of phase from 
the first (Figure 3.35b), creating a Star of David motif when viewed end-on 
(Figure 3.35c). 
 
                                                 
† Dr. Dave Turner is gratefully acknowledged for his assistance in collecting and analysing the  









Figure 3.35: a) X-ray structure of C4a∙BF4, hydrogen atoms, solvent molecules and counterions have been 
omitted for clarity; and b) cartoon of the disordered structure of C4a∙SbF6 with c) end-on view showing 









Similar to L4 and C4, the electrochemical behaviour of L4a and C4a was 
examined. The expected single reversible oxidation of the Fc unit was exhibited 
by L4a in acetonitrile with E° = 0.82 V (vs. decamethylferrocene; E° = 0.00 V). 
Additionally, C4a was also shown to be redox active in acetonitrile, displaying 
a single reversible oxidation process at E° = 0.90 V. This indicates that, akin to 
the C4 cages, there was no electronic communication between the Fc units 
(Figure 3.36). 
 
Figure 3.36: Cyclic voltammograms (CVs) of L4a (green trace) and C4a (blue trace), in acetonitrile 
solution (1 mM), with 0.1 M NBu4PF6 as supporting electrolyte, 100 mV s-1. 
The centre of the system features a cavity, thus the host-guest chemistry of C4a 
was explored with a range of organic molecules (Figure 3.37) via 1H NMR 
spectroscopy in CD3CN. Initial screening of the guests revealed that the vast 
majority either showed no interaction with the host, or decomposition of the 
complex was observed. However, subtle CIS of the ortho pyridyl protons (Hd) 
were observed with excesses of 1,2,3-trihydroxybenzene (THB, Δδ = 0.015 ppm) 
and 2,4,7-trinitrofluorenone (TNF, Δδ = 0.025 ppm); and considerably larger CIS 
were exhibited by the addition of excess anionic p-toluenesulfonate  





Figure 3.37: Guest molecules screened for binding in cage C4a in CD3CN, red = decomposes complex 
or no interaction, orange = minimal interaction, green = strong interaction. 
1H NMR spectroscopic titrations were carried out with TOS to determine the 
association constant. However, despite exhibiting a sizeable CIS in the initial 
screening, the association constant of TOS with C4a was problematic. Binding 
was weak, as evidenced by the binding isotherm (Figure 3.38), thus a mole ratio 
plot was unobtainable. Based on the geometry of C4a, it can be rationalised that 
up to three TOS anions can associate on the external face of each palladium(II) 
centre. Additionally, there are two portals in which TOS anions can be 
positioned such that the sulfonate groups are proximal to the three dicationic 




binding isotherm, fitting the titration data to 1:1 or 1:2 models resulted in most 
fits giving somewhat sensible data ( 
Table 3.3). The titration data does not lend itself to one specific type of 
interaction. It is obvious that there is an interaction between TOS and C4a, and 
while one can reason that the 1:2 non-cooperative flavour gives the best fit, the 
possibility remains that the system exists in a 1:3 stoichiometric ratio.  
 
Figure 3.38: Binding isotherm for C4a with TOS (black dots) and fitted binding isotherms derived from 
different fits: additive (orange trace), full (blue trace), non-cooperative (red trace) and statistical (green 
trace). Simulated data obtained through supramolecular.org.180 
Table 3.3: Calculated binding constants, root mean squares and covariances from the 1:1 host/guest 
binding model and the four different 1:2 host/guest binding models (additive, statistical, non-
cooperative and full) for C4a (0.25 mM) and TOS in CD3CN. Errors are estimated to be less than 5%. 
Fit Binding Constant (TOS, M-1) RMS Covariance 
1:1 K = 35.4 4.21 x 10-3 1.87 x 10-3 
1:2 (Additive) K1 = 560, K2 = 890 1.82 x 10-3 3.79 x 10-4 
1:2 (Statistical) K11 = 71 4.21 x 10-3 1.87 x 10-3 
1:2 (Non-cooperative) K11 = 1767 1.60 x 10-3 2.95 x 10-4 





Unfortunately, mass spectral data of a mixture of TOS and C4a did not display 
peaks pertaining to any host-guest complexes, thus neither confirming nor 




 Conclusions & future directions 
This chapter has discussed the synthesis, characterisation, and host-guest 
chemistry of two redox active [Pd2(L4)4]4+ cages (C4) and a [Pd3(L4a)6]6+ trigonal 
prism (C4a) containing rotationally flexible ferrocene ligands. It was interesting 
to see that, despite the infinite “bend” angles L4 and L4a could adopt, only one 
type of architecture was generated when each ligand was exposed to “naked” 
Pd(II) ions. In the case of the [Pd2(L4)4]4+ cages, the Fc ligands were almost 
completely in the anti-conformer (average “bend” angle = 150.4°), while for the 
[Pd3(L4a)6]6+ trigonal prism, the Fc ligands were significantly more closed 
(average “bend” angle = 35.8°). These metallosupramolecular architectures 
exemplify how subtle changes in ligand design and stoichiometry can lead to 
drastically different structures.  
Host-guest studies with C4 and three different guests (TOS, TNF and BQ) 
revealed that the anionic sulfonate guest exhibits the largest association 
constant (Ka = 900 M-1) in CD3CN. Similar studies with C4a suggested that the 
larger system could exists as a 1:1, 1:2 or even 1:3 host/guest complex with 1H 
NMR titration data hinting at a 1:2 (non-cooperative) binding mode.  
Unfortunately, while the cages and prism were redox active, CV experiments 
did not suggest that the guests have any effect on the redox potentials of the Fc-
based metallosupramolecular architectures. With regards to the cage systems, 
future work will examine generating analogous cages with larger non-
interacting anions such as tetrakis[3,5-bis(trifluoromethyl)phenyl] 
borate (BArF-) as this should lead to enhanced host-guest interactions and 
enable the cages to be exploited as electrochemical sensors184 or for redox 
catalysis.209, 210 In terms of C4a, different geometrical structures could possibly 
be generated using differing ligand-Pd(II) stoichiometric ratios. This could 
increase the scope for interesting host-guest chemistry as architectures with 
larger cavities could be produced.  
It has been demonstrated that with a ferrocene core unit and alkyne linkers, 
[Pdn(L)2n]2n+ metallosupramolecular architectures are accessible with a 1:2 
metal/ligand stoichiometry. Using aryl,140 amide132, 211 or hydrazone211 linkers 
in the ligand backbone has the potential to imbue the system with more 
flexibility. The new systems may be able to mimic enzymes with regards to the 
“induced fit” model, adjusting the cavity size to better accommodate the 
substrate, leading to interesting catalytic chemistry.  
Additionally, stimuli responsive discrete architectures can be synthesised, 
exhibiting guest uptake and release through alteration of the magnetic, 




have also been synthesised using disubstituted ferrocene-based ligands.140, 211 
Using flexible linking units in this manner creates the possibility to have a 
flexible polymer that has the ability to expand and contract in response to an 
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Scheme 3.1: Synthetic scheme to afford C4·BF4, C4·SbF6 and C4a. Conditions: (i) nBuLi, TMEDA, I2, 
Et2O, -78 °C; (ii) FeCl3 (aq), RT; (iii) 3-ethynylpyridine, CuI, Pd(CH3CN)2Cl2, [PH(tBu)3]BF4, iPr2NH,  
100 °C; (iv) [Pd(CH3CN)4](BF4)2, MeCN, RT; (v) Pd(CH3CN)2Cl2, AgSbF6, RT; (vi) 4-ethynylpyridine, 






Synthesis of 8 
The synthesis of 8 was previously reported by Inkpen et al., in 19% yield.213 The 
synthesis of this compound was carried out by Dr. James Findlay. 
 
Freshly distilled TMEDA (30.0 mL, 200 mmol) and n-butyl lithium (100 mL of  
2 M solution in hexanes; 200 mmol) were combined in dry diethyl ether (70 mL) 
under argon. The n-butyl lithium solution was then transferred via cannula to a 
vessel containing a suspension of ferrocene (16.9 g, 91 mmol) in dry diethyl ether 
(130 mL) under argon, and the mixture was stirred at RT overnight. The 
suspension was then cooled to -78 °C and a solution of iodine (50.8 g, 200 mmol) 
in dry diethyl ether (350 mL) was added slowly via cannula under argon. 
Stirring at -78 °C was continued for 30 minutes after completion of the addition 
and then the solution was allowed to reach RT, at which time it was allowed to 
stir for a further 30 minutes. The crude reaction mixture was filtered through 
Celite and concentrated under reduced pressure. The residue was dissolved in 
hexane (200 mL) and washed repeatedly with a 0.5 M aqueous solution of FeCl3 
(12 x 200 mL) until only the desired product was observed by 1H NMR in the 
organic phase. The organic layer was dried over Na2SO4 and the solvents were 
removed under reduced pressure. The crude product was further purified by 
column chromatography (silica gel, petrol) to give a dark red oil upon removal 






Synthesis of L4 
The synthesis of L4 was previously reported by Lindner et al. through a 
different procedure in 30% yield,214 and more recently by Long et al. in 23% 
yield,183 and Scottwell et al. in 27% yield.165 
 
8 (677 mg, 1.55 mmol) was added to DIPA (10 mL) and the solution was purged 
with N2 for 10 minutes. 3-ethynylpyridine (382 mg, 3.71 mmol), CuI (58.9 mg, 
0.309 mmol), Pd(CH3CN)2Cl2 (24.1 mg, 0.0930 mmol) and [PH(tBu)3]BF4  
(53.8 mg, 0.185 mmol) were then added and the reaction mixture was heated 
under microwave radiation at 100 °C for 2 hours. The crude mixture was then 
cooled and taken up in CHCl3 and filtered through Celite before being washed 
with aqueous EDTA/NH4OH (0.1 M, 50 mL). The organic layer was separated 
and washed with water (100 mL) and brine (100 mL), then dried over Na2SO4. 
The solvent was removed under reduced pressure and the crude product was 
purified using column chromatography on silica gel (CH2Cl2 to 1:19 
acetone/CH2Cl2 to 1:4 acetone/CH2Cl2) to give L4 as an orange solid (571 mg, 
1.47 mmol, 95%). 1H NMR (400 MHz, CDCl3, 298 K) δ: 8.63 (dd, J = 2.2, 0.9 Hz, 
2H, Hc), 8.47 (dd, J = 4.9, 1.7 Hz, 2H, Hf), 7.62 (dt, J = 7.9, 1.9 Hz, 2H, Hd), 7.14 
(ddd, J = 7.9, 4.9, 0.9 Hz, 2H, He), 4.58 (t, J = 1.9 Hz, 4H, Hb), 4.36 (t, J = 1.9 Hz, 





Synthesis of L4a 
The synthesis of L4a was previously reported by Lindner et al. in 33% yield.214  
 
8 (658 mg, 1.50 mmol) was dissolved in DIPA (8 mL) and the solution was 
degassed with argon for 15 minutes. To the degassed solution was added 11 
(465 mg, 4.51 mmol, 3 eq.), [Pd(CH3CN)2Cl2] (23.4 mg, 0.900 mmol), 
[PH(tBu)3](BF4) (52.3 mg, 0.180 mmol), and CuI (57.3 mg, 0.301 mmol) and the 
resulting mixture was heated under microwave irradiation at 100 °C for 2 hours. 
The solution was cooled, diluted with DCM (50 mL) and EDTA/NH4OHaq  
(0.1 M, 100 mL) was added. The biphasic mixture was stirred vigorously for 10 
minutes before the organic layer was separated, and the aqueous layer was 
extracted with DCM (2 x 50 mL). The combined organic layers were washed 
with brine (50 mL), dried over Na2SO4, filtered and the solvents were removed 
under reduced pressure. The residue was purified by column chromatography 
on silica gel (gradient CH2Cl2 to 50% acetone in CH2Cl2) and the solvent was 
removed under reduced pressure to give L4a as an orange solid (488 mg, 83%). 
1H NMR (400 MHz, CD3CN, 298 K) δ: 8.40 (d, J = 5.0 Hz, 4H, Hd), 7.17 (d, J = 5.0 




Synthesis of C4∙BF4 
 
[Pd(CH3CN)4](BF4)2 (57 mg, 0.13 mmol) was added to a suspension of L4 (100 
mg, 0.26 mmol) in acetonitrile (15 mL). The mixture was stirred at RT until an 
orange-red solution formed, at which point the product was precipitated with 
diethyl ether (30 mL). The solid was collected via filtration and washed with 
diethyl ether (10 mL) and CH2Cl2 (5 mL), giving the desired product as an 
orange-red solid (135 mg, 0.064 mmol, 99%). 1H NMR (400 MHz, CD3CN,  
298 K) δ: 9.52 (s, 8H, Hc), 8.93 (d, J = 5.8 Hz, 8H, Hf), 7.91 (dd, J = 8.0, 1.9 Hz, 8H, 
Hd), 7.54 (dd, J = 8.0, 5.8 Hz, 8H, He), 4.79 (t, J = 1.9 Hz, 16H, Hb), 4.34 (t, J = 1.8 
Hz, 16H, Ha). 13C NMR (125 MHz, CD3CN, 298 K) δ: 153.8, 149.9, 142.2, 128.2, 
125.8, 96.3, 81.5, 74.7, 73.5, 64.8. 19F NMR (376 MHz, (CD3)2CO, 298 K) δ: -150.3. 
HR-ESI-MS (CH3CN): m/z = 441.0185 [Pd(L4)]2+ (calc. for (C24H16N2Fe)2Pd, 
441.0185); 441.5187 [C4]4+ (calc. for (C24H16N2Fe)4Pd2, 441.5188); 617.6927 
[C4(BF4)]3+ (calc. for (C24H16N2Fe)4Pd2BF4, 617.6931). Anal. calcd. for 
C96H64B4F16Fe4N8Pd2∙3CH2Cl2∙CH3CN: C, 50.36; H, 3.05; N, 5.23%. Found C, 





Synthesis of C4∙SbF6 
 
[Pd(CH3CN)2Cl2] (33 mg, 0.13 mmol) was stirred at RT with AgSbF6 (89 mg, 0.26 
mmol) in acetonitrile (5 mL) in the absence of light for 10 minutes. The resulting 
suspension was filtered through Celite into a solution of L4 (100 mg, 0.26 mmol) 
in acetonitrile (15 mL). The mixture was stirred at RT until an orange-red 
solution formed, at which point the product was precipitated with diethyl ether 
(30 mL). The solid was collected via filtration and washed with diethyl ether (10 
mL) and CH2Cl2 (5 mL), giving the desired product as an orange solid (136 mg, 
0.050 mmol, 78%). 1H NMR (400 MHz, CD3CN, 298 K) δ: 9.24 (d, J = 1.8 Hz, 8H, 
Hc), 8.88 – 8.79 (m, 8H, Hf), 7.96 (dd, J = 8.0, 1.6 Hz, 8H, Hd), 7.58 – 7.54 (m, 8H, 
He), 4.76 (t, J = 1.8 Hz, 16H, Hb), 4.36 (t, J = 1.9 Hz, 16H, Ha). 13C NMR (125 MHz, 
CD3CN, 298 K) δ: 153.5, 150.1, 142.6, 128.4, 125.8, 96.4, 81.6, 74.4, 73.7, 65.2. HR-
ESI-MS (CH3CN): m/z = 441.0182 [Pd(L4)]2+ (calc. for (C24H16N2Fe)2Pd, 441.0185); 
441.5184 [C4]4+ (calc. for (C24H16N2Fe)4Pd2, 441.5188);   666.9897   [C4(SbF6)]3+     
(calc. for (C24H16N2Fe)4Pd2SbF6, 666.9900); 1117.9318 [C4(SbF6)2]2+ (calc. for 
(C24H16N2Fe)4Pd2(SbF6)2, 1117.9325). Anal. calcd. for C96H64F24Fe4N8Pd2Sb4∙ 





Synthesis of C4a 
 
[Pd(CH3CN)4](BF4)2 (45.5 mg, 0.102 mmol) was added to a solution of L4a (79.5 
mg, 0.205 mmol) in acetonitrile (15 mL). The deep red solution was stirred at 
room temperature for 2 hours, at which point the product was precipitated by 
addition of diethyl ether (30 mL). The solid was collected via filtration and 
washed with diethyl ether (10 mL), giving the desired product as a red solid 
(103 mg, 95%). 1H NMR (400 MHz, CD3CN, 298 K) δ: 8.81 (d, J = 6.7 Hz, 12H, 
Hd), 7.31 (d, J = 6.7 Hz, 12H, Hc), 4.67 (m, 12H, Hb), 4.62 (m, 12H, Hb’), 4.52 (m, 
12H, Ha), 4.49 (m, 12H, Ha’). 13C NMR (125 MHz, CD3CN, 298 K) δ: 151.7, 137.7, 
129.6, 120.9, 120.7, 101.1, 83.9, 76.0, 75.4, 73.2, 73.1, 65.3. 19F (376 MHz, CD3CN, 
298 K) δ: -151.10. HR-ESI-MS (CH3CN): m/z = 547.0218 [C4a(BF4)]5+ (calc. for 
(C24H16FeN2)6Pd3BF4, 547.0235; 705.5284 [C4a(BF4)2]4+ (calc. for (C24H16FeN2)6 
Pd3(BF4)2, 705.5304; 969.7060 [C4a(BF4)3]3+ (calc. for (C24H16FeN2)6Pd3(BF4)3, 






3.6.3 1H NMR titration experimental details 
Initial sample volumes were 500 µL with 1 mM concentration of C4a. The 
solutions of the TOS guest were 5 mM in the same stock solution of the host. 1H 
NMR spectra were recorded at 0 – 4.5 equivalents of guest. Association 
constants were obtained by analysis of the resulting titration data using either 
the 1:1 or 1:2 host/guest binding equilibria equations implemented in the 
Bindfit215 algorithm at supramolecular.org.180  
3.6.4 Cyclic voltammetry experimental details 
Cyclic voltammetry experiments were performed in nitromethane and 
acetonitrile solutions, for C4 and C4a, respectively, at 20 °C with a concentration 
of 1 mM of electroactive analyte and 0.1 M NBu4PF6 as the supporting 
electrolyte. A three-electrode cell was used with Cypress Systems 1.4 mm 
diameter glassy carbon working, Ag/AgCl reference and platinum wire 
auxiliary electrodes. Voltammograms were recorded with the aid of a 
Powerlab/4sp computer-controlled potentiostat. Potentials for all complexes 
were referenced to the reversible formal potential (taken as E° = 0.00 V) of the 
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Nature’s enzymes have had roughly 4 billion years217 to evolve into the complex 
and remarkably functional structures we see today. Their inherent complexity 
leads to degrees of substrate binding and catalytic activity beyond any synthetic 
system. Researchers have long since recognised the potential for enzymes to be 
used as practical catalysts,218 which has created a drive for the optimisation of 
catalysis for both naturally occurring enzymes, as well as synthetic biomimetic 
structures. 
Theories on enzyme mechanisms have been developing for over a century, 
starting with Fischer’s “lock and key” model.219 He proposed that the enzyme 
and substrate have complementary rigid geometries, much like that of two 
puzzle pieces (Figure 4.1). This model is able to plausibly explain enzyme 
specificity as subtle differences in the size and shape of the enzyme and/or 
substrate can result in no interactions; similar to how each lock has its own key. 
However the model does not provide reason for transition state stabilisation 
exhibited by enzymes.220 
 
Figure 4.1: Fischer suggested that enzymes and substrates come together like two puzzle pieces, or locks 
and keys. 
Fischer’s theory was prominent for over 60 years until Koshland oppugned this 
and  proposed that enzymes were flexible structures whose active sites could 
mould themselves to specific substrates.221 The new theory was dubbed the 
“induced fit model” (Figure 4.2a). The amino acid chains that constitute the 
active site are continuously changing geometry until the substrate is completely 
bound. In some cases, the substrate also undergoes a slight conformational 
change upon entering the active site.222 The induced fit model explains both 






Figure 4.2: a) Generic enzymatic catalytic cycle exhibiting the induced fit model, and b) generic energy 
profile for an enzyme catalysing a reaction. 
Every single enzyme found in a living organism is essential for it to function 
properly. However, some enzymes are more equal than others. Perhaps the 
most significant (and abundant) enzyme on the planet today is RuBisCO 
(ribulose-1,5-bisphosphate carboxylase/oxygenase) (Figure 4.3),223 which is one 
of the enzymes affiliated with the first major step of carbon fixation in plants. 
This process is the first of three phases of the Calvin cycle,224 the production of 
glucose from carbon dioxide. The active site of RuBisCO comprises an aspartate 
residue, a glutamate residue and kcx (carboxylated lysine residue) which is 
stabilised by a magnesium(II) ion. The remaining coordination sites of the metal 





Figure 4.3: X-ray structure of ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCO) from 
wheat,225 insert shows a magnesium(II) ion (green) in the active site, uncoordinated water molecules 
and all hydrogen atoms have been omitted for clarity. 
The enzymatic mechanism of the carboxylation of ribulose-1,5-bisphosphate 
(RuBP) (Figure 4.4) proceeds as follows: uptake of RuBP displaces two of the 
three water ligands before the substrate undergoes a keto-enediolate 
tautomerisation.226, 227 This transformation is facilitated by the orientation in 
which RuBP is held by the enzyme. The carbamate oxygen on a kcx residue that 
is not coordinated to the Mg(II) ions deprotonates the C3 carbon of the substrate 
to initiate the enolisation.228 Coordination of atmospheric CO2 to the 
magnesium(II) ion (and displacement of the third water molecule) is enabled by 
another lysine residue of the active site. The spatial arrangement of both the 
RuBP and CO2 substrates enables the swift reaction between the two to generate 
the highly unstable six-carbon intermediate, 2′-carboxy-3-keto-D-arabinitol 1,5-
bisphosphate (CKABP),229 which then undergoes immediate hydration. The 
geminal-diol intermediate is then cleaved between carbons C2 and C3 
producing one molecule of 3-phosphoglycerate (PPG) and one anionic 
carboxylate. Stereospecific protonation of this resulting carbanion produces 
another PPG molecule. The PPG molecules are then released by the enzyme to 





Figure 4.4: Scheme showing conversion of RuBP to two molecules of PPG, through CKABP, the highly 
unstable six-carbon intermediate. These steps occur within the RuBisCO enzyme active site.230 
Through spatial arrangements and confinements, RuBisCO is able to transform 
CO2 into energy-generating molecules: the “heavy lifting” in photosynthesis.231 
Kinetic studies on this enzyme have revealed it to be one of the least efficient 
enzymes in existence, performing its choreographed molecular dance up to only 
10 times per second.232 Most enzymes can operate ~100 times faster than this, 
however RuBisCO is an ancient enzyme; it evolved when the composition of the 
atmosphere was significantly different. Additionally, it is also prone to errors 
such as mistaking O2 gas for CO2 gas, resulting in different products.233 
Consequently, its failure to adapt to the modern climate has led to limited 
agricultural output and attempts to improve its performance have produced 
dwindling results as recreating the enzyme from its unfolded constituents in 
vitro has been demonstrated to be impossible. Furthermore, the production of 
RuBP is photo-dependent, hence RuBisCO is only active during daylight hours. 
Researchers have examined other enzymes and have cherry-picked enzymatic 




fixation pathways.234 Unfortunately, the vast majority of these are only 
hypothetical and attempts to create them in the lab have been unsuccessful. 
However there have been a few synthetic systems that have alleviated some of 
the issues with RuBisCO. Erb and co-workers developed the CETCH (crotonyl-
CoA/ethylmalonyl-CoA/hydroxybutyryl-CoA) cycle whereby the use of 
enoyl-CoA carboxylases/reductases eliminates the possibility of O2 being 
adsorbed instead of CO2.231, 235 The new cycle was established using 17 different 
enzymes from nine different organisms, which signifies the enormous effort to 
slightly enhance the activity of one of the most important enzymes. 
While less common, Nature also utilises metal ions to perform catalytic 
reactions. Metalloenzymes generally have the metal ion situated somewhere in 
the active site and are able to catalyse reactions otherwise unachievable by more 
conventional organic catalysis.236, 237 An example of this is vitamin B12  
(Figure 4.5), which plays a vital role in the nervous system. Deficiency of 
vitamin B12 can lead to a range of ailments from mild anaemia to more severe 
neurological symptoms such as psychosis and decreased levels of 
consciousness.238 Vitamin B12 is a methyl-transferase which can act as a cofactor 
to methionine synthase (another metalloenzyme) in animals.239 The methyl 
group from 5-methyltetrahydrofolate (the biologically active form of folate) is 
initially bound to the cobalt(I) centre of vitamin B12 generating a Me-Co(III) 
species. Methionine synthase-bound zinc complexed to homocysteine (to form 
a reactive thiolate) then reacts with the Me-Co(III) which results in the transfer 
of the methyl group to homocysteine, the product of which is then released from 
the enzyme as methionine.240  
 
Figure 4.5: X-ray structure of vitamin B12 from a) top view and b) side view,241 hydrogen atoms and 





 Artificial enzymes 
The first scientific publication mentioning an “artificial enzyme” appeared in 
1917 where Demichelis likened colloids of various transition metals to natural 
oxidases.22 However the field of enzyme mimicry only took hold in the 1960’s 
when researchers began substituting functional groups on natural enzymes. For 
instance, Bender and co-workers,242 and Koshland and co-workers243 
independently generated thiolsubtilisin from natural subtilisin (a protease) and 
chemically substituted a hydroxyl group on the serine residue of the active site 
with a thiol group. Bender found that the activity of thiolsubtilisin was 
increased towards nitrophenyl esters and imidazole amides, and while 
Koshland’s work was in accordance with this, it was also discovered that the 
new compound possessed a distinct lack of activity towards other specific ester 
and peptide substrates, claiming at least a 100-fold decrease, despite thiols 
generally being more reactive than hydroxyl groups. Both parties agreed that 
subtle changes in the active site of enzymes can cause significant catalytic 
disruptions.244 Subsequent mechanistic studies by Koshland and co-workers 
revealed that the inactivity of thiolsubtilisin could not be attributed to substrate 
binding, which they discovered to be essentially unchanged.245 Instead, the 
acylation step of the catalytic cycle was undetectable, leading to the postulate 
that there is a critical alignment of substrates and active sites which can be 
perturbed by altering the polarisability and/or size of either party, thus 
preventing catalysis. 
The past few decades have seen the eruption of researchers attempting to create 
wholly synthetic systems capable of achieving enzyme-like substrate binding 
and catalytic activity. This notion started in the late 1960’s with fundamental 
research by Pederson. He was able to develop cyclic polyether molecules 
(dubbed crown-ethers, Figure 4.6) which were shown to bind alkali metals with 
different selectivities based on the size of the crown ether and the alkali metal 
in question.246 Continuing to lay the paving stones, Lehn synthesised three-
dimensional bicyclic crown ether molecules (cryptands, Figure 4.6) which were 
shown to have even higher binding affinities towards metal ions.247 Cram took 
this further still by adding another layer of preorganisation: forcing the host 
molecule into a specific orientation by using rigid subcomponents, and by doing 
so, imbued chiral functionality to the system (Figure 4.6).248 This pioneering 
work in the new-found field of host-guest chemistry lead the trio to receiving 





Figure 4.6: The first "synthetic-host" molecules as produced by Pedersen,246 Lehn247 and Cram.248 All 
three structures were shown to bind alkali metal ions. 
Since then, myriad organic systems reported in the literature have been shown 
to be capable of interacting with organic cations,249, 250 anions,251 neutral 
molecules,252, 253 as well as metallo-compounds.254 While many successes have 
been enjoyed, synthetic host systems still need to be more specific and complex, 





 Metallosupramolecular catalysts 
As described above, synthetic homogenous host were initially comprised of 
architecturally small molecules. Additionally, their mechanisms mainly 
involved substrate binding at the reaction site. Natural enzymes are 
substantially bigger and more complex, and substrate binding is achieved 
through multiple reversible supramolecular interactions. These dictate the 
orientation in which the substrate is held to favour specific reaction pathways.255 
During the 1990’s and early 2000’s, chemists made advancements towards 
generating metallosupramolecular biomimetic host molecules.256 Judicious 
selection of metallic and organic building blocks were brought together through 
supramolecular interactions, resulting in the formation of cavity-containing 
host architectures, capable of binding small guest molecules.257, 258 One 
particular advantage of these systems is their ability to be generated in higher 
yields and under milder conditions when compared to cyclic organic 
compounds. Using labile metal ions, reversible non-covalent interactions are 
exploited to form (in most cases) the thermodynamic product, which, given 
metal ions and ligands with complimentary coordination preferences, tend to 
be cavity-containing architectures. These host architectures more often than not 
possess a hydrophobic interior, an environment ripe for small molecular 
reactions. There are, however, significant drawbacks to these early systems, 
namely the lack of substrate specificity and the inability for the host molecules 
to precisely orientate the substrate for optimal activity. Furthermore, product 
inhibition has plagued catalytic turnover, thus limiting the efficacy of these 
systems. There is, therefore, a necessity to either improve existing structural 
motifs or to generate new ones in order to produce biomimetic artificial 
enzymes. 
Towards the end of the 2000’s, Fujita and co-workers demonstrated the ability 
of their [Pd6(2,2’-bpy)6(L)4]12+ octahedron to catalyse the bimolecular 
photomediated radical coupling between an ortho-quinone and a substituted 
toluene.259 With both substrates enclatherated (Figure 4.7 X-ray), they are forced 
into close proximity which leads to the unusual reaction, the mechanism of 
which was proposed by the authors to be the following. Photoexcitation of the 
quinone abstracts hydrogen from the substituted toluene to produce a benzylic 
radical and a semi-quinone radical. The two radical centres then combine to 
form the 1,4-radical adduct (Figure 4.7 scheme). Due to the fact that the semi-
quinone radical centre is delocalised over the whole aromatic molecule, various 
other adducts could be generated at aromatic nuclei, such as a C-coupled 1,2-
adduct, however the forced spatial arrangement of the two substrates dictates 





Figure 4.7: X-ray structure of [((4,5-pyrenedione)(p-(1-adamantyl)toluene))Pd6(2,2’-bpy)6(L)4]12+ and 
photomediated catalytic reaction scheme.259 Guests shown in space-filling style, hydrogen atoms, 
counterions and solvent molecules have been omitted for clarity.  
Raymond and co-workers have described the rate enhancement of the Nazarov 
cyclisation by encapsulating the substrate (a 1,4-diene) in a metallo-
supramolecular dodecaanionic tetrahedron (Figure 4.8) aided by the 
hydrophobic effect.260 Under normal circumstances, the Nazarov cyclisation 
requires strong Lewis acids to catalyse the reaction, however Raymond and co-
workers have increased the basicity of the substrate by binding it in their 
tetrahedron, thus requiring weaker acids to catalyse the reaction. The cage-
catalysed reaction deviated from pseudo-first-order kinetics as the scenario 
outlined in Figure 4.8 had essentially ceased after only 25% conversion, which 
is reported as being consistent with product inhibition. To alleviate this issue, 
the authors chemically converted the product into a poor guest, a strategy they 
have used before.149 By adding a dienophile and performing a [4+2] Diels-Alder 
cycloaddition on the product, the initial reaction exhibited pseudo-first-order 
kinetic behaviour. Furthermore, the rate of the production of the Diels-Alder 
adduct was equal to the rate of consumption of the 1,4-diene starting material. 
Studies of the background reaction without the addition of cage revealed the 





Figure 4.8: X-ray structure of [Ga4(L)6]12- tetrahedron and scheme for enhanced Nazarov cyclisation.260 
The substituted cyclopentadiene product of the cyclisation is a good guest for the cage and hence 
product inhibition is observed. Addition of a dienophile converts the product into a Diels-Alder adduct 
which is a poor guest, leaving the cavity free for the next substrate molecule. Hydrogen atoms, 
counterions and solvent molecules have been omitted for clarity. 
Numerous organic reactions use metal catalysts,261-263 some of which require 
high catalyst loading. Using a metallosupramolecular architecture, Reek and co-
workers have shown how a high local catalyst concentration can alleviate this 
issue.264 Through covalent endohedral ligand functionalisation, a gold(I) centre 
has been appended such that combination of a 2:1 ligand-Pd(II) ratio generates 
a [Pd12(L)24]24+ cuboctahedron with 24 AuCl complexes in the centre of the 
cavity. The overall concentration of Au(I) ions in solution is 5 mM, while the 
local concentration is greater than 1 M. This large local concentration enables 
the activation of the gold chloride complexes in the hydroalkoxylation of 2,2-
diphenyl-4,5-hexadien-1-ol at 25 °C with isolated yields up to 88% after 12 
hours. The background reaction was shown not to proceed at all. A subsequent 
study by the same authors focussed on a supramolecular approach to 
endohedral functionalisation (Figure 4.9).265 Guanidinium moieties were 
covalently linked to the same dipyridyl ligand, providing hydrogen bonding 
donor units for sulfonate and carboxylate guests. Gold(I) catalysis was targeted 
again, this time in the cyclisation of acetylenic acid to give an enol lactone. The 
Au(I) ions were introduced to the system as triphenylphosphinomono 
sulfategold(I) with roughly four gold(I) centres per cuboctahedron. The 
acetylenic acid substrate is then treated with base and enters the system as an 
anion. After the rapid cyclisation of the substrate, the neutral cyclic product 
exits the cavity (Figure 4.9 bottom), thus the system does not suffer from 





Figure 4.9: MMFF model of [Pd12(L)24]24+ cage structure and scheme for Au(I) catalysed cyclisation of 
acetylenic acid.265 The Au(I) catalysts (red) in the cavity are preorganised such that the base-activated 
substrate (green) is in close proximity. Generation of the product happens rapidly, ejecting the neutral 
cyclic enol lactone and leaving the cavity free for another substrate molecule, thus achieving turnover. 




Using a metallosupramolecular, nonanuclear, heterometallic “donut”, Preston 
and co-workers have achieved accelerated conversion of anthracene to its 
corresponding endoperoxide (Figure 4.10).266 The cage was shown to bind 
anthracene, and molecular modelling suggested that three guest molecules 
could be bound inside the host. Interestingly, an acetonitrile solution of the host-
guest adduct slowly turned from yellow to colourless when left in the light. 
Closer examination of this process revealed that the host was acting as a 
photosensitiser, enabling the formation of singlet oxygen species, subsequently 
reacting with anthracene to form the endoperoxide. Pleasingly, the product of 
the reaction did not interact with the cage cavity, thus catalytic turnover (≈ 120) 
was possible, however the cage was shown to photodegrade over time.  Control 
experiments with the Pt(II) metallo-ligand suggested that it slightly enhance the 
rate of reaction, but with either the Pd(II) starting material or other ratios of 
metal/ligand, the reaction yielded no enhancement of the rate of conversion to 
the endoperoxide, thereby proving the necessity of the metallosupramolecular 
architecture for the conversion of anthracene to 9,10-dihydro-9,10-
epidioxyanthracene. 
 
Figure 4.10: X-ray structure of the nonanuclear [Pd3Pt6(L)12]18+ doughnut structure with the 
photocatalytic conversion of anthracene to 9,10-dihydro-9,10-epidioxyanthracene through the use of 
singlet oxygen.266 Hydrogen atoms, counterions and solvent molecules have been omitted for clarity. 
These examples provide insight into the different types of reactions which can 
be catalysed by cavity-containing metallosupramolecular architectures. Other 
oxidation reactions,267-269 dimerisations,270 various cyclisations,271-273 inversions 
of product selectivity274 and reduction reactions275, 276 among many others have 
been studied. The remainder of this chapter will focus on catalysing [4+2] Diels-





4.3.1 Catalysing Diels-Alder cycloadditions 
One of the most-studied catalytic reactions is the Diels-Alder [4+2] 
cycloaddition reaction (Figure 4.11), first reported in 1928 by Otto Diels and 
Kurt Alder.277 The pair received the 1950 Nobel Prize in Chemistry for their 
discovery. The reaction is regulated by orbital overlap: the interaction of a 4π 
electron system with a 2π electron system (a diene and a dienophile). With 
normal demand Diels-Alder reactions, the diene is electron rich and the 
dienophile is electron poor, leading to the interaction between the HOMO of the 
diene and the LUMO of the dienophile. The energy gap between the HOMO 
and LUMO is small enough such that switching the electronic substituents on 
the components can reverse their roles. An electron withdrawing group on the 
diene and an electron donating group on the dienophile leads to the interaction 
of the diene LUMO and dienophile HOMO, thus satisfying the conditions for 
an inverse demand Diels-Alder reaction. 
 
Figure 4.11: The Diels-Alder [4+2] cycloaddition reaction, with conditions for normal and inverse 
demand. 
Due to its simplicity, the Diels-Alder reaction is a target reaction for many 
catalytic experiments. The main method of rate enhancement relies on 
encapsulation (or interaction) of at least one of the reactants to lower the energy 
gap between the HOMO and LUMO of the diene and dienophile; while the 
methods of obtaining uncommon regio- and chemo-selectivity are centred 




cavities. While metal-organic frameworks (MOFs)278-281 as well as organic 
cavitands and capsules are popular host molecules,282-287 metallosupra-
molecular systems provide increased synthetic ease and introducing 
functionality can be facile.  
Fujita and co-workers have altered the regio-selectivity of the reaction between 
substituted anthracenes and phthalimides using a [Pd6(tmeda)6(L)4]12+ 
octahedron (Figure 4.12 left).190 When the reaction is performed in the presence 
of either a [Pd6(en)6(L)4]12+ bowl-shaped structure or a ribozyme,288 or under 
“normal” circumstances,  the reaction produces the common 9,10-adduct 
bridging the centre ring due to a) the high localisation of π-electrons in the 
centre of the molecule and b) two 6π electron systems are formed, lowering the 
overall energy of the product. Interestingly, with the diene encapsulated in their 
[Pd6(en)6(L)4]12+ octahedron, the unusual 1,4-adduct was observed due to the 
confined spatial arrangement of the substrates (Figure 4.12). The uncommon 
1,4-adduct is also a poor guest for the host system and hence catalytic turnover 
is not subjected to product inhibition. 
 
Figure 4.12: X-ray structure of [1,4-adductPd6(tmeda)6(L)4]12+ octahedron and Diels-Alder reaction 
between a substituted anthracene and cyclohexylmaleimide yielding the unexpected 1,4-adduct over 
the more common 9,10-adduct. Guest molecule shown in space-filling style, hydrogen atoms, 
counterions and solvent molecules have been omitted for clarity. 
As briefly mentioned in Section 1.2.1, Lusby and co-workers have used a 
dipyridyl ligand (Ldp) and L1 to generate [Pd2(L)4]4+ cage architectures Cdp and 
C1. In a preliminary study, the authors discussed how molecules with a 
dicarbonyl motif interact with the cages.289 The carbonyl groups are involved in 
hydrogen bonding to the inwardly directed protons which line the top and 
bottom of the inner cavity (Figure 4.13). With larger molecules such as 6,13-
pentacenedione (PCD), the peripheral aromatic rings of the guest engage in π-π 




guest molecules such as benzoquinone, the guest protons are able to hydrogen 
bond to the nitrogen of the central pyridine of L1 (Figure 4.13b, significantly 
reduced binding strength is observed with Cdp and benzoquinone due to the 
proton-proton steric clashes).  
 
Figure 4.13: a) X-ray structure of 6,13-pentacenedioneCdp,289 and b) MMFF model of p-
benzoquinoneC1. Guests shown in space-filling style, hydrogens not involved with host-guest 
hydrogen bonding, counterions and solvent molecules have been omitted for clarity. 
The authors also performed experiments to optimise the host-guest interactions 
and hence achieve the highest association constants. Results (Table 4.1) showed 
that increasing the size of the counter anions (OTf < BF4 < PF6 < SbF6 < BArF 
(where BArF = tetrakis[3,5-bis(trifluoromethyl)phenyl]borate) increased the 
association constant. Additionally, using less polar and coordinating solvents 
also led to an increase in the strength of the host-guest interactions. 
Table 4.1: Association constants, Ka for Cdp with naphthoquinone with various counterions in different 
solvents.289 
Counter anion Solvent Ka / M-1 
OTf CD3OD 26 
OTf CD3CN 210 
OTf d8-THF 290 
OTf CD2Cl2 1,800 
OTf CD3NO2 2,000 
BF4 CD3NO2 6,500 
PF6 CD3NO2 13,000 
SbF6 CD3NO2 22,000 
BArF CD3OD 530 
BArF CD3CN 1,600 
BArF CD3NO2 50,000 





Subsequent studies by Lusby and co-workers focussed on the catalytic activity 
of Cdp∙BArF and C1∙BArF. It was proven that the presence of the cage could 
accelerate the rate of a [4 + 2] Diels-Alder cycloaddition over 1000-fold and with 
high turnover (TON ≈ 1000).34 It is proposed that the enhanced rate of the 
reaction stems from the increased reactivity of the dienophile due to a lower 
energy of the LUMO, similar to hydrogen-bonding organocatalysis.284, 290 
Furthermore, substrate stabilisation effects as well as recognition of the 
transition state by C1 contribute to the rate enhancement. Using a range of 
substituted benzo- and naphthoquinones, it was also shown that the cage could 
perform interesting regio- and chemoselective reactions that would otherwise 
be difficult to achieve using small-molecule catalysis. Additionally, the authors 
revealed that Cdp was less catalytically active than C1 due to the steric clashes 
between host and guest protons, resulting in higher catalytic activation 
barriers.291 This indicates that slight changes to the steric and electronic nature 
of the cage cavity can have a drastic effect on how well the system operates as a 
catalyst. Furthermore, Duarte and Lusby and co-workers have published a 
computational study which explores the binding and catalysis of multiple cages 
with various guests.291 Their findings suggest that a good cage catalyst can 
better accommodate the transition state of a Diels-Alder reaction, and that a host 
that has the ability to conformationally adapt to its guest will perform better as 
a catalyst. 
The ability to tune catalytic activity is essential to generating biomimetic 
structures. Thus, this chapter will mainly focus on the altering the electronic 
microenvironment of C1∙BArF through appending electron donating or 
withdrawing groups to the coordinating aromatic groups (as opposed to 
changing the core unit), and studying the effect this has on the rate of reaction 
between benzoquinone (BQ) and isoprene, and maleimide (MI) and isoprene. 
By using BQ as a guest, a direct comparison to the report by Lusby and co-
workers can be made, and MI introduces a related “quinone” motif. Having two 
substrates will allow a more rounded determination of how effective the 
electronic tuning of the cages will be.  
Lusby and co-workers report34 on the initial Diels-Alder catalysis reactions, as 
discussed prior, described the host-guest chemistry of a number of sterically 
and electronically different organic guest molecules. It was discovered that 
electron poor quinones had a lower association constant than those which were 
more electron rich (chlorobenzoquinone Ka = 1200 M-1 vs. methylbenzoquinone  
Ka = 4300 M-1). This is presumably due to the larger amount of electron density 
on the hydrogen bond acceptor (methylbenzoquinone), thus being able to form 




Interestingly however, the larger association constants did not translate into 
increased catalytic activity: kcat/kuncat = 370 for the reaction between the electron 
poor chlorobenzo-quinone and isoprene, and kcat/kuncat = 220 for the reaction 
between the electron rich methylbenzoquinone and isoprene, despite the 
association constants for the products mirroring the same trend as those for the 
corresponding substrates, i.e. product inhibition is not observed in either case.  
A subsequent report by the Lusby group investigated the effects of non-covalent 
allosterism on C1 by binding two molecules of triphenylphosphine oxide on the 
external palladium(II) faces.292 The presence of the larger guest resulted in the 
slight increase of acidity of the internally directed cage proton, and hence 
should have increased the binding affinity for benzoquinone. Intriguingly 
though, the association constant was reduced 4-fold and the catalytic activity 
was also reduced. The authors attribute the lower rate of catalysis to the lower 
concentration of host and substrate. 
Diels-Alder reactions with H-bond catalysts have been reported to perform at a 
maximum rate when strongly electron withdrawing substituents are present 
due to the decreased pKa of the N-H bonds, increasing their H-bond donating  
abilities.290, 293, 294 Electron rich catalysts were shown to perform significantly 
slower, as the H-bond donors were drastically weaker. Combining this with the 
observations of Lusby and co-workers, it can be reasoned that electron 
withdrawing groups on the periphery of the cage would result in more 
electrophilic cage protons, creating a stronger hydrogen bond and therefore a 
larger association constant. Conversely, a peripheral electron donating group 
would have the opposite effect, lessening the interaction between host and 
guest. As there is conflicting data between the reports on how the electronics of 
the systems affects the rate of catalysis, it would be of interest to see if any 
alteration to the electronic nature of the host can increase the catalytic rate of  




 Substituted [Pd2(L)4](BArF)4 systems 
The ligands to be used for these experiments (L1, L3, L5, L6 and L7, Figure 4.14) 
were designed with synthetic ease in mind. The synthesis of L1 has been well 
documented by Crowley and co-workers12, 33, 50, 175 and the synthesis of L3 was 
discussed in Chapter 2. The synthesis of L651 and L735 have also been previously 
reported by the Crowley group.  
 
Figure 4.14: Substituted ligands used for catalytic experiments. The cages used in this study follow the 
same numbering as the ligands, e.g. L6 makes C6. Ticks indicate ligands which were suitable for this 
study. 
As was seen in Chapter 2, L2 generates C2, a twisted cage which does not bind 
guests. To confirm this, BQ was added to a solution of C2∙BF4 in CD3CN. The 
1H NMR spectrum of the mixture showed no CIS of any proton resonances. L4 
was not used as attempts to generate the BArF- salt of the cage resulted in the 
formation of several species present in the 1H NMR spectrum. Due to time 
constraints, efforts were not made to discern the identity of the multiple species, 




The first version of the electron deficient ligand L5 (L5 V1, Figure 4.14) 
comprised of the NO2 group situated in the 3-position of a coordinating 
pyridine. However upon addition to [Pd(3-ClPy)4](BArF)2 (18) (used by Lusby 
and co-workers) the electron-poor 3-nitropyridine was unable to displace 3-
chloropyridine (3-ClPy) as was evidenced by a 1H NMR spectrum of the 
reaction mixture that displayed peaks pertaining to 18 and uncoordinated 
ligand. Consequently, to maintain the electron withdrawing group, an 
isoquinoline donor moiety was used instead of pyridine. Nitration of 
commercially available 4-bromoisoquinoline (2) with KNO3 selectively 
produced 5-nitro-4-bromoisoquinoline (12). Subsequent Sonogashira carbon-
carbon cross-coupling reactions led to the production of L5 in excellent yield 
(96% for final step, Scheme 4.1). The increased spatial distance between the nitro 
group and the coordinating nitrogen lessened the withdrawing effect enough 
for L5 to displace 3-chloropyridine and hence generate C5∙BArF. Pleasingly 
C5∙BF4 could also be accessed through complexation with [Pd(CH3CN)4](BF4)2. 
The synthesis of the BArF- salt of the cages can proceed via two pathways. The 
first is to generate the BF4- salt of the cage using [Pd(CH3CN)4](BF4)2 in 
acetonitrile, precipitate with diethyl ether and suspend the solid in CH2Cl2. To 
this suspension is added NaBArF and sonication facilitates the anion exchange. 
The second is to generate a palladium(II) BArF- salt and complex the ligands 
directly to this in acetonitrile whereupon solvent removal in vacuo gives the 
desired product. The former method is reasonably effective, however 
displacement of the BF4- anions does not always go to completion as the BF4- 
molecules can bind strongly inside the cage cavity.35, 126, 295, 296 The latter method 
circumvents this issue, however palladium(II) BArF- (with no coordinating 
units) would be extremely unstable. Therefore the Pd(II) complex of 3-ClPy (17) 
is generated through first converting palladium(II) acetate (15) to palladium(II) 
triflate (16), then stabilisation of the Pd(II) ions with 4 eq. of 3-ClPy and finally 
addition of NaBArF and sonication in CH2Cl2 produces [Pd(3-ClPy)4](BArF)2 
(18) in excellent yield (98%, Scheme 4.2). 
With all the ligands and the palladium(II) BArF- salt in hand, synthesis of the 
cages was facile. Addition of 2 eq. of 18 to 4 eq. of each ligand in acetonitrile 
quantitatively produced the corresponding [Pd2(L)4](BArF)4 cage. As 3-Clpy has 
a boiling point of 148 °C, an azeotrope was repeatedly formed with CH2Cl2 to 
remove the monodentate ligand using rotary evaporation. 5 – 10 cycles were 
sufficient to remove 3-Clpy as evidenced by 1H NMR spectroscopy. The residual 
solvent was then removed in vacuo to produce the cages as tan/brown 
microcrystalline powders in good to excellent yields (85 – 93%). 1H NMR 




expected downfield shifts of the signals pertaining to the protons ortho- to the 
chelating nitrogen atoms (Figure 4.15, Section 4.8.2). The remaining protons 
resonances of the pyridine or isoquinoline units also exhibited the expected 
downfield shifts. The 1H NMR spectroscopic data is hence consistent with the 
formation of [Pd2(L)4](BArF)4 cage architectures, and HR-ESI-MS (CH3CN, 
Figure 4.16) confirms this. Isotopically resolved peaks corresponding to 
[Pd2(L)4]2+/3+/4+ species (with either BArF- (from the cage) or Cl- (from the mass 
spectrometer) counterions) are predominantly present. 
 
Figure 4.15: Partial stacked 1H NMR spectra (400 MHz, CD3CN, 298 K) of C1, C3, C5, C6 and C7. 
Endohedral protons (a) and exohedral protons (b) have been labelled. 
 




X-ray crystallography once again conclusively proved the formation of one of 
the desired products. Evaporation of a CH2Cl2 solution of C1∙BArF resulted in 
yellow block crystals, the solution of which (𝑃1̅) revealed the structure to be the 
expected [Pd2(L1)4](BArF)4 cage (Figure 4.17). Lining the cavity of the cage are 
four dichloromethane solvent molecules arranged such that one of the 
hydrogen atoms of one CH2Cl2 is pointing towards the central pyridyl nitrogen 
atom of the cage, and the other is directed towards the chlorine atoms of another 
CH2Cl2 molecule (Figure 4.17b). The chlorine atoms of the solvent molecules are 
also involved in hydrogen bonding to the internally directed pyridyl protons of 
the cage. 
 
Figure 4.17: X-ray structure of C1∙BArF: a) the unit cell and b) the cage with four dichloromethane 
solvent molecules showing the hydrogen bonding network, counterion carbon atoms are dark green, 
solvent carbon atoms are dark blue, remaining hydrogen atoms, counterions and solvent molecules 
have been omitted for clarity. 
Unfortunately, crystals suitable for X-ray diffraction of the other cages were not 
obtained, however C6 and C7 have been crystallographically characterised 
before, and the structures of C3 and C5 have been optimised by DFT 
calculations. Figure 4.18 displays all the cages viewed down the Pd-Pd axis. It 
is noteworthy that the structure of C5 possesses a slight twist, as was seen with 
the X-ray structure of C2 in Chapter 2. This twisting is a result of the nitro 
groups being unable to be orientated co-planar with the isoquinoline moiety 





Figure 4.18: View down the Pd-Pd axis of C1 (X-ray), C3 (DFT), C5 (DFT), C6 (X-ray35) and C7 (X-ray35), 




 Electronic effects on binding 
It was presumed that the binding orientation of the aromatic dione guests 
within the cages would be similar to what Lusby and co-workers observed 
(Figure 4.19a).289 Those authors were able to crystallise the 6,13-
pentacenedioneCdp host-guest complex with the guest orientated such that the 
carbonyl moieties hydrogen bond to the α-pyridyl protons (Figure 4.19a). A 
similar result was obtained through slow evaporation of a mixture of C1 and 
6,13-pentacenedione (PCD) in CH2Cl2. This yielded yellow plate crystals 
suitable for X-ray diffraction. The structure solution (C2/c) of the mixture 
revealed the expected [PCDPd2(L1)4](BArF)4 host-guest complex, with the 
guest in much the same orientation as reported by Lusby and co-workers 
(Figure 4.19b). There are also two dichloromethane solvent molecules flanking 
the guest molecule, again hydrogen bonding to the central pyridyl nitrogen 
atom. Additionally, 1H NMR spectroscopy correlated the solid-state evidence, 
indicating that the α-pyridyl protons exhibited a larger downfield shift than 
other proton resonances. 
 
Figure 4.19 X-ray structures of a) 6,13-pentacenedioneCdp,289 and b) 6,13-pentacenedioneC1⋅BArF, 
guests shown in space-filling style, solvent carbon atom is dark blue, remaining hydrogen atoms, 
solvent molecules and counterions have been omitted for clarity. 
For this study, benzoquinone (BQ) and maleimide (MI) have been selected as 
the dienophiles, and their reaction with isoprene in the presence of different 
cages is the main focus of this chapter. Both these small organic molecules 
possess the dicarbonyl motif and have at least one 2π-electron system, rendering 
them ripe for candidates as dienophiles for [4+2] Diels-Alder cycloaddition 
reactions with isoprene (Figure 4.20). For accurate measurements on how well 
a system can perform catalysis, substrate and product binding must first be 
evaluated. Titrations monitored by 1H NMR spectroscopy in CD2Cl2 solution 
were carried out to determine the association constants between each cage and 





Figure 4.20: The two Diels-Alder reactions studied for catalysis in this chapter: a) benzoquinone and 
isoprene and b) maleimide and isoprene. 
C1 was shown to have the highest binding affinity for both substrates, while the 
electron poor cage C5 exhibited higher association constants for the 




Table 4.2). The two electron rich cages C6 and C7, along with C3, displayed 
lower affinities for each guest. Given these results, there is no real observable 
trend, however that is less surprising than was maybe initially thought. As 
mentioned prior, DFT modelling of C5 reveals the cage possesses a slight twist 
(Figure 4.18), similar to what was seen previously with C2, thus reducing the 
attraction for the linear substrates, but increasing the affinity for the non-linear 
products. The association constants for MIprod are significantly larger than those 
for BQprod. Presumably, this is due to the additional hydrogen-bonding between 
the amide proton and the central pyridine nitrogen atom, as well as interactions 
between the relatively acidic protons and an opposing central pyridine nitrogen  
(Figure 4.21). This has the potential to imbue the system with product inhibition. 
 
Figure 4.21: Optimised MMFF model of MIprodC1 with intermolecular H-bonds highlighted in pink. 
It is interesting to note that a larger CIS does not necessarily translate into a 
larger association constant. This is evident from comparison of the data 
presented in Figure 4.22a and b where the maximum overall CIS is roughly the 
same (Δδ ≈ 0.4 ppm). The electronics of the host, the guest, and the host-guest 
adduct are extremely complex and therefore a more rounded indication of 
whether a host binds a guest strongly or weakly is the shape of the binding 
isotherm.215, 297 An isotherm which is near vertical at the start, and near 
horizontal at the end translates into very strong binding (Figure 4.23 left), as 
seen with both the maleimide substrate and Diels-Alder product (Figure 4.22b 
and d), whereas an isotherm which is more or less linear indicates extremely 






Figure 4.22: Binding curves for cages C1 (black trace) C3 (green trace), C5 (blue trace), C6 (red trace) and 
C7 (orange trace) with a) benzoquinone (BQ), b) maleimide (MI), c) the product of the reaction between 
BQ and isoprene, and d) the product of the reaction between MI and isoprene. Curves obtained through 
monitoring the internal cage cavity proton, Ha, via 1H NMR spectroscopic titrations (CD2Cl2, 298 K). 
Solid dots represent experimental data, dashed lines represent the fitted binding isotherms obtained 





Table 4.2: Summary of association constants (M-1) for cages with substrates (BQ and MI) and products 
of the Diels-Alder reaction (BQDA-p and MIDA-p). Data obtained through monitoring the internal cage 
cavity proton, Ha, via 1H NMR spectroscopic titrations (CD2Cl2, 298 K). Constants calculated using 
supramolecular.org.180 Errors are estimated to be less than 10% for Ka (BQ), Ka (BQprod) and Ka (MI); less 
than 20% for Ka (MIprod). 
Cage Ka (BQ) / M-1 Ka (BQprod) / M-1 Ka (MI) / M-1 Ka (MIprod) / M-1 
C1 110034 394 3280 14900 
C3 356 167 1140 8430 
C5 533 1490 1970 16500 
C6 189 65.1 1380 4840 
C7 359 204 1790 4400 
 
 




 Electronic effects on catalysis 
As with the association constants, the results of the catalytic studies do not seem 
to adhere to a specific trend. Each catalytic reaction was performed with 20 
mol% cage at a concentration of 2.5 mM in CD2Cl2 with respect to the dicarbonyl 
substrate. The concentrations of each species in the reaction mixture were 
measured through 1H NMR spectroscopy at regular time intervals until 
sufficient data was collected to obtain the kinetic parameters.  
Focussing on the benzoquinone reactions (Figure 4.24), the rate of catalysis, and 
hence the kcat/kuncat parameter, is significantly lower for the electron-
withdrawing cage, C5, than what might have been expected. This is can be 
reasoned given the high association constant of C5 with BQprod. The slight twist, 
as discussed previously, reduces the binding of BQ and enhances recognition of 
the non-linear product. If a different electron-withdrawing cage, with no twist 
were used, it would be expected that kcat/kuncat would be higher than that 
exhibited by C1. As anticipated, the electron-donating cages, C6 and C7, 
showed a lower rate of catalysis than C1, with C3 also catalysing the Diels-Alder 
reaction slower than the unsubstituted cage system. 
With regards to the maleimide reaction, the rate of reaction was slow in all cases, 
the C1 and C7 displaying the maximum kcat/kuncat (within experimental error). 
As was discussed earlier, the product of this reaction has a remarkably high 
association constant with all cages (much higher than that of maleimide itself). 
Indeed, the low rate of catalysis can therefore be attributed to product inhibition 
and thus this particular reaction is barely accelerated by the presence of any 
cage.  
Table 4.3: Summary of catalytic activity of the cage-catalysed Diels-Alder reactions between 
benzoquinone (BQ) and isoprene (kuncat = 0.0473 M-1 hr-1), and maleimide (MI) and isoprene  
(kuncat = 0.336 M-1 hr-1). Errors are estimated to be less than 10%. [BQ or MI] = 2.5 mM.  aData was not 
obtained. 
Cage 








C1 18.2 450 1.15 3.43 
C3 10.2 215 0.596 1.78 
C5 3.31 70.1 0.826 2.46 
C6 9.57 202 -a -a 







Figure 4.24: Kinetic fitting for the catalysed reaction of benzoquinone (BQ) and isoprene in the presence 







 Conclusions & future directions 
The rate of two [4+2] Diels-Alder cycloaddition reactions has been studied as a 
function of electronic character of a series of [Pd2(L)4]4+ cages. Systems 
peripherally functionalised with electron-donating groups (C6 and C7) were 
shown to decrease the rate of the cycloaddition, as were cages functionalised 
with electron withdrawing moieties (C5) when compared to the unsubstituted 
cage, C1. The electronics suggested that C5 should have enhanced the catalytic 
rate, however DFT modelling showed that the cage possessed a slight twist, 
upsetting the binding of the substrate. Intriguingly, this twist also resulted in 
the non-linear product binding more strongly, resulting in this particular cage 
suffering from product inhibition in the BQ reaction. Interestingly, the DA 
reaction with BQ and isoprene proceeded much quicker than the reaction 
between MI and isoprene. Determination of the association constants of the 
products of both reactions indicated that MIprod binds much more strongly in 
the cage cavities than BQprod. Thus, the reaction between maleimide and 
isoprene does not undergo turnover in the presence of the cage due to product 
inhibition. 
In combination with peripheral electron withdrawing groups, which do not 
cause cavity-twisting, to enhance catalytic activity, a multicavity system could, 
in theory, have a positive linear scaling effect if the cavities were spatially 
distanced from each other. If the cavities were proximal to each other, then 
positive or negative cooperation or allosterism could be observed, either 
enhancing or decreasing catalytic activity compared to a single cavity system. 
Several multicavity systems have already been reported,298 showing 
allosterism299 and potential to bind multiple different guests.126 One proposed 
multicavity system where the cavities are separated is depicted in Figure 4.25. 
Synthesis of the proposed tetra-cage system uses well-established chemistry to 
obtain the ligand (Figure 4.25 top), followed by a platinum(II) complexation to 
generate a metallo-ligand. The ensuing polymerisation step will most likely 
prove the most difficult due to entropic penalties. To the polymer in Figure 4.25 
will be added a tripyridyl ligand functionalised in the 2-positions with amino 
substituents. Previous reports from Crowley and co-workers have shown that 
addition of this ligand to C6 results in the displacement of two L6 ligands to 
cleanly generate a cis-heteroleptic Pd(II) cage.54 The result of the addition of this 
ligand to the polymer will ideally be a cis-heteroleptic tetra-cage system with 
the cages linked by platinum(II) 2-pyridyl-1,2,3-triazole bidentate units. A 
single heteroleptic cage will also be synthesised as a control system to reference 
binding and catalytic data to, to see whether or not these applications can be 











4.8.1 Synthetic schemes 
 
 
Scheme 4.1: Synthetic scheme to afford L5. Conditions: (i) KNO3, H2SO4, 0 °C → RT; (ii) 
ethynyltrimethylsilane, [Pd(PPh3)3Cl2], CuI, (iPr)2NH, 80 °C; (iii) Na2CO3, MeOH, RT; (iv) 2,6-
dibromopyridine, [Pd(PPh3)3Cl2], CuI, (iPr)2NH, 80 °C.  
 
Scheme 4.2: Synthetic scheme to afford 18. Conditions: (i) HOTf, CH3CN, RT; (ii) 3-chloropyridine, 





Synthesis of 15 
 
HOTf (2.61 g, 1.54 mL, 17.4 mmol) was added dropwise with stirring to a 
solution of Pd(OAc)2 (1.347 g, 6.00 mmol) in dry CH3CN (120 mL), and the 
mixture was stirred at RT for 10 minutes. Dry diethyl ether (120 mL) was added 
and the resulting precipitate was left to settle for 5 minutes before the 
supernatant was decanted. The washing process was repeated twice more. The 
precipitate was dried in vacuo, then taken up in CH3NO2 (150 mL).  
3-chloropyridine (5.44 g, 4.56 mL, 48 mmol) was added via syringe and the 
solution was stirred at RT for 30 minutes. The solvent was reduced to 2 mL and 
diethyl ether (100 mL) was added resulting in precipitation. The precipitate was 
filtered and washed with diethyl ether then dried in vacuo. The solid was then 
added to a suspension of sodium tetrakis[3,5-bis(trifluoromethyl)phenyl]borate 
(2.44 g, 2.75 mmol) in CH2Cl2 (90 mL) and the mixture was sonicated for 10 
minutes before being filtered and washed with CH2Cl2 (60 mL). The resulting 
solid was dried in vacuo giving the desired product as a white solid (3.1 g, 1.36 
mmol, 98%). 1H NMR (400 MHz, CD2Cl2, 298 K) δ: 8.51 (dd, J = 2.2, 0.6 Hz, 4H, 
Ha), 8.39 (ddd, J = 5.7, 1.2, 0.7 Hz, 4H, Hb), 8.04 (ddd, J = 8.4, 2.2, 1.2 Hz, 4Hc), 
7.74 – 7.71 (m, 16H, H1), 7.57 – 7.52 (m, 12H, Hd,2). 19F NMR (376 MHz, CD2Cl2, 





Synthesis of 12 
The synthesis of 12 has previously been reported by Nichols and co-workers in 
89% yield.300 
 
KNO3 (2.67 g, 26.4 mmol) was added to conc. H2SO4 (20 mL) and dissolved by 
slow heating. The resulting solution was added dropwise to a solution of 2  
(5.01 g, 24.1 mmol) in H2SO4 (40 mL) at 0 °C. The ice bath was removed and the 
solution was stirred for 1 hr at RT. The crude mixture was then poured onto ice 
(~300 mL) and NH4OH was added until the mixture turned basic. The yellow 
precipitate was then filtered and the filtrate was extracted with diethyl ether  
(3 x 200 mL), dried over Na2SO4 and concentrated under reduced pressure. The 
resulting solid was added to the filtered precipitate and recrystallisation from 
methanol gave 12 as a yellow powder (4.84 g, 19.3 mmol, 79%). 1H NMR  
(400 MHz, CDCl3, 298 K) δ: 9.29 (s, 1H, Hb), 8.88 (s, 1H, Ha), 8.22 (dd, J = 8.3, 1.2 









Diisopropylamine (4 mL) and THF (1 mL) were added to a glass tube and 
degassed with N2 for 15 minutes. 2 (1.00 g, 3.95 mmol), CuI (0.075 g, 0.40 mmol) 
and Pd(PPh3)2Cl2 (0.069 g, 0.099 mmol) were then added, followed by TMS-
acetylene (0.675 mL, 0.466 g, 4.74 mmol). The tube was sealed and the mixture 
was heated at 80 °C for 14 hours. The contents of the tube were then filtered 
through Celite® with CHCl3 and the organic solution was washed with aqueous 
EDTA/NH4OH (0.1 M, 20 mL), followed by water (20 mL) and brine (20 mL) 
before being dried over Na2SO4. The solvent was removed under reduced 
pressure and the crude mixture was purified by column chromatography on 
silica gel (CHCl3) to yield 3 as an off-white solid. Yield: 903 mg, 3.34 mmol, 85%. 
1H NMR (400 MHz, CDCl3, 298 K) δ: 9.27 (s, 1H, Hb), 8.83 (s, 1H, Ha), 8.18  
(dd, J = 8.3, 1.2 Hz, 1H, Hc), 7.93 (dd, J = 7.5, 1.2 Hz, 1H, He), 7.70 (dd, J = 8.2, 7.5 
Hz, 1H, Hd), 0.31 (s, 9H, Hf). 13C NMR (100 MHz, CDCl3, 298 K) δ: 152.11, 150.92, 






Synthesis of L5 
 
 
14 (535 mg, 2.70 mmol), 2,6-dibromopyridine (291 mg, 1.22 mmol), CuI (23 mg, 
0.12 mmol) and Pd(PPh3)2Cl2 (22 mg, 0.031 mmol) were added to a degassed 
combination of THF (1 mL) and diisopropylamine (5 mL). The resulting mixture 
was heated at 80 °C for 14 hours under an N2 atmosphere. The contents of the 
flask were extracted with CHCl3 (50 mL), washed with aqueous EDTA/NH4OH 
(1 M, 20 mL), followed by water (20 mL) and brine (20 mL) before being dried 
over Na2SO4. The solvent was removed under reduced pressure and the crude 
mixture was purified by column chromatography on silica gel (CHCl3 to 
acetone) to yield L4 as an off-white solid. Yield: 558 mg, 1.18 mmol, 96%.  
1H NMR (500 MHz, CDCl3, 298 K) δ: 9.35 (s, 2H, Hb), 9.03 (s, 2H, Ha), 8.25  
(d, J = 8.4 Hz, 2H, Hc), 8.02 (d, J = 7.8 Hz, 2H, He), 7.84 (dd, J = 8.8, 6.6 Hz, 1H, 
Hg), 7.81 – 7.74 (m, 4H, Hf,d). 13C NMR (125 MHz, CDCl3, 298 K) δ: 152.7, 151.1, 
147.3, 143.0, 137.2, 132.4, 128.4, 128.2, 127.2, 126.6, 125.7, 111.2, 97.6, 83.0. HR ESI-
MS (MeOH) m/z = 494.0851 [L5 + Na]+ (calc. for C27H13N5O4Na, 494.0860). ATR-









To a stirring suspension of L1 (24 mg, 0.087 mmol) in MeCN (15 mL) was added 
18 (100 mg, 0.044 mmol). The mixture was stirred at RT for 20 minutes before 
the solvent was removed under reduced pressure. The residue was taken up in 
DCM and sonicated for 5 minutes. The solvent was removed under vacuum and 
the process was repeated five times, giving the product as a white solid (95 mg, 
0.02 mmol, 90%).  1H NMR (400 MHz, CD2Cl2, 298 K) δ: 9.14 (s, 8H, Ha), 8.63 (d, 
J = 5.8 Hz, 8H, Hb), 8.05 (d, J = 8.1 Hz, 8H, Hd), 7.75 (t, J = 7.9 Hz, 4H, Hf), 7.71 
(d, J = 4.1 Hz, 32H, H1), 7.58 – 7.54 (m, 16H, Hc,e), 7.52 (s, 16H, H2). 13C NMR (100 
MHz, CD3CN, 298 K) δ: 162.5 (q, J = 50 Hz), 154.5 (Ca), 151.4 (Cb), 144.5 (Cd), 
143.3, 138.7 (Cf), 135.6 (C1), 129.9 (qq, J = 32, 3 Hz), 129.4 (Ce), 128.5 (Cc), 125.5 (d, 
J = 270 Hz), 124.1, 118.6 (C2 under solvent peak), 94.6, 83.5. 19F NMR (470 MHz, 
CD2Cl2, 298 K) δ: -62.77 (s). HR ESI-MS (MeCN) m/z = 334.5529 [C1 – 4BArF]4+ 
(calc. for C76H44N12Pd2, 334.5473); 387.0001 [C1 – 4BArF – 2L – Pd + H + 3Cl]2+ 
(calc. for C38H23N6Pd·3Cl, 387.0037); 733.7589 [C1 – 3BArF]3+ (calc. for 
C76H44N12Pd2·C32H12BF24, 733.7523); 1118.1108 [C1 – 3BArF + Cl]2+ (calc. for 
C76H44N12Pd2·C32H12BF24·Cl, 1118.1127); 1131.6221 [C1 – 3BArF + HCOO + 
OH]2+ (calc. for C76H44N12Pd2·C32H12BF24·CHO2·OH, 1131.6289); 1532.1585  
[C1 – 2BArF]2+ (calc. for C76H44N12Pd2·C64H24B2F48, 1532.1621). Anal. calcd. for 
C76H44N12Pd2·C128H48B4F96·2CH2Cl2: C, 49.88; H, 1.95; N, 3.39%. Found: C, 49.58; 
H, 2.08; N, 3.76 %. 
Crystals suitable for X-ray diffraction were obtained through evaporation of a 








To a stirring suspension of L3 (33 mg, 0.087 mmol) in MeCN (15 mL) was added 
18 (100 mg, 0.044 mmol). The mixture was stirred at RT for 20 minutes before 
the solvent was removed under reduced pressure. The residue was taken up in 
DCM and sonicated for 5 minutes. The solvent was removed under vacuum and 
the process was repeated five times, giving the product as a beige solid. Yield: 
97 mg, 0.019 mmol, 85%. 1H NMR (400 MHz, CD2Cl2, 298 K) δ: 9.54 (s, 8H, Hb), 
9.09 (s, 8H, Ha), 8.38 (dd, J = 8.4, 1.0 Hz, 8H, Hc), 8.09 (d, J = 8.5 Hz, 8H, Hf), 8.03 
(ddd, J = 8.3, 6.9, 1.2 Hz, 8H, Hd), 7.82 – 7.68 (m, 52H, He,g,h,1), 7.46 (s, 16H, H2). 
13C NMR (100 MHz, CD3CN, 298 K) δ: 162.8 (q, J = 50 Hz), 157.2, 145.8, 143.5, 
138.6, 137.5, 137.0, 136.5, 135.6, 131.6, 130.5, 130.1 – 129.3 (m), 126.8, 125.9, 124.1, 
121.4, 120.2, 98.6, 82.2. 19F NMR (376 MHz, CD3CN, 298 K) δ: -63.26 (s). HR ESI-
MS (MeCN) m/z = 434.5856 [C3 – 4BArF]4+ (calc. for C108H60N12Pd2, 434.5789); 
867.1384 [C3 – 3BArF]3+ (calc. for C108H60N12Pd2C32H12BF24, 867.1277); 1732.2361 








To a stirring suspension of L5 (41 mg, 0.087 mmol) in MeCN (15 mL) was added 
18 (100 mg, 0.044 mmol). The mixture was stirred at RT for 20 minutes before 
the solvent was removed under reduced pressure. The residue was taken up in 
DCM and sonicated for 5 minutes. The solvent was removed under vacuum and 
the process was repeated five times, giving the product as an orange-brown 
solid. Yield: 113 mg, 0.021 mmol, 93%. 1H NMR (400 MHz, CD2Cl2, 298 K)  
δ: 9.56 (s, 8H, Hb), 9.28 (s, 8H, Ha), 8.20 – 8.13 (m, 16H, Hc,e), 7.94 – 7.88 (m, 16H, 
Hf,d), 7.81 – 7.75 (m, 4H, Hg), 7.75 – 7.71 (m, 32H, H1), 7.53 (s, 16H, H2). 13C NMR 
(100 MHz, CD3CN, 298 K) δ: 206.5, 161.6 (q, J = 50 Hz), 156.9, 148.6, 146.1, 142.2, 
138.0, 134.7, 134.0, 130.3, 130.1, 129.5 – 128.4 (m), 125.9, 125.8, 123.1, 120.4, 115.1, 
99.1, 80.3. 19F NMR (376 MHz, CD3CN, 298 K) δ: -63.26 (s). HR ESI-MS (MeCN) 
m/z = 524.5533 [C5 – 4BArF]4+ (calc. for C108H52N20O16Pd2, 524.5491); 987.0952 





Synthesis of C6∙BArF4 
 
 
To a stirring suspension of L6 (45 mg, 0.087 mmol) in MeCN (15 mL) was added 
18 (100 mg, 0.044 mmol). The mixture was stirred at RT for 20 minutes before 
the solvent was removed under reduced pressure. The residue was taken up in 
DCM and sonicated for 5 minutes. The solvent was removed under vacuum and 
the process was repeated five times, giving the product as a tan solid. Yield: 108 
mg, 0.019 mmol, 87%. 1H NMR (400 MHz, CD2Cl2, 298 K) δ: 8.72 (s, 8H, Hb), 8.54 
(s, 8H, Ha), 7.74 – 7.64 (m, 40H, Hd,1), 7.60 (s, 8H, Hc), 7.49 – 7.51 (m, 20H, He,2), 
4.21 (s (br), 16H, Hf), 3.82 (s (br), 16H, Hg), 3.66 (s (br), 16H, Hh), 3.57 (s (br), 16H, 
Hi), 3.36 (s, 24H, Hj). 13C NMR (100 MHz, CD3CN, 298 K) δ: 162.6 (q, J = 50 Hz), 
161.0, 158.0, 146.1, 143.3, 140.3, 138.8, 135.6, 130.4 - 129.3 (m), 126.8, 124.1, 123.9, 
121.4, 94.3, 83.4, 72.5, 71.3, 70.5, 69.8, 58.9. 19F NMR (367 MHz, CD3CN, 298 K) δ: 
-63.26 (s). HR ESI-MS (MeCN) m/z = 570.6730 [C6 – 4BArF]4+ (calc. for 
C116H124N12O24Pd2, 570.6737); 1048.5861 [C6 – 3BArF]3+ (calc. for C116H124N12O24 
Pd2C32H12BF24, 1048.5874); 2004.4093 [C6 – 2BArF]2+ (calc. for C116H124N12O24Pd2 




Synthesis of C7∙BArF4 
 
 
To a stirring suspension of L7 (100 mg, 0.208 mmol) in MeCN (15 mL) was 
added 18 (237 mg, 0.104 mmol). The mixture was stirred at RT for 20 minutes 
before the solvent was removed under reduced pressure. The residue was taken 
up in DCM and sonicated for 5 minutes. The solvent was removed under 
vacuum and the process was repeated five times, giving the product as a tan 
solid. Yield: 262 mg, 0.047 mmol, 90%. 1H NMR (400 MHz, CD2Cl2, 298 K)  
δ: 8.50 (s, 8H, Ha), 8.31 (s, 8H, Hb), 7.71 – 7.62 (m, 36H, He,1), 7.56 (s, 8H, Hc), 7.51 
– 7.47 (m, 24H, Hd,2), 4.00 (t, J = 6.5 Hz, 16H, Hf), 1.81 (m, 16H, Hg) (peak is under 
water signal),  1.48 – 1.39 (m, 16H, Hh), 1.38 – 1.30 (m, 32H, Hi,j), 0.94 – 0.89 (m, 
24H, Hk). 13C NMR (100 MHz, CD3CN, 298 K) δ: 162.6 (q, J = 50 Hz), 158.0, 145.8, 
143.3, 140.0, 138.8, 135.6, 130.3 – 129.4 (m), 129.1, 126.8, 124.1, 124.0, 121.4, 94.2, 
83.4, 71.0, 32.1, 29.3, 26.1, 23.2, 14.3. 19F NMR (376 MHz, CD3CN, 298 K) δ: -63.25 
(s). HR ESI-MS (MeCN) m/z = 534.7255 [C7 – 4BArF]4+ (calc. for C124H140N12 






4.8.3 1H NMR titration experimental details 
Initial sample volumes were 500 µL with 1 mM concentration of cage. The 
solutions of the guests were 5 mM in the same stock solution of the host. 1H 
NMR spectra were recorded at 0 – 30 equivalents of guest. Association constants 
were obtained by analysis of the resulting titration data using the 1:1 host-guest 
binding equilibria equations implemented in the Bindfit215 algorithm at 




4.8.4 1H NMR catalytic experimental details 
 
 





All kinetic constants were determined using the following procedure. To a 
screwcap NMR tube was added either a solution containing the cage (C1, C3, 
C5, C6 or C7) compound (450 µL of a 0.50 mM stock solution in CD2Cl2) or just 
CD2Cl2 (450 µL) for the uncatalysed reactions, quinone (20 µL of a 62.5 mM stock 
solution in CD2Cl2), and the internal standard tetrakis(trimethylsilyl)silane  
(10 µL of a 17.4 µL stock solution in CD2Cl2). The Diels-Alder reaction was then 
started by the addition of isoprene (20 µL of a 33.3 mM stock solution in CD2Cl2, 
10 eq.). 1H NMR spectra were recorded at regular time intervals until sufficient 
data were collected to determine the kinetic parameters. In all cases, the 
reactions were kept at 298 K. Kinetic data were processed using the 
MestReNova 12 software, and the concentrations of all chemical species were 
determined for each reaction time. 
The data presented in this thesis was obtained with the help of Dr. Vicente 
Martí-Centelles and Cora Wang. Their efforts in writing the program in R, 
enabling the determination of the kinetic parameters, are highly praised. The 
following information details how the 1H NMR spectroscopic data was 
manipulated to give the catalytic values. 
Uncatalysed Diels-Alder reactions 
The kinetic constant (kuncat) of the uncatalyzed reaction has been determined by 
fitting the concentration of the quinone experimentally determined by 1H NMR 
spectroscopy at different reaction times to the integrated second order reaction 
law ([A] vs. time). This was carried out using the Levenberg-Marquardt 
Nonlinear Least-Squares Algorithm301 implemented in the R software302 and the 
RStudio303 software interface. The errors of the determined kinetic constants are 
estimated to be less than 10%. 
𝑑[𝑨]
𝑑𝑡
= −𝑘𝑢𝑛𝑐𝑎𝑡 ∙ [𝑨] ∙ [𝑩]  [4.1] 
𝑑[𝑩]
𝑑𝑡
= −𝑘𝑢𝑛𝑐𝑎𝑡 ∙ [𝑨] ∙ [𝑩]  [4.2] 
𝑑[𝑪]
𝑑𝑡
= 𝑘𝑢𝑛𝑐𝑎𝑡 ∙ [𝑨] ∙ [𝑩]  [4.3] 
[𝑨] = [𝑨]0 − [𝑪]  [4.4] 






Cage catalysed Diels-Alder reactions 
The kinetic model considers both the second order uncatalyzed background 
reaction (A + B → C, Figure 4.26a) and the second order catalysed reaction  
(E + B → F, Figure 4.26b) by the cage compound.284 The active species E is 
obtained by the formation of a supramolecular complex between the quinone 
and the cage compound (A + D ⇄ E, Figure 4.26b). The model also considers the 
possible product inhibition by the formation of a supramolecular complex 
between the Diels–Alder adduct and the cage compound (E + D ⇄ F,  
Figure 4.26b). These two equilibria steps are assumed to be fast relative to 
cycloaddition, in accordance with NMR observations. From the reactions 
described in Figure 4.26, the following set of differential equations [4.6] – [4.11] 
can be obtained. 
𝑑[𝑨]
𝑑𝑡
= −𝑘𝑢𝑛𝑐𝑎𝑡 ∙ [𝑨] ∙ [𝑩] − 𝑘𝑐𝑎𝑡 ∙ [𝑬] ∙ [𝑨]  [4.6] 
𝑑[𝑩]
𝑑𝑡
= −𝑘𝑢𝑛𝑐𝑎𝑡 ∙ [𝑨] ∙ [𝑩] − 𝑘𝑆𝑀 𝐴𝑠𝑠 ∙ [𝑩] ∙ [𝑫] + 𝑘𝑆𝑀 𝐷𝑖𝑠𝑠𝑜𝑐 ∙ [𝑬]  [4.7] 
𝑑[𝑪]
𝑑𝑡
= 𝑘𝑢𝑛𝑐𝑎𝑡 ∙ [𝑨] ∙ [𝑩] − 𝑘𝑃 𝐴𝑠𝑠 ∙ [𝑪] ∙ [𝑫] + 𝑘𝑃 𝐷𝑖𝑠𝑠𝑜𝑐 ∙ [𝑭]  [4.8] 
𝑑[𝑫]
𝑑𝑡
= −𝑘𝑆𝑀 𝐴𝑠𝑠 ∙ [𝑩] ∙ [𝑫] + 𝑘𝑆𝑀 𝐷𝑖𝑠𝑠𝑜𝑐 ∙ [𝑬] − 𝑘𝑃 𝐴𝑠𝑠 ∙ [𝑪] ∙ [𝑫] +




= 𝑘𝑆𝑀 𝐴𝑠𝑠 ∙ [𝑩] ∙ [𝑫] − 𝑘𝑆𝑀 𝐷𝑖𝑠𝑠𝑜𝑐 ∙ [𝑬] − 𝑘𝑐𝑎𝑡 ∙ [𝑬] ∙ [𝑨]  [4.10] 
𝑑[𝑭]
𝑑𝑡
= 𝑘𝑃 𝐴𝑠𝑠 ∙ [𝑪] ∙ [𝑫] − 𝑘𝑃 𝐷𝑖𝑠𝑠𝑜𝑐 ∙ [𝑭] + 𝑘𝑐𝑎𝑡 ∙ [𝑬] ∙ [𝑨]  [4.11] 
 
The differential equations [4.6] – [4.11] were solved using the package deSolve304 
implemented in the R software302 and the RStudio303 software interface. It is 
assumed that the rates of the equilibrium steps (associations and dissociations) 
are significantly faster than the catalysed and uncatalysed steps of the cycle. 
This is not an unreasonable assumption based on the fast exchange 1H NMR 



















X-ray data were collected at 100 K on an Agilent Technologies Supernova 
system using Cu Kα radiation with exposures over 1.0˚, and data were treated 
using CrysAlisPro software.305 The structures were solved using SHELXT306 and 
weighted full-matrix refinement on F2 was carried out using SHELXL-97,306 
both running within the OLEX2-v1.2.9 package.307 All non-hydrogen atoms 
were refined anisotropically. Hydrogen atoms attached to carbons were placed 
in calculated positions and refined using a riding model. 
Ellipsoid plots of asymmetric units (ASUs) 
Ellipsoid plots (at 50% probability level) are displayed in the order they appear 
in the text. 
 
 






Figure A2: ASU of C4⋅BF4 
 
 






Figure A4: ASU of C1⋅BArF 
 
 




X-ray data tables 
 
Compound C2∙BF4 C4∙BF4 C4∙SbF6 
Empirical formula C124H84B2F8N20Pd2 C100H70B4F16Fe4N10Pd2 C98H67F24Fe4N9Pd2Sb4 
Formula weight / g mol-1 2240.53 2195.10 2749.80 
Temperature / K 90 100 100 
Crystal system tetragonal triclinic triclinic 
Space group P4/mnc P-1 P-1 
a / Å 16.9365(2) 14.7833(9) 12.7055(6) 
b / Å 16.9365(2) 15.2557(13) 19.5133(7) 
c / Å 22.8144(5) 21.7631(10) 25.8602(7) 
α / ° 90 78.150(5) 86.322(2) 
β / ° 90 89.339(4) 77.790(3) 
γ / ° 90 85.522(6) 88.585(3) 
Volume / Å3 6544.2(2) 4788.9(6) 6253.1(4) 
Z 2 2 2 
ρcalc / g cm-3 1.137 1.522 1.460 
µ / mm-1 2.724 8.407 13.266 
F(000) 2284.0 2200.0 2668.0 
Crystal size / mm3 0.222 × 0.182 × 0.109 0.199 × 0.056 × 0.041 0.262 x 0.069 x 0.05 
Radiation Cu Kα (λ = 1.54184) Cu Kα (λ = 1.54184) Cu Kα (λ = 1.54184) 
2Θ range for data collection 7.382 to 149.382 7.31 to 98.174 7.118 to 140.15 
Index ranges -21 ≤ h ≤ 21, -20 ≤ k ≤ 20, -21 ≤ l ≤ 28 -14 ≤ h ≤ 14, -14 ≤ k ≤ 14, -21 ≤ l ≤ 19 -15 ≤ h ≤ 15, -23 ≤ k ≤ 23, -31 ≤ l ≤ 28 
Reflections collected 35093 45798 43061 
Independent reflections 3419 [Rint = 0.0401, Rsigma = 0.0164] 9376 [Rint = 0.1666, Rsigma = 0.1185] 23570 [Rint = 0.0587, Rsigma = 0.0802] 
Data/restraints/parameters 3419/0/182 9376/2766/1227 23570/48/1271 
Goodness-of-fit on F2 1.069 1.014 1.226 
Final R indexes [I>=2σ (I)] R1 = 0.0721, wR2 = 0.2005 R1 = 0.0822, wR2 = 0.1908 R1 = 0.1202, wR2 = 0.3237 
Final R indexes [all data] R1 = 0.0779, wR2 = 0.2084 R1 = 0.1231, wR2 = 0.2199 R1 = 0.1532, wR2 = 0.3632 





Compound C1∙BArF PCD⊂C1⋅BArF 
Empirical formula C104H50B2Cl4F48N6Pd C228H108B4Cl4F96N12Pd2 
Formula weight / g mol-1 2565.32 5269.10 
Temperature / K 100 100 
Crystal system triclinic monoclinic 
Space group P-1 C2/c 
a / Å 14.4273(17) 40.4917(5) 
b / Å 20.5558(18) 14.28760(10) 
c / Å 21.1077(17) 42.8608(6) 
α / ° 80.895(7) 90 
β / ° 70.295(9) 107.7970(10) 
γ / ° 72.121(9) 90 
Volume / Å3 5598.2(10) 23609.6(5) 
Z 2 4 
ρcalc / g cm-3 1.522 1.482 
µ / mm-1 3.379 2.822 
F(000) 2544.0 10480.0 
Crystal size / mm3 0.187 × 0.164 × 0.097 0.237 × 0.13 × 0.074 
Radiation Cu Kα (λ = 1.54184) Cu Kα (λ = 1.54184) 
2Θ range for data collection 8.916 to 79.944 7.16 to 150.05 
Index ranges -12 ≤ h ≤ 11, -17 ≤ k ≤ 17, -17 ≤ l ≤ 17 -43 ≤ h ≤ 49, -17 ≤ k ≤ 17, -53 ≤ l ≤ 53 
Reflections collected 12773 118465 
Independent reflections 6697 [Rint = 0.0602, Rsigma = 0.1029] 23829 [Rint = 0.0561, Rsigma = 0.0343] 
Data/restraints/parameters 6697/1188/1486 23829/1193/1567 
Goodness-of-fit on F2 1.242 1.026 
Final R indexes [I>=2σ (I)] R1 = 0.1102, wR2 = 0.2982 R1 = 0.0904, wR2 = 0.2385 
Final R indexes [all data] R1 = 0.1497, wR2 = 0.3301 R1 = 0.0991, wR2 = 0.2467 

















All DFT calculations were performed using the ORCA program version 4.0.308 All 
structures were fully optimized using the BP86309-311 functional with a def2-SVP 
basis set.312 The resolution of identity approximation313 was also used in the BP86 
calculations, with a def2-SVP/J auxiliary basis set.314-316 Calculations were 
performed in a polarizable continuum solvent using both the COSMO317-319 and 
SMD320 solvation models with acetonitrile (ε = 35.69), DMSO (ε = 47.24). SCF 
iterations were considered converged when the energy change was less than  
1×10-8 a.u. The geometry was considered optimized when the following tolerances 
were met: Gradient = 3×10-4 a.u., RMS gradient = 1×10-4 a.u., maximum gradient = 
3×10-4 a.u., RMS displacement = 2×10-3 a.u., maximum displacement = 4×10-3 a.u.. 
To reduce numerical error in the DFT integration, more grid points were used for 
both the angular and radial grids via the keyword “Grid4” for the SCF iterations 
and the final energy evaluation. 
All Merck molecular force field (MMFF) models were optimised using the 
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